0001437749-24-005719 | 10-K | XBRL Viewer | Horizon Technology Finance Corp

Investment Holdings [Text Block]

Note 4. Investments

The following table shows the Company’s investments as of December 31, 2023 and 2022:

	*December 31, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	721,231	$	670,172	$	701,074	$	686,458
Warrants		16,526		24,594		14,790		29,712
Other		6,982		6,430		1,200		1,300
Equity		14,443		7,889		4,184		2,556
Total investments	$	759,182	$	709,085	$	721,248	$	720,026

The following table shows the Company’s investments by industry sector as of December 31, 2023 and 2022:

	*December 31, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	145,544	$	117,781	$	193,372	$	195,006
Medical Device		147,064		145,019		132,803		135,960
Technology
Communications		19,192		22,188		22,892		26,176
Consumer-Related		105,669		101,327		121,961		114,050
Data Storage		417		418		476		1,316
Internet and Media		329		1,582		329		1,159
Networking		5,451		5,297		11,831		11,710
Power Management		1,585		2,700		1,585		2,610
Semiconductors		45		—		56		—
Software		164,133		160,749		120,157		118,716
Sustainability
Energy Efficiency		111		13		8		27
Other Sustainability		98,906		80,370		84,633		85,524
Healthcare Information and Services
Diagnostics		19,735		19,701		9,851		9,858
Other		102		1,366		7,559		3,870
Software		50,899		50,574		13,735		14,044
Total investments	$	759,182	$	709,085	$	721,248	$	720,026

Note 8 - Federal Income Tax (Details Textual) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Federal Excise Tax, Percent	4.00%
Operating Loss Carryforwards	$ 38.6	$ 18.8
Sales and Excise Tax Payable	1.5	0.7
Investment, Tax Basis, Cost	759.2	721.2
Investment, Tax Basis, Unrealized Gain	14.9	18.5
Investment, Tax Basis, Unrealized Loss	$ 65.0	$ 19.8

Note 8 - Federal Income Tax - Tax Characters of Distributions Paid (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Ordinary income	$ 42,576	$ 31,490	$ 25,099
Total	$ 42,576	$ 31,490	$ 25,099

Note 4 - Investments (Tables)

12 Months Ended

Dec. 31, 2023

Investment Holdings, Schedule of Investments [Table Text Block]

	*December 31, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	721,231	$	670,172	$	701,074	$	686,458
Warrants		16,526		24,594		14,790		29,712
Other		6,982		6,430		1,200		1,300
Equity		14,443		7,889		4,184		2,556
Total investments	$	759,182	$	709,085	$	721,248	$	720,026

	*December 31, 2023*				*December 31, 2022*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	145,544	$	117,781	$	193,372	$	195,006
Medical Device		147,064		145,019		132,803		135,960
Technology
Communications		19,192		22,188		22,892		26,176
Consumer-Related		105,669		101,327		121,961		114,050
Data Storage		417		418		476		1,316
Internet and Media		329		1,582		329		1,159
Networking		5,451		5,297		11,831		11,710
Power Management		1,585		2,700		1,585		2,610
Semiconductors		45		—		56		—
Software		164,133		160,749		120,157		118,716
Sustainability
Energy Efficiency		111		13		8		27
Other Sustainability		98,906		80,370		84,633		85,524
Healthcare Information and Services
Diagnostics		19,735		19,701		9,851		9,858
Other		102		1,366		7,559		3,870
Software		50,899		50,574		13,735		14,044
Total investments	$	759,182	$	709,085	$	721,248	$	720,026

Note 10 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Investment Concentration Risk [Member] \| Reported Value Measurement [Member]
Concentration Risk, Percentage	23.00%	23.00%
Investment Concentration Risk [Member] \| Estimate of Fair Value Measurement [Member]
Concentration Risk, Percentage	22.00%	23.00%
Interest Income [Member] \| Reported Value Measurement [Member]
Concentration Risk, Percentage	17.00%	15.00%	17.00%
Interest Income [Member] \| Estimate of Fair Value Measurement [Member]
Concentration Risk, Percentage	15.00%	15.00%	17.00%

Consolidated Statements of Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Investments at fair value	$ 709,085	$ 720,026
Cash	46,630	20,612
Investments in money market funds	26,450	7,066
Restricted investments in money market funds	2,642	2,788
Interest receivable	13,926	13,573
Other assets	3,623	2,761
Total assets	802,356	766,826
Liabilities
Borrowings (Note 7)	462,235	434,078
Distributions payable	11,011	9,159
Base management fee payable (Note 3)	1,052	1,065
Incentive fee payable (Note 3)	0	1,392
Other accrued expenses	4,077	2,684
Total liabilities	478,375	448,378
Commitments and contingencies (Notes 3 and 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 33,534,854 and 27,920,838 shares issued and 33,367,389 and 27,753,373 shares outstanding as of December 31, 2023 and 2022, respectively	36	29
Paid-in capital in excess of par	450,949	385,921
Distributable loss	(127,004)	(67,502)
Total net assets	323,981	318,448
Total liabilities and net assets	$ 802,356	$ 766,826
Net asset value per common share (in dollars per share)	$ 9.71	$ 11.47
Investment, Unaffiliated Issuer [Member]
Assets
Investments at fair value	$ 693,730	$ 720,026
Investment, Affiliated Issuer, Noncontrolled [Member]
Assets
Investments at fair value	1,132	0
Investment, Affiliated Issuer, Controlled [Member]
Assets
Investments at fair value	$ 14,223	$ 0

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Net unrealized appreciation (depreciation) on investments

$ 720,026

(48,780)

$ (5,552)

$ 3,205

(29,702)

(9,484)

(3,248)

709,085

720,026

8,433

(0)

Investment, Affiliated Issuer, Noncontrolled [Member]

(709,085)

(720,026)

(11,000)

(30)

38,599

Net unrealized appreciation (depreciation) on investments

(26,513)

(848)

(390)

1,132

1,245

252

38,599

Investment, Affiliated Issuer, Noncontrolled [Member] | MVI (ABC) LLC fka StereoVision, Inc [Member]

(1,132)

(30)

Net unrealized appreciation (depreciation) on investments

Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member]

Net unrealized appreciation (depreciation) on investments

Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]

^[1]

^[1]

^[1]

^[1]

(906)

Net unrealized appreciation (depreciation) on investments

^[1]

^[1]

906

^[1]

^[1]

^[1]

^[1]

(906)

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment One [Member]

^[1]

(2,443)

7,663

Net unrealized appreciation (depreciation) on investments

(5,006)

222

277

7,663

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Two [Member]

(222)

(3,667)

11,509

Net unrealized appreciation (depreciation) on investments

(7,528)

336

414

11,509

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Three [Member]

(336)

(1,467)

4,601

Net unrealized appreciation (depreciation) on investments

(3,006)

133

166

4,601

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Four [Member]

(133)

(1,467)

4,598

Net unrealized appreciation (depreciation) on investments

(3,001)

133

163

4,598

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Five [Member]

(133)

(978)

3,067

Net unrealized appreciation (depreciation) on investments

(2,005)

114

3,067

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Six [Member]

(88)

(978)

3,067

Net unrealized appreciation (depreciation) on investments

(2,005)

111

3,067

Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Seven [Member]

(88)

5,000

Net unrealized appreciation (depreciation) on investments

(4,868)

132

5,000

Investment, Affiliated Issuer, Controlled [Member]

(132)

1,457

(516)

(300)

10,734

Net unrealized appreciation (depreciation) on investments

2,222

1,450

(1,450)

(1,150)

14,223

320

10,734

Investment, Affiliated Issuer, Controlled [Member] | Investment [Member]

(14,223)

Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment One [Member]

337

1,675

Net unrealized appreciation (depreciation) on investments

1,385

3,339

225

213

1,675

Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Two [Member]

(3,339)

844

Net unrealized appreciation (depreciation) on investments

678

1,630

112

107

844

Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Three [Member]

(1,630)

1,250

2,061

Net unrealized appreciation (depreciation) on investments

(287)

3,024

2,061

Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member]

(3,024)

(300)

Net unrealized appreciation (depreciation) on investments

1,450

(1,150)

Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member]

$ 0

146

(516)

6,154

Net unrealized appreciation (depreciation) on investments

446

6,230

6,154

$ (6,230)

$ 0

[1]	As of December 31, 2023, the Company no longer owns 5% of more of the portfolio company.

Note 11 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands				9 Months Ended	12 Months Ended
	Mar. 18, 2024	Feb. 23, 2024	Oct. 27, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Distributions declared per share (in dollars per share)			$ 0.11	$ 1.37	$ 1.37	$ 1.28	$ 1.25
Dividends, cash				$ 38,418		$ 32,659
Dividends, shares (in shares)				127,486		61,859
Dividends, stock				$ 1,623		$ 754
May 16, 2024 Dividend [Member] \| Forecast [Member]
Distributions declared per share (in dollars per share)		$ 0.11
March 18, 2024 Dividend [Member] \| Forecast [Member]
Distributions declared per share (in dollars per share)	$ 0.05	0.11
May 17, 2024 Dividend [Member] \| Forecast [Member]
Distributions declared per share (in dollars per share)		$ 0.11
First 10/27/2023 Dividend [Member]
Record date					Feb. 16, 2024
Payment date					Mar. 15, 2024
Distributions declared per share (in dollars per share)					$ 0.11
Dividends, cash					$ 0
Dividends, shares (in shares)					0
Dividends, stock					$ 0
Second 10/27/2023 Dividend [Member]
Record date					Jan. 18, 2024
Payment date					Feb. 14, 2024
Distributions declared per share (in dollars per share)					$ 0.11
Dividends, cash					$ 3,462
Dividends, shares (in shares)					15,873
Dividends, stock					$ 210
Third 10/27/2023 Dividend [Member]
Record date					Dec. 19, 2023
Payment date					Jan. 16, 2024
Distributions declared per share (in dollars per share)					$ 0.11
Dividends, cash					$ 3,472
Dividends, shares (in shares)					14,563
Dividends, stock					$ 199
Fourth 10/27/2023 Dividend [Member]
Record date					Nov. 17, 2023
Payment date					Dec. 15, 2023
Distributions declared per share (in dollars per share)					$ 0.05
Dividends, cash					$ 1,574
Dividends, shares (in shares)					7,137
Dividends, stock					$ 93
First 7/28/2023 Dividend [Member]
Record date				Nov. 17, 2023
Payment date				Dec. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,463
Dividends, shares (in shares)				15,701
Dividends, stock				$ 206
Second 7/28/2023 Dividend [Member]
Record date				Oct. 18, 2023
Payment date				Nov. 11, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,493
Dividends, shares (in shares)				14,022
Dividends, stock				$ 173
Third 7/28/2023 Dividend [Member]
Record date				Sep. 19, 2023
Payment date				Oct. 16, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,445
Dividends, shares (in shares)				15,067
Dividends, stock				$ 184
First 4/28/2023 Dividend [Member]
Record date				Aug. 17, 2023
Payment date				Sep. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,458
Dividends, shares (in shares)				8,665
Dividends, stock				$ 106
Second 4/28/2023 [Member]
Record date				Jul. 18, 2023
Payment date				Aug. 15, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,427
Dividends, shares (in shares)				8,307
Dividends, stock				$ 105
Third 4/28/2023 Dividend [Member]
Record date				Jun. 16, 2023
Payment date				Jul. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,434
Dividends, shares (in shares)				7,424
Dividends, stock				$ 96
First 2/23/2023 Dividend [Member]
Record date				May 18, 2023
Payment date				Jun. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,087
Dividends, shares (in shares)				7,128
Dividends, stock				$ 86
Second 2/23/2023 Dividend [Member]
Record date				Apr. 18, 2023
Payment date				May 16, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,068
Dividends, shares (in shares)				6,705
Dividends, stock				$ 84
Third 2/23/2023 Dividend [Member]
Record date				Mar. 17, 2023
Payment date				Apr. 14, 2023
Distributions declared per share (in dollars per share)				$ 0.11
Dividends, cash				$ 3,035
Dividends, shares (in shares)				6,894
Dividends, stock				$ 81
First 10/28/2022 Dividend [Member]
Record date						Feb. 17, 2023
Payment date						Mar. 15, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 3,040
Dividends, shares (in shares)						6,764
Dividends, stock						$ 75
Second 10/28/2022 Dividend [Member]
Record date						Jan. 18, 2023
Payment date						Feb. 15, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 3,021
Dividends, shares (in shares)						5,754
Dividends, stock						$ 74
Third 10/28/2022 Dividend [Member]
Record date						Dec. 19, 2022
Payment date						Jan. 13, 2023
Distributions declared per share (in dollars per share)						$ 0.11
Dividends, cash						$ 2,978
Dividends, shares (in shares)						5,618
Dividends, stock						$ 69
Fourth 10/28/2022 Dividend [Member]
Record date						Nov. 17, 2022
Payment date						Dec. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.05
Dividends, cash						$ 1,319
Dividends, shares (in shares)						2,171
Dividends, stock						$ 27
First 7/29/2022 Dividend [Member]
Record date						Nov. 17, 2022
Payment date						Dec. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,638
Dividends, shares (in shares)						4,341
Dividends, stock						$ 57
Second 7/29/2022 Dividend [Member]
Record date						Oct. 18, 2022
Payment date						Nov. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,580
Dividends, shares (in shares)						4,621
Dividends, stock						$ 60
Third 7/29/2022 Dividend [Member]
Record date						Sep. 19, 2022
Payment date						Oct. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,558
Dividends, shares (in shares)						7,703
Dividends, stock						$ 81
First 4/29/22 Dividend [Member]
Record date						Aug. 18, 2022
Payment date						Sep. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,528
Dividends, shares (in shares)						4,925
Dividends, stock						$ 60
Second 4/29/2022 Dividend [Member]
Record date						Jul. 19, 2022
Payment date						Aug. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,484
Dividends, shares (in shares)						3,939
Dividends, stock						$ 55
Third 4/29/2022 Dividend [Member]
Record date						Jun. 17, 2022
Payment date						Jul. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,434
Dividends, shares (in shares)						4,286
Dividends, stock						$ 51
First 2/25/2022 Dividend [Member]
Record date						May 18, 2022
Payment date						Jun. 15, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,378
Dividends, shares (in shares)						4,428
Dividends, stock						$ 50
Second 2/25/2022 Dividend [Member]
Record date						Apr. 19, 2022
Payment date						May 16, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,349
Dividends, shares (in shares)						4,088
Dividends, stock						$ 49
Third 2/25/2022 Dividend [Member]
Record date						Mar. 18, 2022
Payment date						Apr. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.1
Dividends, cash						$ 2,352
Dividends, shares (in shares)						3,221
Dividends, stock						$ 46

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended			32 Months Ended
	Jun. 02, 2023	Mar. 14, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023	Sep. 22, 2023	Apr. 23, 2023	Aug. 02, 2021	Jul. 30, 2020
Investments, Nonaccrual, Interest Income			$ 0	$ 0	$ 1,300
Investment, Income Attributable to Non-cash Paid-in-Kind Interest, Percent			7.40%
Interest Income, Operating, Paid in Kind			$ 8,433	$ (0)	$ 0
Investment, Nonaccrual, Income Not Received in Cash, Percent			4.20%	7.40%	5.90%
Debt Issuance Costs, Net			$ 5,800	$ 7,100		$ 5,800
Deferred Finance Costs, Accumulated Amortization			6,900	4,800		$ 6,900
Amortization of Debt Issuance Costs			1,852	1,604	$ 1,091
Adjustments to Additional Paid in Capital, Non-deductible Excise Taxes Paid			$ 1,500	700	400
Federal Excise Tax, Percent			4.00%			4.00%
Excise and Sales Taxes			$ 1,500	700	400
Unrecognized Tax Benefits, Ending Balance			$ 0	0		$ 0
Open Tax Year			2020 2021 2022 2023
Proceeds from Issuance of Common Stock			$ 65,093	$ 84,603	$ 30,086
Stock Repurchase Program, Remaining Authorized Repurchase Amount								$ 5,000
Stock Repurchased During Period, Shares (in shares)			0	0	0	167,465
Stock Repurchased During Period, Per Share (in dollars per share)						$ 11.22
Stock Repurchased During Period, Value						$ 1,900
The 2020 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value										$ 100,000
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value									$ 100,000
Equity Sales Agreement, Remaining Amount Available for Issuance							$ 0
Stock Issued During Period, Shares, New Issues (in shares)				3,982,684
Proceeds from Issuance of Common Stock				$ 50,300
Payments of Stock Issuance Costs				1,000
The 2023 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value							$ 150,000
Equity Sales Agreement, Remaining Amount Available for Issuance			$ 146,700			146,700
The2023 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,248,830
Proceeds from Issuance of Common Stock			$ 26,200
Payments of Stock Issuance Costs			700
The 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					1,907,234
Proceeds from Issuance of Common Stock					$ 30,100
Payments of Stock Issuance Costs					$ 800
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,250,000	2,500,000
Proceeds from Issuance of Common Stock	$ 38,900	$ 34,300
Shares Issued, Price Per Share (in dollars per share)	$ 12.5	$ 14.35
Four Investments [Member]
Investments, Cost, Nonaccrual Status			72,500			72,500
Investments, Fair Value, Nonaccrual Status			27,600			$ 27,600
Three Investments [Member]
Investments, Cost, Nonaccrual Status				20,900
Investments, Fair Value, Nonaccrual Status				8,300
Two Investments [Member]
Interest Income, Operating, Paid in Kind			$ 3,900	$ 200

Note 8 - Federal Income Tax - Reconciliation of Net Increase in Net Assets to Taxable Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net (decrease) increase in net assets resulting from operations	$ (17,185)	$ 21,151	$ 27,782
Net unrealized appreciation (depreciation) on investments	(48,780)	(5,552)	3,205
Other book-tax differences	931	3,292	1,462
Change in capital loss carry forward	29,853	9,484	3,643
Taxable income before deductions for distributions	$ 62,379	$ 39,479	$ 29,682

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Consolidated Schedule of Investments

12 Months Ended

Dec. 31, 2023

Schedule of Investments [Text Block]

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 214.2% (8)
Non-Affiliate Debt Investments — 205.0% (8)
Non-Affiliate Debt Investments — Life Science — 75.6% (8)
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,987		2,987
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,987		2,987
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,414		1,410		1,410
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,414		1,410		1,410
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,950		4,950
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,949		4,949
Greenlight Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		3,000		2,914		2,870
		Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		1,500		1,458		1,436
KSQ Therapeutics, Inc. (2)(12)	Biotechnology	Term Loan		13.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,199		6,199
		Term Loan		13.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,199		6,199
Native Microbials, Inc (2)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,716		3,716
		Term Loan		13.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,478		2,478
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,911		9,911
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,717		3,717
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,579		4,414
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,579		4,414
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,199
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,199
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,278		2,196
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,278		2,196
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		4,250		4,193		4,193
		Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,125		2,096		2,096
Tallac Therapeutics, Inc. (2)(12)	Biotechnology	Term Loan		12.75	%	Prime		4.25	%		12.25	%		-			4.00	%	August 1, 2027		2,500		2,230		2,230
		Term Loan		12.75	%	Prime		4.25	%		12.25	%		-			4.00	%	August 1, 2027		2,500		2,459		2,459
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		9.00	%	Fixed		-			-			-			18.00	%	April 1, 2028		2,500		2,468		2,342
		Term Loan		9.00	%	Fixed		-			-			-			18.00	%	April 1, 2028		2,500		2,468		2,342
		Term Loan		9.00	%	Fixed		-			-			-			18.00	%	June 30, 2024		200		200		190
Candesant Biomedical, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		5,000		4,757		4,757
		Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		2,500		2,454		2,454
		Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		2,500		2,454		2,454
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		3,750		3,738		3,738
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		3,750		3,738		3,738
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		1,875		1,866		1,866
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		1,875		1,866		1,866
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		4,583		4,546		4,546
		Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,292		2,273		2,273
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		13.32	%	Prime		4.82	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,923		3,923
		Term Loan		13.32	%	Prime		4.82	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,923		3,923
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	January 1, 2024		500		500		500
		Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	January 1, 2024		33		33		33
		Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	March 1, 2024		800		794		794
MicroTransponder, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		3.75	%		12.25	%		-			3.50	%	January 1, 2029		3,750		3,689		3,689
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-			3.50	%	January 1, 2029		3,750		3,689		3,689

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Robin Healthcare, Inc. (2)(12)(13)	Medical Device	Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,469		1,574
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,563		1,617
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,722		3,722
		Term Loan		13.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,722		3,722
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	January 1, 2027		5,000		4,943		4,943
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	January 1, 2027		5,000		4,900		4,900
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		2,500		2,297		2,297
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		2,500		2,473		2,473
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		5,000		4,946		4,946
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		5,000		4,946		4,946
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,978		4,978
		Term Loan		15.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,489		2,489
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,467		3,467
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,467		3,467
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,456		3,456
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,456		3,456
Vero Biotech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		15,000		14,675		14,675
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		10,000		9,784		9,784
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		5,000		4,892		4,892
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		2,500		2,446		2,446
Total Non-Affiliate Debt Investments — Life Science																						249,642		244,815
Non-Affiliate Debt Investments — Sustainability — 24.6% (8)
New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		4.33	%	December 1, 2026		3,750		3,685		3,685
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		4.33	%	December 1, 2026		3,750		3,685		3,685
Nexii Building Solutions, Inc. (2)(12)(13)(14)(18)	Other Sustainability	Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,353		4,549
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,229		4,481
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,229		4,481
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		5,617		5,480		2,984
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		5,617		5,480		2,984
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		735		726		395
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		586		578		315
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		292		288		157
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		290		286		156
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		174		172		93
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		802		791		431
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		1,091		1,083		590
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,959		4,959
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,479		2,479
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,956		4,956
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,478		2,478
		Term Loan		14.00	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,934		4,934
		Term Loan		14.00	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,467		2,467
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,694		3,694
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,694		3,694
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		7,500		7,379		7,379
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,690		3,690
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,690		3,690
		Term Loan		14.50	%	Prime		6.00	%		10.00	%		-		2.00	%	January 1,2029		4,500		4,446		4,446
		Term Loan		14.50	%	Prime		6.00	%		10.00	%		-		2.00	%	January 1,2029		2,000		1,976		1,976
Total Non-Affiliate Debt Investments — Sustainability																						97,907		79,828

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Debt Investments — Technology — 83.3% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	%	Prime		7.25	%		10.50	%		-			3.00	%	May 1, 2026		3,383		3,356		3,356
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			5.50	%	August 1, 2025		1,667		1,656		1,656
		Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			5.50	%	August 1, 2025		1,583		1,573		1,573
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,608		3,608
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,726		3,726
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,726		3,726
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,706		3,706
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,707		3,707
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,707		3,707
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,421		1,421
		Term Loan		13.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		2,131		2,131
		Term Loan		12.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		12.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.00	%	Prime		3.50	%		9.00	%		-			1.00	%	September 1, 2027		2,500		2,591		2,429
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		3,667		3,647		3,647
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		1,833		1,824		1,824
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,752		5,752		5,018
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,301		2,301		2,007
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,509
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,451		3,451		3,011
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,752		5,752		5,018
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,416		2,416
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2028		1,875		1,787		1,787
Unagi, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,204		1,086		872
		Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		602		543		436
		Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		602		543		436
Liqid, Inc. (2)(12)	Networking	Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,500		1,481		1,481
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,500		1,481		1,481
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		750		740		740
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		667		656		656
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		750		729		729
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		5,000		4,860		4,860
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Dropoff, Inc. (2)(12)	Software	Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,625		6,519		6,176
		Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,116		6,018		5,701
		Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	August 1, 2026		2,548		2,507		2,375
Engage3, LLC (2)(12)	Software	Term Loan		14.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,728		3,728
		Term Loan		14.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,728		3,728
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,895		9,895
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,895		9,895
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,947		4,947
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		15.00	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		5,000		4,971		4,971
		Term Loan		15.00	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		2,500		2,486		2,486
Lytics, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	November 1, 2026		2,500		2,471		2,373
		Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	December 1, 2026		1,250		1,237		1,188
		Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	April 1, 2027		1,000		994		954
Mirantis, Inc. (2)(12)	Software	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,779		4,779
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
Noodle Partners, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		10,000		9,885		9,885
		Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,942		4,942
		Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,942		4,942
Reputation Institute, Inc. (2)(12)	Software	Term Loan		15.75	%	Prime		7.25	%		10.50	%		-		3.00	%	August 1, 2025		3,667		3,625		3,625
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,457		2,457
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		3,500		3,489		3,489
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,492		2,492
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		1,500		1,495		1,495
Viken Detection Corporation (2)(12)	Software	Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		5,000		4,773		4,773
		Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,467		2,467
		Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,467		2,467
Total Non-Affiliate Debt Investments — Technology																						275,026		269,790
Non-Affiliate Debt Investments — Healthcare information and services — 21.5% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,484		2,484
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,484		2,484
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		5,000		4,968		4,968
Parse Biosciences, Inc. (2)(12)	Diagnostics	Term Loan		11.75	%	Prime		3.25	%		11.50	%		-		5.00	%	January 1, 2028		5,000		4,633		4,633
		Term Loan		11.75	%	Prime		3.25	%		11.50	%		-		5.00	%	January 1, 2028		5,000		4,884		4,884
BrightInsight, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		7,000		6,684		6,684
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,463		3,463
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,463		3,463
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	April 1, 2028		2,750		2,710		2,710
Elligo Health Research, Inc. (2)(12)	Software	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		10,000		9,656		9,656
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
SafelyYou, Inc. (2)(12)	Software	Term Loan		11.75	%	Prime		3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,648		4,648
		Term Loan		11.75	%	Prime		3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,918		4,918
Total Non-Affiliate Debt Investments — Healthcare information and services																						69,770		69,770
Total Non- Affiliate Debt Investments																						692,345		664,203

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 7.6% (8)
Non-Affiliate Warrants — Life Science — 2.3% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		117		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		318
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		178		246
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		65		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		53
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,611		146		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		157
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		606
Provivi, Inc. (2)(12)	Biotechnology	Common Stock Warrant		175,098		278		—
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		691,895		312		225
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		113
Tallac Therapeutics, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		1,600,002		194		172
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		33
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,199
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		8,800		48		9
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,305
Candesant Biomedical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		93,336		152		135
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		229
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		4,106,174		149		167
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		206
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		3,341,376		174		124
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		980
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		2,010,424		124		26
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		368
Meditrina, Inc. (12)	Medical Device	Preferred Stock Warrant		233,993		83		93
MicroTransponder, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		103,172		47		47
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		34,410		103		215
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		2,637,043		275		269
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		4,109		432		379
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		1
Total Non-Affiliate Warrants — Life Science						4,702		7,675

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Sustainability — 0.2% (8)
New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15)	Other Sustainability	Preferred Stock Warrant		400,000		81		72
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		50
Nexii Building Solutions, Inc. (2)(12)(14)(18)	Other Sustainability	Common Stock Warrant		215,171		490		—
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		340
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		46,311		175		80
Total Non-Affiliate Warrants — Sustainability						999		542
Non-Affiliate Warrants — Technology — 4.5% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		47		61
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,036
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		131
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		—
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		65		1,055
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		75,997		22		27
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		29		122
CZV, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		65,569		81		71
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		37,282		94		250
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,259
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		250		29		56
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		12,618		188		—
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,224,752		9		—
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		11,550		182		145
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		591
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		533
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		—
Updater, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		114,659		34		—
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		294
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		394,110		175		124
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		63
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		318
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		1,201
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		210
Halio, Inc. (2)(12)	Power Management	Common Stock Warrant		38,241,466		1,585		2,700
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred Stock Warrant		5,938		45		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		161,215		98		174
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		46
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		—
Everstream Holdings, LLC (2)(12)	Software	Preferred Stock Warrant		350,000		70		63
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		13
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		32		120
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		71,305		18		42
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		85,543		43		1
Mirantis, Inc. (2)(12)	Software	Common Stock Warrant		948,275		223		247
Noodle Partners, Inc. (2)(12)	Software	Preferred Stock Warrant		84,037		115		2
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		80
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		44		91
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		135
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
Viken Detection Corporation (2)(12)	Software	Preferred Stock Warrant		345,443		120		105
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		5
Total Non-Affiliate Warrants — Technology						9,733		14,506

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		171,370		46		12
Parse Biosciences, Inc. (2)(12)	Diagnostics	Common Stock Warrant		32,244		70		70
Parse Biosciences, Inc. (2)(12)	Diagnostics	Preferred Stock Warrant		184,253		166		166
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,366
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		85,066		167		—
Elligo Health Research, Inc. (2)(12)	Software	Preferred Stock Warrant		652,250		192		99
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		108
SafelyYou, Inc. (2)(12)	Software	Preferred Stock Warrant		150,353		163		50
Total Non-Affiliate Warrants — Healthcare information and services						966		1,871
*Total Non-Affiliate Warrants*						16,400		24,594
Non-Affiliate Other Investments — Life Science — 0.1% (8)
Lumithera, Inc. (12)	Medical Device	Royalty Agreement				1,200		200
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		—
*Total Non-Affiliate Other Investments*						1,200		200
Non-Affiliate Equity — 1.5% (8)
Cadrenal Therapeutics, Inc. (5)	Biotechnology	Common Stock		600,000		—		443
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)	Biotechnology	Common Stock		32,831		355		355
Axiom Space, Inc. (12)	Communication	Preferred Stock		1,810		261		306
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		20
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock		2,688,971		89		89
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (5)	Other Sustainability	Common Stock		5,205		111		13
Decisyon, Inc. (12)	Software	Preferred Stock		280,000		2,800		1,281
Lotame, Inc. (12)	Software	Preferred Stock		66,127		4		193
*Total Non-Affiliate Equity*						6,132		4,733
*Total Non-Affiliate Portfolio Investment Assets*					$	716,077	$	693,730

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Controlled Affiliate Investments — 0.3% (8)
Non-Controlled Affiliate Debt Investments — Life Sciences — 0.3% (8)
Evelo Biosciences, Inc. (2)(5)(12)(13)	Biotechnology	Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		5,532		5,228		222
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		8,298		7,867		336
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		3,319		3,137		133
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		3,319		3,137		133
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		2,213		2,091		88
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		2,213		2,091		88
Total Non-Controlled Affiliate Debt Investments																						23,551		1,000

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-controlled Affiliate Equity — Life Sciences — 0.0% (8)
Aulea Medical, Inc. (12)(16)	Medical Device	Common Stock		660,537		—		—
Evelo Biosciences, Inc. (5)	Biotechnology	Common Stock		2,164,502		5,000		132
Total Non-Controlled Affiliate Equity						5,000		132
Non-controlled Affiliate Warrants — Life Sciences — 0.0% (8)
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock		23,196		126		—
Total Non-Controlled Affiliate Warrants						126		—
*Total Non-Controlled Affiliate Portfolio Investment Assets*					$	28,677	$	1,132

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2023

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Controlled Affiliate Investments — 4.4% (8)
Controlled Affiliate Debt Investments — Technology — 1.6% (8)
Better Place Forests Co. (12)	Consumer-related Technologies	Term Loan		12.25	% (11)	Prime		3.75	%		12.00	%		-		1.85	%	August 1, 2029		3,547		3,585		3,339
		Term Loan		12.25	% (11)	Prime		3.75	%		12.00	%		-		1.85	%	August 1, 2029		1,773		1,750		1,630
Total Controlled Affiliate Debt Investments																						5,335		4,969

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Controlled Affiliate Equity — Technology — 0.9% (8)
Better Place Forests Co. (12)	Consumer-related Technologies	Common Stock		2,278,272		2,061		2,165
Better Place Forests Co. (12)	Consumer-related Technologies	Preferred Stock		3,124,448		1,250		859
Total Controlled Affiliate Equity						3,311		3,024
Controlled Affiliate Other Investments — Life Sciences — 1.9% (8)
HIMV LLC (12)(17)	Biotechnology	Other Investment				5,782		6,230
Total Controlled Affiliate Other						5,782		6,230
*Total Controlled Affiliate Portfolio Investment Assets*					$	14,428	$	14,223
*Total Portfolio Investment Assets — 218.9% (8)*					$	759,182	$	709,085

(1)	All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted.

(2)

Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”) with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”) and/or the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $157.8 million securitization of secured loans the Company completed on November 9, 2022 (the “2022 Asset-Backed Notes”).

(3)

All non-affiliate investments are investments in which the Company owns less than 5% of the voting securities of the portfolio company. All non-controlled affiliate investments are investments in which the Company owns 5% or more of the voting securities of the portfolio company but not more than 25% of the voting securities of the portfolio company. All controlled affiliate investments are investments in which the Company owns more than 25% of the portfolio company’s outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement).

(4)

All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”), and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of December 31, 2023 is provided.

(5)	Portfolio company is a public company.

(6)	For debt investments, represents principal balance less unearned income.

(7)	Warrants, Equity and Other Investments are non-income producing.

(8)	Value as a percent of net assets.

(9)

As of December 31, 2023, 4.7% and 2.7% of the Company’s total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10)

ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11)	Debt investment has a payment-in-kind (“PIK”) feature in which the accrued interest is added to the then-outstanding principal amount of the debt investment.

(12)	The fair value of the investment was valued using significant unobservable inputs.

(13)	Debt investment is on non-accrual status as of December 31, 2023.

(14)	Entity is organized under the laws of Canada and has a principal place of business in Canada.

(15)	On or about September 13, 2023, in connection with New Aerofarms, Inc. purchase of substantially all of the assets of Aerofarms, Inc. in a bankruptcy process, New Aerofarms, Inc. assumed all of the debt investments of Horizon in Aerofarms, Inc.

(16)	On July 31, 2023, pursuant to a certain Secured Party Bill of Sale and Transfer Agreement, the Company sold substantially all of the assets of Corinth MedTech, Inc., a borrower of the Company, to Aulea Medical Inc. (“Aulea”) in consideration of 660,537 shares of the common stock of Aulea.

(17)

By an Order of the Supreme Court of Nova Scotia made May 1, 2023, as amended and restated by an Order of the CCAA Court made May 5, IMV, Inc. (“IMV”) commenced proceedings (the “CCAA Proceedings”) under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended to seek creditor protection for IMV and on June 2, 2023, IMV obtained recognition of the CCAA Proceedings under Chapter 15 of the United States Bankruptcy Code in proceedings before the United States Bankruptcy Court for the District of Delaware. In September 2023, the Company, with its co-lender to IMV, credit-bid and acquired substantially all of the assets of IMV through HIMV LLC, an entity formed to acquire the assets of IMV. HIMV LLC is 70% owned by the Company and 30% owned by the co-lender.

(18)

On January 11, 2024, Nexii Building Solutions Inc., and its affiliates, obtained an Initial Order under the Companies’ Creditors Arrangement Act from the Supreme Court of British Columbia in Vancouver. The Initial Order provides for, among other things, a stay of proceedings in favour of Nexii, the approval of debtor-in-possession financing and the appointment of KSV Restructuring Inc. as monitor of Nexii.

(19)

Debt investment has a partial PIK feature in which (a) a portion of the accrued interest on the debt investment, in an amount equal to four and one half percent (4.5%) on the then-outstanding principal amount of the debt investment is added to the then-outstanding principal amount of the debt investment and (b) the remaining accrued interest on the debt investment is paid in cash.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)(14)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)(14)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
*Total Non- Affiliate Debt Investments*																							701,074		686,458

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)(14)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)(14)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148
*Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)*
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
*Total Non-Affiliate Warrants*						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
*Total Non-Affiliate Equity*						4,184		2,556
*Total Non-Affiliate Portfolio Investment Assets*					$	721,248	$	720,026
*Total Portfolio Investment Assets — 226.1% (8)*					$	721,248	$	720,026

(1)	All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted.

(2)

Has been pledged as collateral under the Key Facility, the NYL Facility, the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 (the “2019 Asset-Backed Notes”) and/or the 2022 Asset-Backed Notes.

See Notes to Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Schedule of Investments

December 31, 2022

(Dollars in thousands)

(3)

(4)

All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETPs, and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. Debt investments are at variable rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of December 31, 2022 is provided.

(5)	Portfolio company is a public company.

(6)	For debt investments, represents principal balance less unearned income.

(7)	Warrants, Equity and Other Investments are non-income producing.

(8)	Value as a percent of net assets.

(9)

As of December 31, 2022, 6.5% and 6.6% of the Company's total assets on a cost and fair value basis, respectively, are in non-qualifying assets. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets.

(10)

(11)	Debt investment has a PIK feature.

(12)	The fair value of the investment was valued using significant unobservable inputs.

(13)	Debt investment is on non-accrual status as of December 31, 2022.

(14)	Entity is organized under the laws of Canada and has a principal place of business in Canada.

See Notes to Consolidated Financial Statements

Note 7 - Borrowings - Borrowings (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Nov. 09, 2022

Jun. 15, 2022

Dec. 31, 2021

Mar. 30, 2021

Dec. 31, 2020

Dec. 31, 2019

Aug. 13, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

$ 615,000

$ 582,573

^[1]

466,000

439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

$ 95,375

$ 96,000

$ 115,546

$ 81,753

Unamortized debt issuance costs attributable to term borrowings

149,000

143,250

(3,765)

(5,245)

Total borrowings outstanding, net

462,235

434,078

Key Facility [Member]

150,000

125,000

70,000

5,000

80,000

120,000

NYL Facility [Member]

250,000

200,000

181,000

176,750

Asset-backed Notes 2019 [Member]

69,000

23,250

42,573

$ 160,000

42,573

Asset-backed Notes 2022 [Member]

100,000

$ 157,800

100,000

The 2027 Notes [Member]

57,500

$ 50,000

^[2]

57,500

The 2026 Notes [Member]

57,500

$ 57,500

^[2]

57,500

$ 57,500

$ 0

$ 0

[1]	Total amount of senior securities outstanding at the end of the period presented.
[2]	Total amount of senior securities outstanding at the end of the period presented.

Note 6 - Fair Value (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	*December 31, 2023*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Debt investments	$	—	$	—	$	670,172	$	670,172
Warrant investments		—		1,619		22,975		24,594
Other investments		—		—		6,430		6,430
Equity investments		608		—		7,281		7,889
Total investments	$	608	$	1,619	$	706,858	$	709,085

	*December 31, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

*December 31, 2023*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	617,529	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 24%		15	%

		52,643	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 100%		50	%

Warrant investments		22,913	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	64.95
				Average Industry Volatility	25%		25	%
				Marketability Discount	0% – 20%		18	%
				Estimated Time to Exit (in years)	1 to 5		3
		62	Expected Proceeds	Price Per Share	$0.25	$	0.25

Other investments		6,430	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	30% – 100%		81	%

Equity investments		7,281	Last Equity Financing	Price Per Share	0.566 –215.0303	$	17.15

Total Level 3 investments	$	706,858

*December 31, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%

		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%

		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93

Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93

Total Level 3 investments	$	716,319

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	*Year ended December 31, 2023*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319
Purchase of investments		217,285			—			1,260			144			218,689
Warrants and equity received and classified as Level 3		—			2,763			89			—			2,852
Principal payments received on investments		(151,777	)		—			—			(516	)		(152,293	)
Payment-in-kind interest on investments		8,433			—			—			—			8,433
Proceeds from sale of investments		(9,565	)		(1,495	)		(6	)		—			(11,066	)
Net realized (loss) gain on investments		(29,146	)		1,003			(121	)		—			(28,264	)
Unrealized depreciation included in earnings		(35,564	)		(5,436	)		(2,496	)		(652	)		(44,148	)
Transfer out of Level 3		(5,000	)		—			(111	)		—			(5,111	)
Transfer out of debt and warrant investments		(12,399	)		(5	)		6,250			6,154			—
Other		1,447			—			—			—			1,447
Level 3 assets, end of period	$	670,172		$	22,975		$	7,281		$	6,430		$	706,858

	*Year ended December 31, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		421,372			—			606			—			421,978
Warrants and equity received and classified as Level 3		—			5,664			8			—			5,672
Principal payments received on investments		(95,558	)		—			—			(313	)		(95,871	)
Proceeds from sale of investments		(49,371	)		(464	)		—			—			(49,835	)
Net realized (loss) gain on investments		(8,221	)		264			—			(1,137	)		(9,094	)
Unrealized (depreciation) appreciation included in earnings		(10,044	)		2,215			(401	)		1,350			(6,880	)
Transfer out of Level 3		—			(1,371	)		—			—			(1,371	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(5,837	)		—			—			—			(5,837	)
Level 3 assets, end of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319

Note 1 - Organization

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1. Organization

Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.

On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”.

Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.

The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the 2019 Asset-Backed Notes.

Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company.

The Company formed Horizon Funding 2022‑1 LLC (“2022‑1 LLC”) as a Delaware limited liability company on September 30, 2022 and Horizon Funding Trust 2022‑1 on October 18, 2022 (“2022‑1 Trust” and, together with the 2022‑1 LLC, the “2022‑1 Entities”). The 2022‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2022‑1 Entities for purposes of securitizing the 2022 Asset-Backed Notes.

The Company has established wholly owned subsidiaries, which are structured as Delaware limited liability companies, either to hold assets of portfolio companies acquired in connection with a foreclosure or bankruptcy, or to hold equity in portfolio companies which the Company may control. Such wholly-owned subsidiaries are separate legal entities from the Company.

The Company, together with its co-lender to IMV, established HIMV LLC, a Delaware limited liability company to purchase and sell the assets of IMV, a borrower of the Company. HIMV LLC is 70% owned by the Company and 30% owned by the co-lender.

The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Investment income
Payment-in-kind interest income	$ 8,433	$ (0)	$ 0
Total investment income	113,475	79,191	60,015
Expenses
Interest expense	28,971	19,202	12,034
Base management fee (Note 3)	12,799	10,566	7,617
Performance based incentive fee (Note 3)	3,094	7,745	7,055
Administrative fee (Note 3)	1,658	1,667	1,285
Professional fees	2,178	1,650	1,892
General and administrative	1,837	1,459	1,511
Total expenses	50,537	42,289	31,394
Net investment income before excise tax	62,938	36,902	28,621
Provision for excise tax	1,490	715	401
Net investment income	61,448	36,187	28,220
Net realized and unrealized loss
Net realized gain (loss) on investments	(29,702)	(9,484)	(3,248)
Net realized loss on extinguishment of debt	(151)	0	(395)
Net realized loss	(29,853)	(9,484)	(3,643)
Net unrealized appreciation (depreciation) on investments	(48,780)	(5,552)	3,205
Net realized and unrealized loss	(78,633)	(15,036)	(438)
Net (decrease) increase in net assets resulting from operations	$ (17,185)	$ 21,151	$ 27,782
Net investment income per common share (in dollars per share)	$ 1.98	$ 1.46	$ 1.41
Net (decrease) increase in net assets resulting from operations per common share (in dollars per share)	(0.56)	0.86	1.39
Distributions declared per share (in dollars per share)	$ 1.37	$ 1.28	$ 1.25
Weighted average shares outstanding (in shares)	30,957,849	24,726,079	20,027,420
Investment, Unaffiliated Issuer [Member]
Investment income
Interest income	$ 100,435	$ 77,366	$ 54,159
Payment-in-kind interest income	8,113	0	0
Prepayment fee income	1,880	1,568	4,111
Fee income	1,465	257	1,481
Net realized and unrealized loss
Net realized gain (loss) on investments	(29,702)	(8,364)	(2,858)
Net unrealized appreciation (depreciation) on investments	(24,489)	(7,002)	5,503
Investment, Affiliated Issuer, Noncontrolled [Member]
Investment income
Interest income	1,245	0	252
Fee income	0	0	12
Net realized and unrealized loss
Net realized gain (loss) on investments	0	30	(390)
Net unrealized appreciation (depreciation) on investments	(26,513)	0	(848)
Investment, Affiliated Issuer, Controlled [Member]
Investment income
Interest income	17	0	0
Payment-in-kind interest income	320	0	0
Net realized and unrealized loss
Net realized gain (loss) on investments	0	(1,150)	0
Net unrealized appreciation (depreciation) on investments	$ 2,222	$ 1,450	$ (1,450)

Note 8 - Federal Income Tax (Tables)

12 Months Ended

Dec. 31, 2023

Federal Income Tax Note [Table Text Block]

	*Years Ended December 31,*
	*2023*			*2022*		*2021*
	(In thousands)
Net (decrease) increase in net assets resulting from operations	$	(17,185	)	$	21,151	$	27,782
Net unrealized depreciation (appreciation) on investments		48,780			5,552		(3,205	)
Other book-tax differences		931			3,292		1,462
Change in capital loss carry forward		29,853			9,484		3,643
Taxable income before deductions for distributions	$	62,379		$	39,479	$	29,682

Schedule of Tax Characters of Distribution Paid [Table Text Block]

	*Years Ended December 31,*
	*2023*		*2022*		*2021*
	(In thousands)
Ordinary income	$	42,576	$	31,490	$	25,099
Total	$	42,576	$	31,490	$	25,099

Schedule of Investment Company, Distributable Earnings (Loss) [Table Text Block]

	*As of December 31,*
	*2023*			*2022*			*2021*
	(In thousands)
Undistributed ordinary income	$	38,616		$	18,813		$	10,825
Long term capital loss carry forward		(102,908	)		(73,055	)		(63,571	)
Unrealized appreciation		14,935			18,542			12,973
Unrealized depreciation		(65,032	)		(19,771	)		(8,738	)
Other temporary differences		12,547			11,875			7,465
Total	$	(101,842	)	$	(43,596	)	$	(41,046	)

Note 2 - Basis of Presentation and Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑K and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of December 31, 2023, there were four investments on non-accrual status with a cost of $72.5 million and a fair value of $27.6 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the year ended December 31, 2023 and 2022, the Company did not recognize any interest income from debt investments while on non-accrual status. For the year ended December 31, 2021, the Company recognized, as interest income, payments of $1.3 million received from two portfolio companies whose debt investments were on non-accrual status.

The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. For the year ended December 31, 2023, 7.4% of the Company’s total investment income was attributable to non-cash PIK interest. For the years ended December 31, 2022 and 2021, the Company recorded no PIK interest income. The Company will generally cease accruing PIK interest if management does not expect the portfolio company to be able to pay all principal and interest due. For the year ended December 31, 2023, two debt investments, which had accrued PIK interest into income of $3.9 million and $0.2 million during the years ended December 31, 2023 and 2022, respectively, were placed on nonaccrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the years ended December 31, 2023, 2022 and 2021 was 4.2%, 7.4% and 5.9%, respectively.

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2023 and 2022 was $5.8 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of December 31, 2023 and 2022 were $6.9 million and $4.8 million, respectively. The amortization expense for the years ended December 31, 2023, 2022 and 2021 was $1.9 million, $1.6 million and $1.1 million, respectively.

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the years ended December 31, 2023, 2022 and 2021, the Company reclassified $1.5 million, $0.7 million and $0.4 million, respectively, to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the years ended December 31, 2023, 2022 and 2021, $1.5 million, $0.7 million and $0.4 million, respectively, was recorded for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at December 31, 2023 and 2022. The Company’s income tax returns for the 2023, 2022, 2021 and 2020 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders’ Equity

On July 30, 2020, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2020 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2020 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company.

On August 2, 2021, the Company entered into an ATM sales agreement (the “2021 Equity Distribution Agreement”), with the Sales Agents.

The 2021 Equity Distribution Agreement provided that the Company may offer and sell its shares of common stock from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company.

On September 22, 2023, the Company terminated the 2021 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2023 Equity Distribution Agreement”), with the Sales Agents. The remaining shares available under the 2021 Equity Distribution Agreement are no longer available for issuance. The 2023 Equity Distribution Agreement provides that the Company may offer and sell its shares of its common stock from time to time through the Sales Agents up to $150.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the year ended December 31, 2023, the Company sold 2,248,830 shares of common stock under the 2023 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $26.2 million, including $0.7 million of offering expenses, from these sales.

During the year ended December 31, 2022, the Company sold 3,982,684 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $50.3 million, including $1.0 million of offering expenses, from these sales.

During the year ended December 31, 2021, the Company sold 1,907,234 shares of common stock under the 2021 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $30.1 million, including $0.8 million of offering expenses, from these sales.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2023, shares representing approximately $146.7 million of its common stock remain available for issuance and sale under the 2023 Equity Distribution Agreement.

On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

On June 2, 2023, the Company completed a follow-on public offering of 3,250,000 shares of its common stock at a public offering price of $12.50 per share, for total net proceeds to the Company of $38.9 million, after deducting underwriting commission and discounts and other offering expenses.

Stock Repurchase Program

On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the years ended December 31, 2023, 2022 and 2021, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through December 31, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently adopted accounting pronouncement

In October 2023, the FASB issued Accounting Standards Update No. 2023-06, Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (“ASU 2023-06”). ASU 2023-06 amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification including requiring investment companies to disclose the components of capital on the balance sheet. The amendments in ASU 2023-06 were effective on the date which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K became effective. The adoption of ASU 2023-06 did not have an impact on the Company's consolidated financial statements.

Recently issued accounting pronouncement

In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company has concluded that the adoption of ASU 2022-03 will not have a material impact on its consolidated financial statements.

Note 8 - Federal Income Tax

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Text Block]

Note 8. Federal income tax

The Company has elected to be treated as a RIC under Subchapter M of the Code and to distribute substantially all of its taxable income. Accordingly, no provision for federal, state or local income tax has been recorded in the financial statements. Taxable income differs from net increase in net assets resulting from operations primarily due to unrealized appreciation on investments as investment gains and losses are not included in taxable income until they are realized.

The following table reconciles net (decrease) increase in net assets resulting from operations to taxable income:

	*Years Ended December 31,*
	*2023*			*2022*		*2021*
	(In thousands)
Net (decrease) increase in net assets resulting from operations	$	(17,185	)	$	21,151	$	27,782
Net unrealized depreciation (appreciation) on investments		48,780			5,552		(3,205	)
Other book-tax differences		931			3,292		1,462
Change in capital loss carry forward		29,853			9,484		3,643
Taxable income before deductions for distributions	$	62,379		$	39,479	$	29,682

The tax characters of distributions paid are as follows:

	*Years Ended December 31,*
	*2023*		*2022*		*2021*
	(In thousands)
Ordinary income	$	42,576	$	31,490	$	25,099
Total	$	42,576	$	31,490	$	25,099

The components of undistributed ordinary income earnings on a tax basis were as follows:

	*As of December 31,*
	*2023*			*2022*			*2021*
	(In thousands)
Undistributed ordinary income	$	38,616		$	18,813		$	10,825
Long term capital loss carry forward		(102,908	)		(73,055	)		(63,571	)
Unrealized appreciation		14,935			18,542			12,973
Unrealized depreciation		(65,032	)		(19,771	)		(8,738	)
Other temporary differences		12,547			11,875			7,465
Total	$	(101,842	)	$	(43,596	)	$	(41,046	)

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% excise tax on such income, as required. For the years ended December 31, 2023 and 2022, the Company elected to carry forward taxable income in excess of current year distributions of $38.6 million and $18.8 million, respectively. At December 31, 2023 and 2022, a provision for excise tax of $1.5 million and $0.7 million, respectively was recorded.

Capital losses in excess of capital gains earned in a tax year may generally be carried forward, without expiration, and used to offset capital gains, subject to certain limitations. During the years ended December 31, 2023, 2022 and 2021, the Company did not use any material capital loss carry forwards to offset capital gains.

For federal income tax purposes, the tax cost of investments at December 31, 2023 and 2022 was $759.2 million and $721.2 million, respectively. The gross unrealized appreciation on investments at December 31, 2023 and 2022 was $14.9 million and $18.5 million, respectively. The gross unrealized depreciation on investments at December 31, 2023 and 2022 was $65.0 million and $19.8 million, respectively.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

Note 9 - Financial Instruments With Off-balance-sheet Risk (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]

	*December 31, 2023*				*December 31, 2022*
			*Fair Value of*				*Fair Value of*
			*Unfunded*				*Unfunded*
	*Principal*		*Commitment*		*Principal*		*Commitment*
	*Balance*		*Liability*		*Balance*		*Liability*
	(In thousands)				(In thousands)
BrightInsight, Inc.	$	15,500	$	241	$	21,000	$	278
Britecore Holdings, Inc.		5,000		72		5,000		66
Candesant Biomedical Corporation		10,000		151		—		—
Castle Creek Biosciences		—		—		4,000		72
Divergent Technologies, Inc.		11,250		118		22,500		236
Elligo Healthcare Research, Inc.		15,000		194		—		—
Engage3, LLC		—		—		8,000		40
Groundspeed Analytics, Inc.		—		—		15,000		150
Hound Labs, Inc.		—		—		7,500		88
KSQ Therapeutics, Inc.		—		—		10,000		100
Lytics, Inc.		—		—		5,000		65
MicroTransponder, Inc.		22,500		—		—		—
Mirantis, Inc.		15,000		136		—		—
Native Microbials, Inc.		—		—		7,500		72
Optoro, Inc.		6,250		—		15,000		38
Parse Biosciences, Inc.		15,000		251		—		—
PDS Biotechnology Corporation		—		—		10,000		158
Robin Healthcare, Inc.		—		—		10,000		100
SafelyYou, Inc.		20,000		270		—		—
Scientia Vascular, Inc.		—		—		10,000		110
Slingshot Aerospace, Inc.		—		—		5,000		64
Sonex Health, Inc.		15,000		176		—		—
Supply Network Visibility Holdings, LLC		10,000		35		—		—
Swift Health Systems Inc.		—		—		25,500		105
Tallac Therapeutics, Inc.		10,000		229		—		—
Temperpack Technologies, Inc.		—		—		9,000		19
Viken Detection Corporation		10,000		160		—		—
Total	$	180,500	$	2,033	$	190,000	$	1,761

Note 1 - Organization (Details Textual) - Investment, Affiliated Issuer, Controlled [Member]	Dec. 31, 2023
HIMV LLC [Member] \| Co-lender [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	30.00%
HIMV LLC [Member] \| Horizon Technology Finance Corporation [Member]
Investment Owned, Net Assets, Percentage	70.00%

Percentage of investment owned to net assets.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480493/946-210-55-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column D))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Note 11 - Distributions

12 Months Ended

Dec. 31, 2023

Equity [Text Block]

Note 11. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the years ended December 31, 2023 and 2022:

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Year Ended December 31, 2023
10/27/2023	2/16/24	3/15/24	$	0.11	$	—		—	$	—
10/27/2023	1/18/24	2/14/24		0.11		3,462		15,873		210
10/27/2023	12/19/23	1/16/24		0.11		3,472		14,563		199
10/27/2023	11/17/23	12/15/23		0.05		1,574		7,137		93
7/28/2023	11/17/23	12/15/23		0.11		3,463		15,701		206
7/28/2023	10/18/23	11/15/23		0.11		3,493		14,022		173
7/28/2023	9/19/23	10/16/23		0.11		3,445		15,067		184
4/28/2023	8/17/23	9/15/23		0.11		3,458		8,665		106
4/28/2023	7/18/23	8/15/23		0.11		3,427		8,307		105
4/28/2023	6/16/23	7/14/23		0.11		3,434		7,424		96
2/23/2023	5/18/23	6/14/23		0.11		3,087		7,128		86
2/23/2023	4/18/23	5/16/23		0.11		3,068		6,705		84
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	1.37	$	38,418		127,486	$	1,623
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754

On February 23, 2024, the Board declared monthly distributions per share and a special distribution per share, payable as set forth in the following table:

Monthly distributions

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
May 16, 2024	May 17, 2024	June 14, 2024	$	0.11
April 17, 2024	April 18, 2024	May 15, 2024	$	0.11
March 18, 2024	March 19, 2024	April 16, 2024	$	0.11

Special distributions

Ex-Dividend Date		*Record Date*		*Payment Date*		*Distributions Declared*
March 18, 2024		March 19, 2024		April 16, 2024		$	0.05

After paying distributions of $1.37 per share deemed paid for tax purposes in 2023, declaring on October 27, 2023 a distribution of $0.11 per share payable January 16, 2024, and taxable earnings of $2.01 per share in 2023, the Company’s undistributed spillover income as of December 31, 2023 was $1.25 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Note 7 - Borrowings (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Debt [Table Text Block]

	*December 31, 2023*							*December 31, 2022*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	150,000	$	70,000		$	80,000	$	125,000	$	5,000		$	120,000
NYL Facility		250,000		181,000			69,000		200,000		176,750			23,250
2019 Asset-Backed Notes		—		—			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		615,000		466,000			149,000		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(3,765	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	615,000	$	462,235		$	149,000	$	582,573	$	434,078		$	143,250

Schedule of Long-Term Debt Instruments [Table Text Block]

	*Total Amount*
	*Outstanding*				*Involuntary*		*Average*
	*Exclusive of*		*Asset*		*Liquidation*		*Market*
	*Treasury*		*Coverage*		*Preference*		*Value per*
Class and Year	*Securities(1)*		*per Unit(2)*		*per Unit(3)*		*Unit(4)*
	(In thousands, except unit data)
Credit facilities
2023	$	251,000	$	3,147		—		N/A
2022	$	181,750	$	4,169		—		N/A
2021	$	132,250	$	3,823		—		N/A
2020	$	50,250	$	7,965		—		N/A
2019	$	17,000	$	19,908		—		N/A
2018	$	90,500	$	2,896		—		N/A
2017	$	58,000	$	3,973		—		N/A
2016	$	63,000	$	3,733		—		N/A
2015	$	68,000	$	4,048		—		N/A
2014	$	10,000	$	22,000		—		N/A
2027 Notes
2023	$	57,500	$	13,739		—	$	24.26
2022	$	57,500	$	13,179		—	$	24.09
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2026 Notes
2023	$	57,500	$	13,739		—	$	23.75
2022	$	57,500	$	13,179		—	$	24.45
2021	$	57,500	$	8,793		—	$	25.90
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2022 Notes
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020	$	37,375	$	10,708		—	$	24.60
2019	$	37,375	$	9,055		—	$	25.53
2018	$	37,375	$	7,014		—	$	25.52
2017	$	37,375	$	6,166		—	$	25.66
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—

	Total Amount
	Outstanding				Involuntary		Average
	Exclusive of		Asset		Liquidation		Market
	Treasury		Coverage		Preference		Value per
Class and Year	Securities(1)		per Unit(2)		per Unit(3)		Unit(4)
	(In thousands, except unit data)
2019 Notes
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016	$	33,000	$	7,127		—	$	25.42
2015	$	33,000	$	8,342		—	$	25.26
2014	$	33,000	$	6,667		—	$	25.64
2022-1 Securitization
2023	$	100,000	$	7,900		—		N/A
2022	$	100,000	$	7,578		—		N/A
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2019-1 Securitization
2023	$	—	$	—		—		N/A
2022	$	42,573	$	17,799		—		N/A
2021	$	70,500	$	7,171		—		N/A
2020	$	100,000	$	4,002		—		N/A
2019	$	100,000	$	3,384		—		N/A
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2013-1 Securitization
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015	$	14,546	$	18,926		—		N/A
2014	$	38,753	$	5,677		—		N/A
Total senior securities
2023	$	466,000	$	1,695		—		N/A
2022	$	439,323	$	1,725		—		N/A
2021	$	260,250	$	1,943		—		N/A
2020	$	187,625	$	2,133		—		N/A
2019	$	154,375	$	2,192		—		N/A
2018	$	127,875	$	2,050		—		N/A
2017	$	95,375	$	2,416		—		N/A
2016	$	96,000	$	2,450		—		N/A
2015	$	115,546	$	2,383		—		N/A
2014	$	81,753	$	2,691		—		N/A

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

Consolidated Schedule of Investments (Tables)

12 Months Ended

Dec. 31, 2023

Investment [Table Text Block]

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 214.2% (8)
Non-Affiliate Debt Investments — 205.0% (8)
Non-Affiliate Debt Investments — Life Science — 75.6% (8)
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,987		2,987
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,979		4,979
		Term Loan		13.25	%	Prime		4.75	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,987		2,987
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,414		1,410		1,410
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	June 1, 2024		1,414		1,410		1,410
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,950		4,950
		Term Loan		13.22	%	Prime		4.72	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,949		4,949
Greenlight Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		3,000		2,914		2,870
		Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		1,500		1,458		1,436
KSQ Therapeutics, Inc. (2)(12)	Biotechnology	Term Loan		13.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,199		6,199
		Term Loan		13.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,199		6,199
Native Microbials, Inc (2)(12)	Biotechnology	Term Loan		13.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,716		3,716
		Term Loan		13.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,478		2,478
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,911		9,911
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,717		3,717
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,579		4,414
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,579		4,414
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,199
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,199
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,278		2,196
		Term Loan		13.86	%	Prime		5.36	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,278		2,196
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		4,250		4,193		4,193
		Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,125		2,096		2,096
Tallac Therapeutics, Inc. (2)(12)	Biotechnology	Term Loan		12.75	%	Prime		4.25	%		12.25	%		-			4.00	%	August 1, 2027		2,500		2,230		2,230
		Term Loan		12.75	%	Prime		4.25	%		12.25	%		-			4.00	%	August 1, 2027		2,500		2,459		2,459
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		9.00	%	Fixed		-			-			-			18.00	%	April 1, 2028		2,500		2,468		2,342
		Term Loan		9.00	%	Fixed		-			-			-			18.00	%	April 1, 2028		2,500		2,468		2,342
		Term Loan		9.00	%	Fixed		-			-			-			18.00	%	June 30, 2024		200		200		190
Candesant Biomedical, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		5,000		4,757		4,757
		Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		2,500		2,454		2,454
		Term Loan		12.00	%	Prime		3.50	%		11.50	%		-			5.00	%	September 1, 2027		2,500		2,454		2,454
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		3,750		3,738		3,738
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		3,750		3,738		3,738
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		1,875		1,866		1,866
		Term Loan		12.00	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		1,875		1,866		1,866
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		4,583		4,546		4,546
		Term Loan		14.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,292		2,273		2,273
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		13.32	%	Prime		4.82	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,923		3,923
		Term Loan		13.32	%	Prime		4.82	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,923		3,923
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	January 1, 2024		500		500		500
		Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	January 1, 2024		33		33		33
		Term Loan		13.59	%	Prime		5.09	%		10.00	%		-			5.00	%	March 1, 2024		800		794		794
MicroTransponder, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		3.75	%		12.25	%		-			3.50	%	January 1, 2029		3,750		3,689		3,689
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-			3.50	%	January 1, 2029		3,750		3,689		3,689

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Robin Healthcare, Inc. (2)(12)(13)	Medical Device	Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,469		1,574
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,563		1,617
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,722		3,722
		Term Loan		13.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,722		3,722
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	January 1, 2027		5,000		4,943		4,943
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	January 1, 2027		5,000		4,900		4,900
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		2,500		2,297		2,297
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		2,500		2,473		2,473
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		5,000		4,946		4,946
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		8.00	%	September 1, 2027		5,000		4,946		4,946
Spineology, Inc. (2)(12)	Medical Device	Term Loan		15.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,978		4,978
		Term Loan		15.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,489		2,489
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,467		3,467
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,467		3,467
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,456		3,456
		Term Loan		13.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,456		3,456
Vero Biotech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		15,000		14,675		14,675
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		10,000		9,784		9,784
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		5,000		4,892		4,892
		Term Loan		12.25	%	Prime		3.75	%		12.25	%		-		4.00	%	January 1, 2029		2,500		2,446		2,446
Total Non-Affiliate Debt Investments — Life Science																						249,642		244,815
Non-Affiliate Debt Investments — Sustainability — 24.6% (8)
New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		4.33	%	December 1, 2026		3,750		3,685		3,685
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		4.33	%	December 1, 2026		3,750		3,685		3,685
Nexii Building Solutions, Inc. (2)(12)(13)(14)(18)	Other Sustainability	Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,353		4,549
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,229		4,481
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		8,425		8,229		4,481
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		5,617		5,480		2,984
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		2.50	%	March 31, 2024		5,617		5,480		2,984
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		735		726		395
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		586		578		315
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		292		288		157
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		290		286		156
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		174		172		93
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		802		791		431
		Term Loan		15.50	% (11)	Prime		7.00	%		10.25	%		-		-		March 31, 2024		1,091		1,083		590
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,959		4,959
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,479		2,479
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,956		4,956
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,478		2,478
		Term Loan		14.00	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		5,000		4,934		4,934
		Term Loan		14.00	%	Prime		5.50	%		11.75	%		-		2.75	%	December 1, 2026		2,500		2,467		2,467
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,694		3,694
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,694		3,694
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		7,500		7,379		7,379
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,690		3,690
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-		2.50	%	April 1, 2028		3,750		3,690		3,690
		Term Loan		14.50	%	Prime		6.00	%		10.00	%		-		2.00	%	January 1,2029		4,500		4,446		4,446
		Term Loan		14.50	%	Prime		6.00	%		10.00	%		-		2.00	%	January 1,2029		2,000		1,976		1,976
Total Non-Affiliate Debt Investments — Sustainability																						97,907		79,828

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Debt Investments — Technology — 83.3% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-			2.50	%	June 1, 2026		6,250		6,218		6,218
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.75	%	Prime		7.25	%		10.50	%		-			3.00	%	May 1, 2026		3,383		3,356		3,356
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			5.50	%	August 1, 2025		1,667		1,656		1,656
		Term Loan		14.25	%	Prime		5.75	%		9.00	%		-			5.50	%	August 1, 2025		1,583		1,573		1,573
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,608		3,608
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,726		3,726
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,726		3,726
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,242		1,242
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	April 1, 2028		3,750		3,706		3,706
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,707		3,707
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2028		3,750		3,707		3,707
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,421		1,421
		Term Loan		13.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		2,131		2,131
		Term Loan		12.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		12.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.00	%	Prime		3.50	%		9.00	%		-			1.00	%	September 1, 2027		2,500		2,591		2,429
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		3,667		3,647		3,647
		Term Loan		15.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		1,833		1,824		1,824
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,752		5,752		5,018
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,301		2,301		2,007
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,509
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		3,451		3,451		3,011
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		5,752		5,752		5,018
		Term Loan		14.25	% (11)	Prime		5.75	%		9.00	%		-			5.25	%	October 31, 2023		2,876		2,876		2,510
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,416		2,416
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2028		1,875		1,787		1,787
Unagi, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		1,204		1,086		872
		Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		602		543		436
		Term Loan		16.25	% (11)	Prime		7.75	%		11.00	%		-			-		May 1, 2027		602		543		436
Liqid, Inc. (2)(12)	Networking	Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,500		1,481		1,481
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,500		1,481		1,481
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		750		740		740
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		667		656		656
		Term Loan		14.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		750		729		729
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		5,000		4,860		4,860
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466
		Term Loan		14.00	%	Prime		5.50	%		14.00	%		-			3.00	%	October 1, 2028		2,500		2,466		2,466

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Dropoff, Inc. (2)(12)	Software	Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,625		6,519		6,176
		Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,116		6,018		5,701
		Term Loan		15.00	% (19)	Prime		6.50	%		9.75	%		-		3.50	%	August 1, 2026		2,548		2,507		2,375
Engage3, LLC (2)(12)	Software	Term Loan		14.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,728		3,728
		Term Loan		14.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,728		3,728
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,895		9,895
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,895		9,895
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,947		4,947
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		15.00	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		5,000		4,971		4,971
		Term Loan		15.00	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		2,500		2,486		2,486
Lytics, Inc. (2)(12)	Software	Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	November 1, 2026		2,500		2,471		2,373
		Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	December 1, 2026		1,250		1,237		1,188
		Term Loan		14.50	%	Prime		6.00	%		14.25	%		-		4.00	%	April 1, 2027		1,000		994		954
Mirantis, Inc. (2)(12)	Software	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,779		4,779
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2028		5,000		4,915		4,915
Noodle Partners, Inc. (2)(12)	Software	Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		10,000		9,885		9,885
		Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,942		4,942
		Term Loan		13.50	%	Prime		5.00	%		12.00	%		-		3.00	%	March 1, 2027		5,000		4,942		4,942
Reputation Institute, Inc. (2)(12)	Software	Term Loan		15.75	%	Prime		7.25	%		10.50	%		-		3.00	%	August 1, 2025		3,667		3,625		3,625
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
		Term Loan		14.25	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,959		4,959
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,457		2,457
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		3,500		3,489		3,489
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		2,500		2,492		2,492
		Term Loan		12.75	%	Prime		4.25	%		12.00	%		-		2.50	%	June 1, 2028		1,500		1,495		1,495
Viken Detection Corporation (2)(12)	Software	Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		5,000		4,773		4,773
		Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,467		2,467
		Term Loan		12.50	%	Prime		4.00	%		11.75	%		-		3.50	%	June 1, 2027		2,500		2,467		2,467
Total Non-Affiliate Debt Investments — Technology																						275,026		269,790
Non-Affiliate Debt Investments — Healthcare information and services — 21.5% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,484		2,484
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,484		2,484
		Term Loan		14.50	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		5,000		4,968		4,968
Parse Biosciences, Inc. (2)(12)	Diagnostics	Term Loan		11.75	%	Prime		3.25	%		11.50	%		-		5.00	%	January 1, 2028		5,000		4,633		4,633
		Term Loan		11.75	%	Prime		3.25	%		11.50	%		-		5.00	%	January 1, 2028		5,000		4,884		4,884
BrightInsight, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		7,000		6,684		6,684
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,463		3,463
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,463		3,463
		Term Loan		14.00	%	Prime		5.50	%		9.50	%		-		3.00	%	April 1, 2028		2,750		2,710		2,710
Elligo Health Research, Inc. (2)(12)	Software	Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		10,000		9,656		9,656
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
		Term Loan		12.00	%	Prime		3.50	%		11.75	%		-		4.00	%	October 1, 2027		5,000		4,925		4,925
SafelyYou, Inc. (2)(12)	Software	Term Loan		11.75	%	Prime		3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,648		4,648
		Term Loan		11.75	%	Prime		3.25	%		11.00	%		-		5.00	%	June 1, 2027		5,000		4,918		4,918
Total Non-Affiliate Debt Investments — Healthcare information and services																						69,770		69,770
Total Non- Affiliate Debt Investments																						692,345		664,203

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 7.6% (8)
Non-Affiliate Warrants — Life Science — 2.3% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		117		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		318
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		178		246
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		19,671		65		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,076		50		53
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,611		146		—
Native Microbials, Inc (2)(12)	Biotechnology	Preferred Stock Warrant		103,679		64		157
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		606
Provivi, Inc. (2)(12)	Biotechnology	Common Stock Warrant		175,098		278		—
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		691,895		312		225
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		113
Tallac Therapeutics, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		1,600,002		194		172
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		33
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		1,199
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		8,800		48		9
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		86		1,305
Candesant Biomedical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		93,336		152		135
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		229
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		4,106,174		149		167
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		206
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		3,341,376		174		124
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		980
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		2,010,424		124		26
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		368
Meditrina, Inc. (12)	Medical Device	Preferred Stock Warrant		233,993		83		93
MicroTransponder, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		103,172		47		47
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		34,410		103		215
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		2,637,043		275		269
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		4,109		432		379
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		1
Total Non-Affiliate Warrants — Life Science						4,702		7,675

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Sustainability — 0.2% (8)
New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15)	Other Sustainability	Preferred Stock Warrant		400,000		81		72
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		50
Nexii Building Solutions, Inc. (2)(12)(14)(18)	Other Sustainability	Common Stock Warrant		215,171		490		—
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		340
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		46,311		175		80
Total Non-Affiliate Warrants — Sustainability						999		542
Non-Affiliate Warrants — Technology — 4.5% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		47		61
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,036
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		131
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		—
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		65		1,055
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		75,997		22		27
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		29		122
CZV, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		65,569		81		71
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		37,282		94		250
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,259
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		250		29		56
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		12,618		188		—
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,224,752		9		—
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		11,550		182		145
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		591
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		533
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		—
Updater, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		114,659		34		—
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		294
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		394,110		175		124
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		63
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		318
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		1,201
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		210
Halio, Inc. (2)(12)	Power Management	Common Stock Warrant		38,241,466		1,585		2,700
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred Stock Warrant		5,938		45		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		161,215		98		174
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		46
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		—
Everstream Holdings, LLC (2)(12)	Software	Preferred Stock Warrant		350,000		70		63
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		13
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		32		120
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		71,305		18		42
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		85,543		43		1
Mirantis, Inc. (2)(12)	Software	Common Stock Warrant		948,275		223		247
Noodle Partners, Inc. (2)(12)	Software	Preferred Stock Warrant		84,037		115		2
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		80
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		44		91
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		135
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		135
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
Viken Detection Corporation (2)(12)	Software	Preferred Stock Warrant		345,443		120		105
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		5
Total Non-Affiliate Warrants — Technology						9,733		14,506

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		171,370		46		12
Parse Biosciences, Inc. (2)(12)	Diagnostics	Common Stock Warrant		32,244		70		70
Parse Biosciences, Inc. (2)(12)	Diagnostics	Preferred Stock Warrant		184,253		166		166
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,366
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		85,066		167		—
Elligo Health Research, Inc. (2)(12)	Software	Preferred Stock Warrant		652,250		192		99
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		108
SafelyYou, Inc. (2)(12)	Software	Preferred Stock Warrant		150,353		163		50
Total Non-Affiliate Warrants — Healthcare information and services						966		1,871
*Total Non-Affiliate Warrants*						16,400		24,594
Non-Affiliate Other Investments — Life Science — 0.1% (8)
Lumithera, Inc. (12)	Medical Device	Royalty Agreement				1,200		200
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		—
*Total Non-Affiliate Other Investments*						1,200		200
Non-Affiliate Equity — 1.5% (8)
Cadrenal Therapeutics, Inc. (5)	Biotechnology	Common Stock		600,000		—		443
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (12)	Biotechnology	Common Stock		32,831		355		355
Axiom Space, Inc. (12)	Communication	Preferred Stock		1,810		261		306
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		20
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock		2,688,971		89		89
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Lumithera, Inc. (12)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (5)	Other Sustainability	Common Stock		5,205		111		13
Decisyon, Inc. (12)	Software	Preferred Stock		280,000		2,800		1,281
Lotame, Inc. (12)	Software	Preferred Stock		66,127		4		193
*Total Non-Affiliate Equity*						6,132		4,733
*Total Non-Affiliate Portfolio Investment Assets*					$	716,077	$	693,730

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Controlled Affiliate Investments — 0.3% (8)
Non-Controlled Affiliate Debt Investments — Life Sciences — 0.3% (8)
Evelo Biosciences, Inc. (2)(5)(12)(13)	Biotechnology	Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		5,532		5,228		222
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		8,298		7,867		336
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		3,319		3,137		133
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		3,319		3,137		133
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		2,213		2,091		88
		Term Loan		12.75	% (11)	Prime		4.25	%		11.00	%		-		2.27	%	January 1, 2028		2,213		2,091		88
Total Non-Controlled Affiliate Debt Investments																						23,551		1,000

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-controlled Affiliate Equity — Life Sciences — 0.0% (8)
Aulea Medical, Inc. (12)(16)	Medical Device	Common Stock		660,537		—		—
Evelo Biosciences, Inc. (5)	Biotechnology	Common Stock		2,164,502		5,000		132
Total Non-Controlled Affiliate Equity						5,000		132
Non-controlled Affiliate Warrants — Life Sciences — 0.0% (8)
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock		23,196		126		—
Total Non-Controlled Affiliate Warrants						126		—
*Total Non-Controlled Affiliate Portfolio Investment Assets*					$	28,677	$	1,132

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Controlled Affiliate Investments — 4.4% (8)
Controlled Affiliate Debt Investments — Technology — 1.6% (8)
Better Place Forests Co. (12)	Consumer-related Technologies	Term Loan		12.25	% (11)	Prime		3.75	%		12.00	%		-		1.85	%	August 1, 2029		3,547		3,585		3,339
		Term Loan		12.25	% (11)	Prime		3.75	%		12.00	%		-		1.85	%	August 1, 2029		1,773		1,750		1,630
Total Controlled Affiliate Debt Investments																						5,335		4,969

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Controlled Affiliate Equity — Technology — 0.9% (8)
Better Place Forests Co. (12)	Consumer-related Technologies	Common Stock		2,278,272		2,061		2,165
Better Place Forests Co. (12)	Consumer-related Technologies	Preferred Stock		3,124,448		1,250		859
Total Controlled Affiliate Equity						3,311		3,024
Controlled Affiliate Other Investments — Life Sciences — 1.9% (8)
HIMV LLC (12)(17)	Biotechnology	Other Investment				5,782		6,230
Total Controlled Affiliate Other						5,782		6,230
*Total Controlled Affiliate Portfolio Investment Assets*					$	14,428	$	14,223
*Total Portfolio Investment Assets — 218.9% (8)*					$	759,182	$	709,085

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 226.1% (8)
Non-Affiliate Debt Investments — 215.5% (8)
Non-Affiliate Debt Investments — Life Science — 99.7% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,853	$	2,777
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,823		2,750
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,411		1,374
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,821		2,748
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,408		1,371
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,891		4,891
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,963		4,963
		Term Loan		12.50	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,978		2,978
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,962		1,962
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		1,979		1,963		1,963
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,923		4,923
		Term Loan		12.07	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,912		4,912
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		10,000		9,872		9,872
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		15,000		14,808		14,808
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		6,000		5,923		5,923
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
		Term Loan		11.75	%	Prime		4.75	%		11.00	%		-			4.25	%	January 1, 2028		4,000		3,949		3,949
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,476		2,476
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,473		2,473
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,857		4,857
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,430		2,430
IMV Inc. (2)(5)(12)(14)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,946		4,946
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,473		2,473
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,947		4,947
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,077		6,077
		Term Loan		12.25	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,177		6,177
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,630		3,630
		Term Loan		12.75	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		2,500		2,469		2,469
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,701		9,701
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,697		3,697
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,667		4,597		4,597
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,280		2,280
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
		Term Loan		12.67	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,274		2,274
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		5,000		4,914		4,914
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	October 1, 2025		2,500		2,457		2,457
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-			6.00	%	April 1, 2026		2,500		2,463		2,364
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,475		2,475
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,489		2,489
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			7.00	%	November 1, 2024		2,500		2,473		2,473
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		5,000		4,973		4,973
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
		Term Loan		10.50	%	Prime		3.50	%		8.25	%		-			5.50	%	October 1, 2024		2,500		2,478		2,478
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		2,500		2,466		2,466
		Term Loan		13.00	%	Prime		5.50	%		8.75	%		-			6.00	%	August 1, 2026		5,000		4,932		4,932
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898
		Term Loan		12.17	%	Libor		8.00	%		9.25	%		-			10.36	%	July 1, 2025		3,960		3,898		3,898

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		12.25	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		1,625		1,610		1,610
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		108		107		107
		Term Loan		12.37	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,000		1,983		1,983
Embody, Inc. (2)(12)	Medical Device	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,482		2,482
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,208		3,143		3,143
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		974		974
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,939		4,939
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.00	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,933		4,933
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
		Term Loan		12.50	%	Prime		5.00	%		9.75	%		-		4.00	%	January 1, 2027		5,000		4,913		4,913
Robin Healthcare, Inc. (2)(12)	Medical Device	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,360		3,360
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-		4.00	%	November 1, 2026		3,500		3,460		3,460
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,597		3,597
		Term Loan		11.75	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,706		3,706
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	June 1, 2025		2,500		2,476		2,476
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,453		2,453
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-		8.00	%	May 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,966		4,966
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,481		2,481
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,349		3,349
		Term Loan		12.25	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,454		3,454
Total Non-Affiliate Debt Investments — Life Science																						318,172		317,568
Non-Affiliate Debt Investments — Sustainability — 26.3% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,699		3,699
Nexii Building Solutions, Inc. (2)(12)(14)	Other Sustainability	Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,371		7,371
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
		Term Loan		14.50	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,903		4,903
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,463		2,463
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,927		4,927
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,924		4,924
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,462		2,462
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		5,000		4,900		4,900
		Term Loan		13.00	%	Prime		5.50	%		10.00	%		-		2.75	%	December 1, 2026		2,500		2,450		2,450
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,697		3,697
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,717		3,717
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,424		7,424
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,712		3,712
Total Non-Affiliate Debt Investments — Sustainability																						83,705		83,705
Non-Affiliate Debt Investments — Technology — 81.4% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Term Loan		13.00	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,455		7,455
		Convertible Note		3.00	%													July 1, 2023		250		250		306
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,966		4,966
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,979		2,979
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		976		976
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		977		977
Better Place Forests Co. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,951		3,834
		Term Loan		13.75	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		1,916
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.75	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,461		3,461
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,482		2,482

Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,478		3,478
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,715		3,715
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,238		1,238
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	January 1, 2028		3,750		3,698		3,698
Havenly, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		2,000		1,082		1,082
		Term Loan		12.50	%	Prime		5.00	%		5.00	%		-			4.00	%	March 1, 2027		3,000		1,623		1,623
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
		Term Loan		11.00	%	Prime		3.50	%		10.50	%		-			7.78	%	February 1, 2028		2,813		2,813		2,813
Interior Define, Inc. (2)(12)(13)	Consumer-related Technologies	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		3,210		3,151		—
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		2,963		2,886		—
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			-		September 1, 2027		2,500		2,588		2,279
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,954		4,954
		Term Loan		14.25	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,477		2,477
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,943		4,715
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,000		1,981		1,890
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,477		2,363
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		3,000		2,971		2,835
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,459		2,345
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		5,000		4,914		4,688
		Term Loan		12.75	%	Prime		5.75	%		9.00	%		-			2.00	%	December 30, 2022		2,500		2,456		2,342
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,347		2,347
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,700		2,673		2,673
		Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,967		2,967
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,473		2,473
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
		Term Loan		15.25	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,236		1,236
Liqid, Inc. (2)(12)	Networking	Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,333		3,286		3,286
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,641		1,641
		Term Loan		13.25	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,667		1,613		1,613
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,421		2,421
		Term Loan		13.75	%	Prime		6.75	%		10.00	%		-			5.00	%	March 1, 2026		2,500		2,487		2,487
Decisyon, Inc. (12)	Software	Term Loan		16.93	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,295		3,295		3,295
Dropoff, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,347		6,347
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,859		5,859
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			3.50	%	August 1, 2026		2,500		2,436		2,436
Engage3, LLC (2)(12)	Software	Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,678		3,678
		Term Loan		13.25	%	Prime		6.25	%		9.75	%		-			4.50	%	July 1, 2027		3,750		3,718		3,718
Groundspeed Analytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,798		4,798
		Term Loan		13.00	%	Prime		5.50	%		11.00	%		18.00	%		3.00	%	December 1, 2026		5,000		4,948		4,948
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		10,000		9,826		9,826
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
		Term Loan		13.00	%	Prime		5.50	%		10.25	%		-			4.00	%	April 1, 2026		5,000		4,913		4,913
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		5,000		4,947		4,947
		Term Loan		14.00	%	Prime		6.50	%		9.75	%		-			2.50	%	March 1, 2026		2,500		2,474		2,474
Lytics, Inc. (2)(12)	Software	Term Loan		13.00	%	Prime		6.00	%		9.25	%		-			3.00	%	July 1, 2025		2,500		2,396		2,396
		Term Loan		13.00	%	Prime		6.00	%		12.25	%		-			3.00	%	December 1, 2026		1,250		1,231		1,231
Reputation Institute, Inc. (2)(12)	Software	Term Loan		14.25	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,932		4,932
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,870		4,870
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
		Term Loan		13.25	%	Prime		5.75	%		9.75	%		-			5.00	%	August 1, 2026		5,000		4,933		4,933
Supply Network Visibility Holdings LLC (2)(12)	Software	Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,472		3,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
		Term Loan		13.50	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,472		2,472
Total Non-Affiliate Debt Investments — Technology																							268,468		259,366
Non-Affiliate Debt Investments — Healthcare information and services — 8.1% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,385		2,385
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		2,500		2,473		2,473
		Term Loan		13.50	%	Prime		6.00	%		9.25	%		-			3.50	%	June 1, 2026		5,000		4,946		4,946
Secure Transfusion Services, Inc. (2)(12)(13)	Other Healthcare	Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	October 1, 2025		4,943		4,943		1,668
		Term Loan		13.25	%	Prime		5.75	%		9.00	%		-			4.00	%	December 31, 2025		2,500		2,467		832
BrightInsight, Inc. (2)(12)	Software	Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		7,000		6,619		6,619
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
		Term Loan		12.50	%	Prime		5.50	%		9.50	%		-			3.00	%	August 1, 2027		3,500		3,448		3,448
Total Non-Affiliate Debt Investments — Healthcare information and services																							30,729		25,819
*Total Non- Affiliate Debt Investments*																							701,074		686,458

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 9.4% (8)
Non-Affiliate Warrants — Life Science — 3.1% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		7,404		214		335
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		53		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		263
Evelo Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		463,915		126		125
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		47,452		366		—
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		66		—
IMV Inc. (2)(5)(12)(14)	Biotechnology	Common Stock Warrant		39,774		67		—
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		51		60
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		103,679		64		162
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		3,024
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		203,017		399		648
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		14
Stealth Biotherapeutics Inc. (2)(12)	Biotechnology	Common Stock Warrant		318,181		264		37
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		3
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,200
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		48		31
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		84		1,864
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		209
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		179
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		226
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		150
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		394
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		113
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		809,931		194		385
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		233,993		83		101
Robin Healthcare, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		86,066		16		16
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		40		46
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		98		123
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		1
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		83
Total Non-Affiliate Warrants — Life Science						4,197		9,792
Non-Affiliate Warrants — Sustainability — 0.6% (8)
Aerofarms, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		201,537		61		74
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		55
Nexii Building Solutions, Inc. (2)(12)(14)	Other Sustainability	Common Stock Warrant		204,832		488		1,061
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		361
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		268
Total Non-Affiliate Warrants — Sustainability						928		1,819

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Technology — 5.1% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		46		67
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		139		3,265
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		173
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		64
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		26		—
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,069
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		20		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		125
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		31,966		56		233
Havenly, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		1,312,500		2,947		2,947
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		37
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		1,261,253		197		17
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		429
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		325		534
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		22
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		42
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		909
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		407
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		357
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		802
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		243
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,610
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		69
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		197
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		147,361		60		3
Groundspeed Analytics, Inc. (2)(12)	Software	Preferred Stock Warrant		86,300		6		6
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		296
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		41
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		312
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		80,197		40		44
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		39
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		682,034		46		99
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		1
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		133
Supply Network Visibility Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		83
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		12
Total Non-Affiliate Warrants — Technology						9,249		16,148
*Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)*
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		54
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		102		1,370
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		47		—
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		160		170
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		359
Total Non-Affiliate Warrants — Healthcare information and services						416		1,953
*Total Non-Affiliate Warrants*						14,790		29,712
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						1,200		1,300
Non-Affiliate Equity — 0.8% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Common Stock		32,831		356		356
Getaround, Inc. (2)(5)	Consumer-related Technologies	Common Stock		87,082		253		57
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Tigo Energy, Inc. (2)	Other Sustainability	Preferred		22,313		8		27
Branded Online, Inc. (2)(5)	Software	Common Stock		108,004		1,079		83
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
*Total Non-Affiliate Equity*						4,184		2,556
*Total Non-Affiliate Portfolio Investment Assets*					$	721,248	$	720,026
*Total Portfolio Investment Assets — 226.1% (8)*					$	721,248	$	720,026

Note 9 - Financial Instruments With Off-balance-sheet Risk

12 Months Ended

Dec. 31, 2023

Financial Instruments Disclosure [Text Block]

Note 9. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $180.5 million and $190.0 million as of December 31, 2023 and 2022, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

The following table provides the Company’s unfunded commitments by portfolio company as of December 31, 2023 and 2022:

	*December 31, 2023*				*December 31, 2022*
			*Fair Value of*				*Fair Value of*
			*Unfunded*				*Unfunded*
	*Principal*		*Commitment*		*Principal*		*Commitment*
	*Balance*		*Liability*		*Balance*		*Liability*
	(In thousands)				(In thousands)
BrightInsight, Inc.	$	15,500	$	241	$	21,000	$	278
Britecore Holdings, Inc.		5,000		72		5,000		66
Candesant Biomedical Corporation		10,000		151		—		—
Castle Creek Biosciences		—		—		4,000		72
Divergent Technologies, Inc.		11,250		118		22,500		236
Elligo Healthcare Research, Inc.		15,000		194		—		—
Engage3, LLC		—		—		8,000		40
Groundspeed Analytics, Inc.		—		—		15,000		150
Hound Labs, Inc.		—		—		7,500		88
KSQ Therapeutics, Inc.		—		—		10,000		100
Lytics, Inc.		—		—		5,000		65
MicroTransponder, Inc.		22,500		—		—		—
Mirantis, Inc.		15,000		136		—		—
Native Microbials, Inc.		—		—		7,500		72
Optoro, Inc.		6,250		—		15,000		38
Parse Biosciences, Inc.		15,000		251		—		—
PDS Biotechnology Corporation		—		—		10,000		158
Robin Healthcare, Inc.		—		—		10,000		100
SafelyYou, Inc.		20,000		270		—		—
Scientia Vascular, Inc.		—		—		10,000		110
Slingshot Aerospace, Inc.		—		—		5,000		64
Sonex Health, Inc.		15,000		176		—		—
Supply Network Visibility Holdings, LLC		10,000		35		—		—
Swift Health Systems Inc.		—		—		25,500		105
Tallac Therapeutics, Inc.		10,000		229		—		—
Temperpack Technologies, Inc.		—		—		9,000		19
Viken Detection Corporation		10,000		160		—		—
Total	$	180,500	$	2,033	$	190,000	$	1,761

The table above also provides the fair value of the Company’s unfunded commitment liability as of December 31, 2023 and 2022 which totaled $2.0 million and $1.8 million, respectively. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2022
Unrealized Gain (Loss) on Investments	$ (48,780)	$ (5,552)	$ 3,205
Fair Value, Inputs, Level 1 [Member] \| Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	100
Fair Value, Inputs, Level 1 [Member] \| Debt Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	5,000
Fair Value, Inputs, Level 1 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		1,300
Fair Value, Inputs, Level 3 [Member] \| Equity Securities [Member]
Unrealized Gain (Loss) on Investments	(1,600)	(400)
Fair Value, Inputs, Level 3 [Member] \| Debt [Member]
Unrealized Gain (Loss) on Investments	(48,400)	(21,000)
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		10
Unrealized Gain (Loss) on Investments	$ (5,300)	2,600
Fair Value, Inputs, Level 2 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3		$ 40
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 23.99
The 2026 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 55,200
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 24.5
The 2027 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure	$ 56,400
Asset-backed Notes 2022 [Member] \| Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure	$ 100,000
Measurement Input, Hypothetical Market Yields [Member]
Debt Instrument, Measurement Input				0.25

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (decrease) increase in net assets resulting from operations	$ (17,185)	$ 21,151	$ 27,782
Adjustments to reconcile net (decrease) increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs	1,852	1,604	1,091
Net realized loss on investments	29,702	9,484	3,248
Net realized loss on extinguishment of debt	151	0	395
Net unrealized depreciation (appreciation) on investments	48,780	5,552	(3,205)
Purchase of investments	(218,689)	(421,978)	(344,445)
Principal payments received on investments	152,293	95,871	188,010
Payment-in-kind interest on investments	(8,433)	0	0
Proceeds from sale of investments	11,066	49,964	52,954
Equity received in settlement of fee income	(89)	0	0
Warrants received in settlement of fee income	(80)	0	0
Changes in assets and liabilities:
Decrease (increase) in interest receivable	1,773	(3,417)	(173)
Increase in end-of-term payments	(2,035)	(4,452)	(1,652)
Decrease in unearned income	(3,700)	(394)	(1,295)
Increase in other assets	(650)	(156)	(394)
Increase in other accrued expenses	1,393	758	509
(Decrease) increase in base management fee payable	(13)	359	143
(Decrease) increase in incentive fee payable	(1,392)	(623)	1,040
Net cash used in operating activities	(5,256)	(246,277)	(75,992)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs	65,093	84,603	30,086
Advances on Credit Facilities	104,250	199,000	127,000
Repayment of Credit Facilities	(35,000)	(149,500)	(45,000)
Debt issuance costs	(735)	(4,364)	(2,645)
Distributions paid	(40,523)	(29,847)	(24,551)
Net cash provided by financing activities	50,512	229,462	75,515
Net increase (decrease) in cash, cash equivalents and restricted cash	45,256	(16,815)	(477)
Cash, cash equivalents and restricted cash:
Beginning of period	30,466	47,281	47,758
End of period	75,722	30,466	47,281
Supplemental disclosure of cash flow information:
Cash paid for interest	26,880	17,028	10,706
Supplemental non-cash investing and financing activities:
Refinanced debt investment balances	32,500	30,625	0
Warrant investments received and recorded as unearned income	2,683	5,616	3,355
Distributions payable	11,011	9,159	6,365
End-of-term payments receivable	11,816	9,690	5,238
Non-cash income	17,123	6,314	4,580
Cash	46,630	20,612	38,054
Investments in money market funds	26,450	7,066	7,868
Restricted investments in money market funds	2,642	2,788	1,359
Total cash, cash equivalents and restricted cash	75,722	30,466	47,281
The 2027 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of Notes	0	57,500	0
The 2026 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of Notes	0	0	57,500
Asset-backed Notes 2022 [Member]
Cash flows from financing activities:
Proceeds from issuance of Notes	0	100,000	0
Asset-backed Notes 2019 [Member]
Cash flows from financing activities:
Repayment of notes	(42,573)	(27,930)	(29,500)
The 2022 Notes [Member]
Cash flows from financing activities:
Repayment of notes	$ 0	$ 0	$ (37,375)

Consolidated Statements of Changes in Net Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Common Stock Outstanding [Member]
Balance (in shares)	27,753,373	21,217,460	19,286,356
Issuance of common stock, net of offering costs (in shares)	5,498,830	6,482,684	1,907,234
Issuance of common stock under dividend reinvestment plan (in shares)	115,186	53,229	23,870
Balance (in shares)	33,367,389	27,753,373	21,217,460
Common Stock [Member]
Balance	$ 29	$ 22	$ 19
Issuance of common stock, net of offering costs	7	7	3
Net investment income, net of excise tax	0	0	0
Net realized gain (loss) on investments	0	0	0
Net realized loss on extinguishment of debt			0
Net unrealized appreciation (depreciation) on investments	0	0	0
Issuance of common stock under dividend reinvestment plan	0	0	0
Distributions declared	0	0	0
Reclassification of permanent tax differences (Note 2)	0	0	0
Balance	36	29	22
Additional Paid-in Capital [Member]
Balance	385,921	301,359	271,287
Issuance of common stock, net of offering costs	65,086	84,596	30,083
Net investment income, net of excise tax	0	0	0
Net realized gain (loss) on investments	0	0	0
Net realized loss on extinguishment of debt			0
Net unrealized appreciation (depreciation) on investments	0	0	0
Issuance of common stock under dividend reinvestment plan	1,432	681	390
Distributions declared	0	0	0
Reclassification of permanent tax differences (Note 2)	(1,490)	(715)	(401)
Balance	450,949	385,921	301,359
Retained Earnings [Member]
Balance	(67,502)	(56,046)	(58,709)
Issuance of common stock, net of offering costs	0	0	0
Net investment income, net of excise tax	61,448	36,187	28,220
Net realized gain (loss) on investments	(29,702)	(9,484)	(3,248)
Net realized loss on extinguishment of debt	(151)		(395)
Net unrealized appreciation (depreciation) on investments	(48,780)	(5,552)	3,205
Issuance of common stock under dividend reinvestment plan	0	0	0
Distributions declared	(43,807)	(33,322)	(25,520)
Reclassification of permanent tax differences (Note 2)	1,490	715	401
Balance	(127,004)	(67,502)	(56,046)
Balance	318,448	245,335	212,597
Issuance of common stock, net of offering costs	65,093	84,603	30,086
Net investment income, net of excise tax	61,448	36,187	28,220
Net realized gain (loss) on investments	(29,702)	(9,484)	(3,248)
Net realized loss on extinguishment of debt	(151)	0	(395)
Net unrealized appreciation (depreciation) on investments	(48,780)	(5,552)	3,205
Issuance of common stock under dividend reinvestment plan	1,432	681	390
Distributions declared	(43,807)	(33,322)	(25,520)
Reclassification of permanent tax differences (Note 2)	0	0	0
Balance	$ 323,981	$ 318,448	$ 245,335

Note 9 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Unfunded commitments, principal balance	$ 180,500	$ 190,000
Fair value of unfunded commitment liability	2,033	1,761
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	15,500	21,000
Fair value of unfunded commitment liability	241	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000	5,000
Fair value of unfunded commitment liability	72	66
Candesant Biomedical Corporation [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	151	0
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	0	4,000
Fair value of unfunded commitment liability	0	72
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	11,250	22,500
Fair value of unfunded commitment liability	118	236
Elligo Healthcare Research, Inc. [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	194	0
Engage3, LLC [Member]
Unfunded commitments, principal balance	0	8,000
Fair value of unfunded commitment liability	0	40
Groundspeed Analytics, Inc. [Member]
Unfunded commitments, principal balance	0	15,000
Fair value of unfunded commitment liability	0	150
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	88
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	0	5,000
Fair value of unfunded commitment liability	0	65
MicroTransponder, Inc. [Member]
Unfunded commitments, principal balance	22,500	0
Fair value of unfunded commitment liability	0	0
Mirantis, Inc [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	136	0
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	0	7,500
Fair value of unfunded commitment liability	0	72
Optoro, Inc. [Member]
Unfunded commitments, principal balance	6,250	15,000
Fair value of unfunded commitment liability	0	38
Parse Biosciences, Inc. [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	251	0
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	158
Robin Healthcare, Inc. [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	100
SafelyYou, Inc [Member]
Unfunded commitments, principal balance	20,000	0
Fair value of unfunded commitment liability	270	0
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	0	10,000
Fair value of unfunded commitment liability	0	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	0	5,000
Fair value of unfunded commitment liability	0	64
Sonex Health, Inc. [Member]
Unfunded commitments, principal balance	15,000	0
Fair value of unfunded commitment liability	176	0
Supply Network Visibility Holdings, LLC [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	35	0
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	0	25,500
Fair value of unfunded commitment liability	0	105
Tallac Therapeutics, Inc [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	229	0
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	0	9,000
Fair value of unfunded commitment liability	0	19
Viken Detection Corporation [Member]
Unfunded commitments, principal balance	10,000	0
Fair value of unfunded commitment liability	$ 160	$ 0

Consolidated Statements of Assets and Liabilities (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Investments at cost	$ 759,182	$ 721,248
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	33,534,854	27,920,838
Common stock, shares outstanding (in shares)	33,367,389	27,753,373
Investment, Unaffiliated Issuer [Member]
Investments at cost	$ 716,077	$ 721,248
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments at cost	28,677	0
Investment, Affiliated Issuer, Controlled [Member]
Investments at cost	$ 14,428	$ 0

Note 6 - Fair Value

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Text Block]

Note 6. Fair value

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input from the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1

Quoted prices in active markets for identical assets and liabilities.

Level 2

Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:

●

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

●

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

●

Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	*December 31, 2023*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Debt investments	$	—	$	—	$	670,172	$	670,172
Warrant investments		—		1,619		22,975		24,594
Other investments		—		—		6,430		6,430
Equity investments		608		—		7,281		7,889
Total investments	$	608	$	1,619	$	706,858	$	709,085

	*December 31, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Debt investments	$	—	$	—	$	686,458	$	686,458
Warrant investments		—		3,567		26,145		29,712
Other investments		—		—		1,300		1,300
Equity investments		140		—		2,416		2,556
Total investments	$	140	$	3,567	$	716,319	$	720,026

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company's investments as of December 31, 2023 and 2022. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2023:

*December 31, 2023*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	617,529	Discounted Expected Future Cash Flows	Hypothetical Market Yield	11% – 24%		15	%

		52,643	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 100%		50	%

Warrant investments		22,913	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	64.95
				Average Industry Volatility	25%		25	%
				Marketability Discount	0% – 20%		18	%
				Estimated Time to Exit (in years)	1 to 5		3
		62	Expected Proceeds	Price Per Share	$0.25	$	0.25

Other investments		6,430	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	30% – 100%		81	%

Equity investments		7,281	Last Equity Financing	Price Per Share	0.566 –215.0303	$	17.15

Total Level 3 investments	$	706,858

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

*December 31, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	669,617	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 22%		14	%

		16,545	Multiple Probability Weighted Cash Flow Model	Probability Weighting	10% - 75%		31	%

		296	Convertible Note Analysis	Price Per Share	$168.93	$	168.93

Warrant investments		26,145	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	58.52
				Average Industry Volatility	28%		28	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 5		3

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,416	Last Equity Financing	Price Per Share	$1.00– $215.03	$	26.93

Total Level 3 investments	$	716,319

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On December 31, 2023, the closing price of the 2026 Notes on the New York Stock Exchange was $23.99 per note and had an aggregate fair value of $55.2 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On December 31, 2023, the closing price of the 2027 Notes on the New York Stock Exchange was $24.50 per note and had an aggregate fair value of $56.4 million. Therefore, the Company has categorized this borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on December 31, 2023, the 2022 Asset-Backed Notes (as defined in Note 7) were trading at par value, or $100.0 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the year ended December 31, 2023:

	*Year ended December 31, 2023*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319
Purchase of investments		217,285			—			1,260			144			218,689
Warrants and equity received and classified as Level 3		—			2,763			89			—			2,852
Principal payments received on investments		(151,777	)		—			—			(516	)		(152,293	)
Payment-in-kind interest on investments		8,433			—			—			—			8,433
Proceeds from sale of investments		(9,565	)		(1,495	)		(6	)		—			(11,066	)
Net realized (loss) gain on investments		(29,146	)		1,003			(121	)		—			(28,264	)
Unrealized depreciation included in earnings		(35,564	)		(5,436	)		(2,496	)		(652	)		(44,148	)
Transfer out of Level 3		(5,000	)		—			(111	)		—			(5,111	)
Transfer out of debt and warrant investments		(12,399	)		(5	)		6,250			6,154			—
Other		1,447			—			—			—			1,447
Level 3 assets, end of period	$	670,172		$	22,975		$	7,281		$	6,430		$	706,858

During the year ended December 31, 2023, there were two transfers out of Level 3. One transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 1 upon the portfolio company becoming a public company. One transfer related to debt investments held in one portfolio company with an aggregate fair value of $5.0 million that were transferred to Level 1 upon the conversion into shares of common stock of a public company.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at December 31, 2023 includes $48.4 million in unrealized depreciation on debt and other investments, $5.3 million in unrealized depreciation on warrant investments, and $1.6 million in unrealized depreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the year ended December 31, 2022:

	*Year ended December 31, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		421,372			—			606			—			421,978
Warrants and equity received and classified as Level 3		—			5,664			8			—			5,672
Principal payments received on investments		(95,558	)		—			—			(313	)		(95,871	)
Proceeds from sale of investments		(49,371	)		(464	)		—			—			(49,835	)
Net realized (loss) gain on investments		(8,221	)		264			—			(1,137	)		(9,094	)
Unrealized (depreciation) appreciation included in earnings		(10,044	)		2,215			(401	)		1,350			(6,880	)
Transfer out of Level 3		—			(1,371	)		—			—			(1,371	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(5,837	)		—			—			—			(5,837	)
Level 3 assets, end of period	$	686,458		$	26,145		$	2,416		$	1,300		$	716,319

During the year ended December 31, 2022, there were three transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.04 million that was transferred to Level 2 upon the portfolio company becoming a public company. Two transfers out of Level 3 related to the conversion of warrants to equity held in two portfolio companies with an aggregate fair value of $1.3 million that were transferred to Level 1 upon the portfolio companies becoming a public company. During the year ended December 31, 2022, there was one transfer in to Level 3. The transfer related to warrants held in one portfolio company with an aggregate fair value of less than $0.01 million that was transferred to Level 3 upon the portfolio company becoming a private company.

The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 investments still held at December 31, 2022 includes $21.0 million in unrealized depreciation on debt and other investments, $2.6 million in unrealized appreciation on warrant investments, and $0.4 million in unrealized depreciation on equity investments.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of December 31, 2023 and 2022, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

Market risk

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item *9B.* *Other Information* None
Rule 10b5-1 Arrangement Terminated [Flag]	false
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2023	Feb. 26, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 382,300,000
Entity Common Stock, Shares Outstanding		33,397,825
Auditor Firm ID	49
Auditor Name	RSM US LLP
Auditor Location	Hartford, Connecticut
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member]
$ in Thousands

Dec. 31, 2023

USD ($)

Dec. 31, 2022

USD ($)

$ 706,858

$ 716,319

^[1]

0.81

Minimum [Member]

0.30

Maximum [Member]

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member]

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member]

$ 617,529

$ 669,617

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member]

0.11

0.03

Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member]

0.24

0.22

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member]

^[1]

0.15

0.14

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member]

$ 52,643

$ 16,545

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member]

0.20

0.10

Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]

0.75

Debt [Member] | Black-scholes Valuation Model [Member]

^[1]

0.50

0.31

Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]

$ 26,145

Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member]

0.28

Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]

0.20

Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]

Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]

Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]

1,899

Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]

^[1]

58.52

Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member]

^[1]

0.28

Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]

^[1]

0.20

Debt [Member] | Convertible Note Analysis [Member]

^[1]

Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member]

$ 296

Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

168.93

Warrant [Member] | Black-scholes Valuation Model [Member]

^[1]

168.93

Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member]

$ 22,913

Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member]

0.25

Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member]

Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member]

^[1]

0.18

Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member]

Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member]

1,899

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member]

^[1]

64.95

Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member]

^[1]

0.25

Warrant [Member] | Expected Proceeds [Member]

^[1]

Warrant [Member] | Expected Proceeds [Member] | Measurement Input, Share Price [Member]

$ 62

Warrant [Member] | Expected Proceeds [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

0.25

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member]

^[1]

0.25

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member]

$ 6,430

$ 1,300

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member]

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member]

0.25

Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member]

^[1]

Equity Securities [Member] | Last Equity Financing [Member]

^[1]

0.25

Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member]

$ 7,281

$ 2,416

Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member]

0.56

Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member]

215.03

^[1]

17.15

26.93

[1]	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Note 11 - Distributions (Tables)

12 Months Ended

Dec. 31, 2023

Dividends Declared [Table Text Block]

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Year Ended December 31, 2023
10/27/2023	2/16/24	3/15/24	$	0.11	$	—		—	$	—
10/27/2023	1/18/24	2/14/24		0.11		3,462		15,873		210
10/27/2023	12/19/23	1/16/24		0.11		3,472		14,563		199
10/27/2023	11/17/23	12/15/23		0.05		1,574		7,137		93
7/28/2023	11/17/23	12/15/23		0.11		3,463		15,701		206
7/28/2023	10/18/23	11/15/23		0.11		3,493		14,022		173
7/28/2023	9/19/23	10/16/23		0.11		3,445		15,067		184
4/28/2023	8/17/23	9/15/23		0.11		3,458		8,665		106
4/28/2023	7/18/23	8/15/23		0.11		3,427		8,307		105
4/28/2023	6/16/23	7/14/23		0.11		3,434		7,424		96
2/23/2023	5/18/23	6/14/23		0.11		3,087		7,128		86
2/23/2023	4/18/23	5/16/23		0.11		3,068		6,705		84
2/23/2023	3/17/23	4/14/23		0.11		3,035		6,894		81
			$	1.37	$	38,418		127,486	$	1,623
Year Ended December 31, 2022
10/28/2022	2/17/23	3/15/23	$	0.11	$	3,040		6,764	$	75
10/28/2022	1/18/23	2/15/23		0.11		3,021		5,754		74
10/28/2022	12/19/22	1/13/23		0.11		2,978		5,618		69
10/28/2022	11/17/22	12/15/22		0.05		1,319		2,171		27
7/29/2022	11/17/22	12/15/22		0.10		2,638		4,341		57
7/29/2022	10/18/22	11/15/22		0.10		2,580		4,621		60
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	1.28	$	32,659		61,859	$	754

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
May 16, 2024	May 17, 2024	June 14, 2024	$	0.11
April 17, 2024	April 18, 2024	May 15, 2024	$	0.11
March 18, 2024	March 19, 2024	April 16, 2024	$	0.11

Ex-Dividend Date		*Record Date*		*Payment Date*		*Distributions Declared*
March 18, 2024		March 19, 2024		April 16, 2024		$	0.05

Note 5 - Transactions With Affiliated Companies (Details Textual)	Dec. 31, 2023
Cadrenal Therapeutics, Inc. [Member] \| Investment, Unaffiliated Issuer [Member]
Investment Owned, Net Assets, Percentage	5.00%

Percentage of investment owned to net assets.

Note 7 - Borrowings (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

May 24, 2023

Feb. 25, 2022

Jun. 22, 2021

Apr. 24, 2021

Apr. 21, 2020

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Jun. 29, 2023

Nov. 09, 2022

Jun. 15, 2022

Mar. 30, 2021

Dec. 31, 2020

Dec. 31, 2019

Sep. 15, 2019

Aug. 13, 2019

Dec. 31, 2018

Dec. 31, 2017

Oct. 11, 2017

Sep. 29, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

$ 2,642

$ 2,788

^[1]

466,000

439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

$ 95,375

$ 96,000

$ 115,546

$ 81,753

Interest Paid, Excluding Capitalized Interest, Operating Activities

615,000

582,573

$ 26,880

$ 17,028

10,706

Key Facility [Member]

Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature

$ 150,000

Line of Credit Facility, Maximum Borrowing Capacity

$ 300,000

Line of Credit Facility, Advance Rate of Eligible Debt Investments

60.00%

Long-Term Debt, Weighted Average Interest Rate, over Time

8.45%

5.33%

Line of Credit Facility, Unused Capacity, Commitment Fee Percentage

0.50%

Line of Credit Facility, Current Borrowing Capacity

$ 80,000

$ 120,000

Line of Credit Facility, Remaining Borrowing Capacity

25,000

40,200

70,000

5,000

Key Facility [Member] | London Interbank Offered Rate (LIBOR) 1 [Member]

$ 150,000

$ 125,000

Key Facility [Member] | Prime Rate [Member]

3.25%

Debt Instrument, Variable Rate

0.25%

8.50%

7.50%

NYL Facility [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 250,000

$ 100,000

Line of Credit Facility, Current Borrowing Capacity

$ 69,000

$ 23,200

Line of Credit Facility, Remaining Borrowing Capacity

17,400

23,200

Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature

$ 200,000

Line of Credit Facility, Advance Rate

67.00%

Line of Credit Facility, Change in Maximum Borrowing Capacity

$ 50,000

$ 100,000

Line of Credit Facility, Interest Rate at Period End

4.60%

Long-Term Line of Credit

$ 181,000

$ 176,800

5.96%

5.57%

$ 1,400

$ 1,000

181,000

176,750

NYL Facility [Member] | USD Mid-market Swap Rate [Member]

250,000

200,000

NYL Facility [Member] | Three Year I Curve [Member]

3.00%

Asset-backed Notes 2019 [Member]

3.50%

4.21%

Payments of Debt Issuance Costs

600

200

42,573

Asset-backed Notes 2022 [Member]

42,573

$ 160,000

7.56%

1,300

1,200

100,000

The 6.25 % Notes Due 2022 [Member]

100,000

$ 157,800

6.25%

Additional 2022 Notes [Member]

$ 32,500

$ 4,900

The 2022 Notes [Member]

Payments of Debt Issuance Costs

6.25%

$ 400

Debt Instrument, Convertible, Conversion Price (in dollars per share)

^[2]

37,375

$ 25

Repayments of Debt

37,400

Interest Paid, Excluding Capitalized Interest, Operating Activities

$ 300

The 2026 Notes [Member]

4.875%

^[2]

57,500

The 2026 Notes Underwriter Option [Member]

57,500

$ 57,500

Debt Instrument, Convertible, Conversion Price (in dollars per share)

$ 7,500

$ 25

The 2027 Notes [Member]

6.25%

^[2]

57,500

$ 0

The 2027 Notes Underwriter Option [Member]

$ 57,500

$ 50,000

Debt Instrument, Convertible, Conversion Price (in dollars per share)

$ 7,500

$ 25

Minimum [Member]

Asset Coverage to Borrowings, Ratio, Percent

150.00%

Minimum [Member] | Key Facility [Member] | London Interbank Offered Rate (LIBOR) 1 [Member]

Minimum [Member] | Key Facility [Member] | Prime Rate [Member]

1.00%

Minimum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member]

4.25%

Asset Coverage to Borrowings, Ratio, Percent

3.55%

Maximum [Member]

170.00%

Maximum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member]

5.15%

[1]	Total amount of senior securities outstanding at the end of the period presented.
[2]	Total amount of senior securities outstanding at the end of the period presented.

Consolidated Schedule of Investments - Investments (Details) (Parentheticals)	Dec. 31, 2023	Dec. 31, 2022
NAV %	218.90%	226.10%
Investment, Affiliated Issuer, Controlled [Member] \| Consumer-related Technologies [Member]
NAV %	1.60%
Investment, Affiliated Issuer, Controlled [Member] \| Consumer-related Technologies [Member] \| Debt Securities [Member]
NAV %	4.40%
Investment, Affiliated Issuer, Controlled [Member] \| Life Science [Member] \| Other Investments [Member]
NAV %	1.90%
Investment, Affiliated Issuer, Controlled [Member] \| Technology Sector [Member] \| Equity Securities [Member]
NAV %	0.90%
Investment, Affiliated Issuer, Noncontrolled [Member] \| Debt Securities [Member]
NAV %	0.30%
Investment, Affiliated Issuer, Noncontrolled [Member] \| Life Science [Member] \| Equity Securities [Member]
NAV %	0.00%
Investment, Affiliated Issuer, Noncontrolled [Member] \| Life Science [Member] \| Warrant [Member]
NAV %	0.00%
Investment, Unaffiliated Issuer [Member]
NAV %	214.20%	226.10%
Investment, Unaffiliated Issuer [Member] \| Debt Securities [Member]
NAV %	205.00%	215.50%
Investment, Unaffiliated Issuer [Member] \| Equity Securities [Member]
NAV %	1.50%	0.80%
Investment, Unaffiliated Issuer [Member] \| Warrant [Member]
NAV %	7.60%	9.40%
Investment, Unaffiliated Issuer [Member] \| Other Long-Term Investments [Member]
NAV %		0.40%
Investment, Unaffiliated Issuer [Member] \| Life Science [Member] \| Debt Securities [Member]
NAV %	75.60%	99.70%
Investment, Unaffiliated Issuer [Member] \| Life Science [Member] \| Warrant [Member]
NAV %		3.10%
Investment, Unaffiliated Issuer [Member] \| Life Science [Member] \| Other Investments [Member]
NAV %	0.10%
Investment, Unaffiliated Issuer [Member] \| Technology Sector [Member] \| Debt Securities [Member]
NAV %	83.30%	81.40%
Investment, Unaffiliated Issuer [Member] \| Technology Sector [Member] \| Warrant [Member]
NAV %	4.50%	5.10%
Investment, Unaffiliated Issuer [Member] \| Healthcare Information and Services Segment [Member] \| Debt Securities [Member]
NAV %	21.50%
Investment, Unaffiliated Issuer [Member] \| Healthcare Information and Services Segment [Member] \| Warrant [Member]
NAV %	0.60%
Investment, Unaffiliated Issuer [Member] \| Life Science Segment [Member] \| Warrant [Member]
NAV %	2.30%
Investment, Unaffiliated Issuer [Member] \| Sustainability Segment [Member] \| Debt Securities [Member]
NAV %	24.60%	26.30%
Investment, Unaffiliated Issuer [Member] \| Sustainability Segment [Member] \| Warrant [Member]
NAV %	0.20%	0.60%
Investment, Unaffiliated Issuer [Member] \| Healthcare Sector [Member] \| Debt Securities [Member]
NAV %		8.10%
Investment, Unaffiliated Issuer [Member] \| Healthcare Sector [Member] \| Warrant [Member]
NAV %		0.60%

Note 7 - Borrowings - Senior Securities (Details) - USD ($)
$ / shares in Units, $ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

^[1]

$ 466,000

$ 439,323

$ 260,250

$ 187,625

$ 154,375

$ 127,875

$ 95,375

$ 96,000

$ 115,546

$ 81,753

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 1,695

$ 1,725

$ 1,943

$ 2,133

$ 2,192

$ 2,050

$ 2,416

$ 2,450

$ 2,383

$ 2,691

^[3]

$ 0

The 2019 Notes [Member]

^[1]

$ 0

$ 33,000

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 0

$ 7,127

$ 8,342

$ 6,667

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 0

$ 25.42

$ 25.26

$ 25.64

Credit Facilities [Member]

^[5]

$ 251,000

$ 181,750

$ 132,250

$ 50,250

$ 17,000

$ 90,500

$ 58,000

$ 63,000

$ 68,000

$ 10,000

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 3,147

$ 4,169

$ 3,823

$ 7,965

$ 19,908

$ 2,896

$ 3,973

$ 3,733

$ 4,048

$ 22,000

^[3]

$ 0

The 2022-1 Securitization [Member]

^[1]

$ 100,000

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 7,900

$ 7,578

$ 0

^[3]

$ 0

Average market value per unit (in dollars per share)

^[4]

$ 0

The 2027 Notes [Member]

^[5]

$ 57,500

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 13,739

$ 13,179

$ 0

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 24.26

$ 24.09

$ 0

The 2019-1 Securitization [Member]

^[1]

$ 0

$ 42,573

$ 70,500

$ 100,000

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 0

$ 17,799

$ 7,171

$ 4,002

$ 3,384

$ 0

^[3]

$ 0

Average market value per unit (in dollars per share)

^[4]

$ 0

The 2026 Notes [Member]

^[5]

$ 57,500

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 13,739

$ 13,179

$ 8,793

$ 0

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 23.75

$ 24.45

$ 25.9

$ 0

The 2013-1 Securitization [Member]

^[1]

$ 0

$ 14,546

$ 38,753

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 0

$ 18,926

$ 5,677

^[3]

$ 0

Average market value per unit (in dollars per share)

^[4]

$ 0

The 2022 Notes [Member]

^[5]

$ 0

$ 37,375

$ 0

Involuntary Liquidation Preference (in dollars per share)

^[2]

$ 0

$ 10,708

$ 9,055

$ 7,014

$ 6,166

$ 0

^[3]

Average market value per unit (in dollars per share)

^[4]

$ 0

$ 24.6

$ 25.53

$ 25.52

$ 25.66

$ 0

[1]	Total amount of senior securities outstanding at the end of the period presented.
[2]	Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not represented by senior securities, to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per $1,000 of indebtedness.
[3]	The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “—” in this column indicates that the SEC expressly does not require this information to be disclosed for certain types of securities.
[4]	Not applicable to the Company’s credit facilities, 2013-1 Securitization, 2019-1 Securitization and 2022-1 Securitization because such securities are not registered for public trading.
[5]	Total amount of senior securities outstanding at the end of the period presented.

Note 13 - Financial Highlights (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Investment Company, Voluntary Fee Waived	$ 1.8

Note 10 - Concentrations of Credit Risk

12 Months Ended

Dec. 31, 2023

Concentration Risk Disclosure [Text Block]

Note 10. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from year to year as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments at cost represented 23% of total debt investments outstanding as of December 31, 2023 and 2022. The Company’s five largest debt investments at fair value represented 22% and 23% of total debt investments outstanding as of December 31, 2023 and 2022, respectively. No single debt investment represented more than 10% of the total debt investments at cost or fair value as of December 31, 2023 or 2022. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments at cost accounted for 17%, 15% and 17% of total interest and fee income on investments for the years ended December 31, 2023, 2022 and 2021, respectively. Interest income from the five largest debt investments at fair value accounted for 15%, 15% and 17% of total interest and fee income on investments for the years ended December 31, 2023, 2022 and 2021, respectively.

Note 13 - Financial Highlights (Tables)

12 Months Ended

Dec. 31, 2023

Investment Company, Financial Highlights [Table Text Block]

	*Year ended December 31,*
	*2023*				*2022*				*2021*				*2020*				*2019*
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56			$	11.02			$	11.83			$	11.64
Net investment income		1.98				1.46				1.41				1.18				1.52
Realized loss		(0.97	)			(0.38	)			(0.18	)			(0.84	)			(0.31	)
Unrealized (depreciation) appreciation on investments		(1.57	)			(0.22	)			0.16				0.02				0.24
Net (decrease) increase in net assets resulting from operations		(0.56	)			0.86				1.39				0.36				1.45
Distributions declared ⁽¹⁾		(1.37	)			(1.28	)			(1.25	)			(1.25	)			(1.20	)
From net investment income		(1.37	)			(1.28	)			(1.25	)			(1.25	)			(1.20	)
From net realized gain on investments		—				—				—				—				—
Return of capital		—				—				—				—				—
Other ⁽²⁾		0.17				0.33				0.40				0.08				(0.06	)
Net asset value at end of period	$	9.71			$	11.47			$	11.56			$	11.02			$	11.83
Per share market value, beginning of period	$	11.60			$	15.92			$	13.24			$	12.93			$	11.25
Per share market value, end of period	$	13.17			$	11.60				15.92				13.24				12.93
Total return based on a market value⁽³⁾		25.3	%			(19.3	)%			29.7	%			12.1	%			25.6	%
Shares outstanding at end of period		33,367,389				27,753,373				21,217,460				19,286,356				15,563,290
Ratios to average net assets:
Expenses without incentive value ⁽⁴⁾		14.1	%			11.5	%			10.5	%			10.0	%			10.8	%
Incentive fees⁽⁴⁾		0.9	%			2.6	%			3.1	%			2.6	%			3.2	%
Net expenses ⁽⁴⁾		15.0	%			14.1	%			13.6	%			12.6	%			14.0	%
Net investment income with incentive fees⁽⁴⁾		18.2	%			12.1	%			12.2	%			10.4	%			12.8	%
Ratios, without waivers, to average net assets:
Expenses without incentive value⁽⁴⁾		14.1	%			11.5	%			10.5	%			10.0	%			10.8	%
Incentive fees ⁽⁴⁾		0.9	%			2.6	%			3.1	%			2.6	%			4.4	%
Net expenses ⁽⁴⁾		15.0	%			14.1	%			13.6	%			12.6	%			15.2	%
Net investment income with incentive fees⁽⁴⁾		18.2	%			12.1	%			12.2	%			10.4	%			11.6	%
Net assets at the end of the period	$	323,981			$	318,448			$	245,335			$	212,597			$	184,055
Average net asset value	$	336,915			$	299,182			$	231,215			$	199,302			$	160,008
Average debt per share	$	13.93			$	13.70			$	11.27			$	9.97			$	10.05
Portfolio turnover ratio		17.2	%	⁽⁵⁾		14.6	%	⁽⁵⁾		45.4	%	⁽⁵⁾		38.7	%	⁽⁵⁾		82.0	%	⁽⁶⁾

Note 11 - Distributions (Details Textual) - $ / shares		9 Months Ended	12 Months Ended
Note 11 - Distributions (Details Textual) - $ / shares	Oct. 27, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)			$ 1.37
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.11	$ 1.37	1.37	$ 1.28	$ 1.25
Taxable Earnings Per Share, Basic (in dollars per share)			2.01
Earnings Per Share, Basic, Undistributed (in dollars per share)			$ 1.25

Note 7 - Borrowings

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Text Block]

Note 7. Borrowings

The following table shows the Company’s borrowings as of December 31, 2023 and 2022:

	*December 31, 2023*							*December 31, 2022*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	150,000	$	70,000		$	80,000	$	125,000	$	5,000		$	120,000
NYL Facility		250,000		181,000			69,000		200,000		176,750			23,250
2019 Asset-Backed Notes		—		—			—		42,573		42,573			—
2022 Asset-Backed Notes		100,000		100,000			—		100,000		100,000			—
2027 Notes		57,500		57,500			—		57,500		57,500			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		615,000		466,000			149,000		582,573		439,323			143,250
Unamortized debt issuance costs attributable to term borrowings		—		(3,765	)		—		—		(5,245	)		—
Total borrowings outstanding, net	$	615,000	$	462,235		$	149,000	$	582,573	$	434,078		$	143,250

As of December 31, 2023, with certain limited exceptions the Company, as a BDC is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of December 31, 2023, the asset coverage for borrowed amounts was 170%.

Credit Facilities

Key Facility

The Company entered into the Key Facility with Key effective November 4, 2013. On June 29, 2023 the Company amended the Key Facility, among other things, to increase the commitment amount to $150 million and to increase the amount of the accordion feature which now allows for the potential increase in the total commitment amount to $300 million. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Company may request advances under the Key Facility through June 22, 2024 and the Key Facility is scheduled to mature on June 22, 2026. Through June 21, 2021, the interest rate on the Key Facility was based upon the one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. From and after June 30, 2021, the interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 8.50% and 7.50% on December 31, 2023 and 2022, respectively. The average interest rate for the years ended December 31, 2023 and 2022 was 8.45% and 5.33%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of December 31, 2023 and 2022, the Company had borrowing capacity under the Key Facility of $80.0 million and $120.0 million, respectively. At December 31, 2023 and 2022, $25.0 million and $40.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

NYL Facility

On April 21, 2020, the Company purchased all of the limited liability company interests in HSLFI. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility was based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility to, among other things, reduce the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings were priced at the three-year USD mid-market swap rate plus 3.00%.

On May 24, 2023, the Company amended its NYL Facility to, among other things, increase the commitment by $50.0 million to enable its wholly-owned subsidiary to issue up to $250.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2024 and the maturity date of all advances to June 2029. In addition, the amendment amended the interest rate for advances made after May 24, 2023, fixing the interest rate at the greater of (i) 4.60% and (ii) the Three Year I Curve plus 3.50%, with the interest rate to be reset on any advance date.

There were $181.0 million and $176.8 million in advances made by the NYL Noteholders as of December 31, 2023 and 2022, respectively. The interest rate as of December 31, 2023 and 2022 was 5.96% and 5.57%, respectively. As of December 31, 2023 and 2022, the Company had borrowing capacity under the NYL Facility of $69.0 million and $23.2 million, respectively. At December 31, 2023 and 2022, $17.4 million and $23.2 million, respectively, was available for borrowing, subject to existing terms and advance rates.

Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may be used to pay monthly interest and principal payments on the NYL Facility. The Company has segregated these funds and classified them as restricted investments in money market funds. At December 31, 2023 and 2022, there were approximately $1.4 million and $1.0 million, respectively, of restricted investments.

Securitizations

2019 Asset-Backed Notes

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2019 Asset-Backed Notes. The 2019 Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC. There was no change in the rating since August 13, 2019. The 2019 Asset-Backed Notes were repaid in full on November 22, 2023.

The 2019 Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and were backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and were to be serviced by the Company. Interest on the 2019 Asset-Backed Notes was paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the 2019 Asset-Backed Notes ended July 15, 2021 and the maturity date was September 15, 2027.

As of December 31, 2023, the 2019 Asset-Backed Notes were repaid in full. The Company accelerated $0.2 million of unamortized debt issuance costs related to the 2019 Asset-Backed Notes. As of December 31, 2022, the 2019 Asset-Backed Notes had an outstanding principal balance of $42.6 million.

Under the terms of the 2019 Asset-Backed Notes, the Company was required to maintain a reserve cash balance, funded through proceeds from the sale of the 2019 Asset-Backed Notes, which may have been used to pay monthly interest and principal payments on the 2019 Asset-Backed Notes. The Company had segregated these funds and classified them as restricted investments in money market funds. At December 31, 2022, there were approximately $0.6 million of restricted investments.

2022 Asset-Backed Notes

On November 9, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the 2022 Asset-Backed Notes. The 2022 Asset-Backed Notes were rated A by DBRS, Inc. There has been no change in the rating since November 9, 2022.

The 2022 Asset-Backed Notes were issued by the 2022‑1 Trust pursuant to a note purchase agreement, dated as of November 9, 2022, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2022 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 7.56% per annum. The reinvestment period of the 2022 Asset-Backed Notes ends November 15, 2024 and the maturity date is November 15, 2030.

As of December 31, 2023 and 2022, the 2022 Asset-Backed Notes had an outstanding principal balance of $100.0 million.

Under the terms of the 2022 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2022 Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the 2022 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At December 31, 2023 and 2022, there were approximately $1.3 million and $1.2 million, respectively, of restricted investments.

Unsecured Notes

2022 Notes

On September 29, 2017, the Company issued and sold an aggregate principal amount of $32.5 million of 6.25% notes due in 2022 and on October 11, 2017, pursuant to the underwriters’ 30-day option to purchase additional notes, the Company sold an additional $4.9 million of such notes (collectively, the “2022 Notes”). The 2022 Notes had a stated maturity of September 15, 2022 and were redeemable in whole or in part at the Company’s option at any time or from time to time on or after September 15, 2019 at a redemption price of $25 per security plus accrued and unpaid interest. The 2022 Notes bore interest at a rate of 6.25% per year, payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2022 Notes were the Company’s direct unsecured obligations and (i) ranked equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) were senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2022 Notes; (iii) were effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) were structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. On April 24, 2021 (the “Redemption Date”), the Company redeemed all of the issued and outstanding 2022 Notes in an aggregate principal amount of $37.4 million and paid accrued interest of $0.3 million. The Company accelerated $0.4 million of unamortized debt issuance costs related to the 2022 Notes. The 2022 Notes were delisted effective on the Redemption Date.

2026 Notes

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million in aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of December 31, 2023, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

2027 Notes

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30-day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of December 31, 2023, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

The following table shows information about our senior securities as of December 31, 2023, 2022, 2021, 2020, 2019, 2018, 2017, 2016, 2015 and 2014:

	*Total Amount*
	*Outstanding*				*Involuntary*		*Average*
	*Exclusive of*		*Asset*		*Liquidation*		*Market*
	*Treasury*		*Coverage*		*Preference*		*Value per*
Class and Year	*Securities(1)*		*per Unit(2)*		*per Unit(3)*		*Unit(4)*
	(In thousands, except unit data)
Credit facilities
2023	$	251,000	$	3,147		—		N/A
2022	$	181,750	$	4,169		—		N/A
2021	$	132,250	$	3,823		—		N/A
2020	$	50,250	$	7,965		—		N/A
2019	$	17,000	$	19,908		—		N/A
2018	$	90,500	$	2,896		—		N/A
2017	$	58,000	$	3,973		—		N/A
2016	$	63,000	$	3,733		—		N/A
2015	$	68,000	$	4,048		—		N/A
2014	$	10,000	$	22,000		—		N/A
2027 Notes
2023	$	57,500	$	13,739		—	$	24.26
2022	$	57,500	$	13,179		—	$	24.09
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2026 Notes
2023	$	57,500	$	13,739		—	$	23.75
2022	$	57,500	$	13,179		—	$	24.45
2021	$	57,500	$	8,793		—	$	25.90
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2022 Notes
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020	$	37,375	$	10,708		—	$	24.60
2019	$	37,375	$	9,055		—	$	25.53
2018	$	37,375	$	7,014		—	$	25.52
2017	$	37,375	$	6,166		—	$	25.66
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—

	Total Amount
	Outstanding				Involuntary		Average
	Exclusive of		Asset		Liquidation		Market
	Treasury		Coverage		Preference		Value per
Class and Year	Securities(1)		per Unit(2)		per Unit(3)		Unit(4)
	(In thousands, except unit data)
2019 Notes
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016	$	33,000	$	7,127		—	$	25.42
2015	$	33,000	$	8,342		—	$	25.26
2014	$	33,000	$	6,667		—	$	25.64
2022-1 Securitization
2023	$	100,000	$	7,900		—		N/A
2022	$	100,000	$	7,578		—		N/A
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2019-1 Securitization
2023	$	—	$	—		—		N/A
2022	$	42,573	$	17,799		—		N/A
2021	$	70,500	$	7,171		—		N/A
2020	$	100,000	$	4,002		—		N/A
2019	$	100,000	$	3,384		—		N/A
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015		—		—		—		—
2014		—		—		—		—
2013-1 Securitization
2023		—		—		—		—
2022		—		—		—		—
2021		—		—		—		—
2020		—		—		—		—
2019		—		—		—		—
2018		—		—		—		—
2017		—		—		—		—
2016		—		—		—		—
2015	$	14,546	$	18,926		—		N/A
2014	$	38,753	$	5,677		—		N/A
Total senior securities
2023	$	466,000	$	1,695		—		N/A
2022	$	439,323	$	1,725		—		N/A
2021	$	260,250	$	1,943		—		N/A
2020	$	187,625	$	2,133		—		N/A
2019	$	154,375	$	2,192		—		N/A
2018	$	127,875	$	2,050		—		N/A
2017	$	95,375	$	2,416		—		N/A
2016	$	96,000	$	2,450		—		N/A
2015	$	115,546	$	2,383		—		N/A
2014	$	81,753	$	2,691		—		N/A

(1)	Total amount of senior securities outstanding at the end of the period presented.

(2)

Asset coverage per unit is the ratio of the original cost less accumulated depreciation, amortization or impairment of the Company’s total consolidated assets, less all liabilities and indebtedness not represented by senior securities, to the aggregate amount of senior securities representing indebtedness. Asset coverage per unit is expressed in terms of dollar amounts per $1,000 of indebtedness.

(3)

The amount which the holder of such class of senior security would be entitled upon the voluntary liquidation of the applicable issuer in preference to any security junior to it. The “ — ” in this column indicates that the SEC expressly does not require this information to be disclosed for certain types of securities.

(4)	Not applicable to the Company’s credit facilities, 2013-1 Securitization, 2019‑1 Securitization and 2022-1 Securitization because such securities are not registered for public trading.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Note 5 - Transactions With Affiliated Companies (Tables)

12 Months Ended

Dec. 31, 2023

Investments in and Advances to Affiliates [Table Text Block]

					*Year ended December 31, 2023*
	*Fair value at*							*Transfers*					*Net*					*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*		*December 31,*		*Interest*
Company	*2022*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*		*2023*		*income*
	(In thousands)
Aulea Medical, Inc.	$	—	$	—	$	—		$	—		$	—	$	—		$	—	$	—	$	—
Cadrenal Therapeutics, Inc. (1)		—		—		—			(906	)		—		906			—		—		—
Evelo Biosciences, Inc.		—		—		(2,443	)		7,663			8		(5,006	)		—		222		277
		—		11		(3,667	)		11,509			11		(7,528	)		—		336		414
		—		—		(1,467	)		4,601			5		(3,006	)		—		133		166
		—		—		(1,467	)		4,598			3		(3,001	)		—		133		163
		—		—		(978	)		3,067			4		(2,005	)		—		88		114
		—		—		(978	)		3,067			4		(2,005	)		—		88		111
		—		—		—			5,000			—		(4,868	)		—		132		—
Total non-controlled affiliates	$	—	$	11	$	(11,000	)	$	38,599		$	35	$	(26,513	)	$	—	$	1,132	$	1,245

					Year ended December 31, 2022

	*Fair value at*							*Transfers*				*Net*				*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Discount*		*unrealized*		*Net realized*		*December 31,*		*Interest*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*Accretion*		*gain/(loss)*		*gain/(loss)*		*2022*		*income*
	(In thousands)
MVI (ABC) LLC fka StereoVision, Inc.		—		—		(30	)		—		—		—		30		—		—
Total non-controlled affiliates	$	—	$	—	$	(30	)	$	—	$	—	$	—	$	30	$	—	$	—

					*Year ended December 31, 2023*

	*Fair value at*									*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*				*Principal*					*in/(out) at*		*Discount*		*unrealized*			*Net realized*		*December 31,*		*Interest*
Company	*2022*		*Purchases*		*Payments*			*PIK*		*fair value*		*accretion*		*gain/(loss)*			*gain/(loss)*		*2023*		*income*
	(In thousands)
Better Place Forests Co.	$	—	$	61	$	—		$	213	$	1,675	$	5	$	1,385		$	—	$	3,339	$	225
		—		—		—			107		844		1		678			—		1,630		112
		—		1,250		—			—		2,061		—		(287	)		—		3,024		—
HIMV LLC		—		146		(516	)		—		6,154		—		446			—		6,230		—
Total controlled affiliates	$	—	$	1,457	$	(516	)	$	320	$	10,734	$	6	$	2,222		$	—	$	14,223	$	337

					*Year ended December 31, 2022*
	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Discount*		*unrealized*		*Net realized*			*December 31,*		*Interest*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*accretion*		*gain/(loss)*		*gain/(loss)*			*2022*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($)	Feb. 20, 2024	Feb. 07, 2024	Jan. 18, 2024	Jan. 09, 2024
BioVaxys Technology Corp. [Member] \| HIMV LLC [Member]
Proceeds from Sale of Productive Assets	$ 750,000
Disposal Group, Consideration, Stock	$ 250,000
Better Place Forests Co. [Member]
Payments to Acquire Investments				$ 800,000
Nexii Building Solutions, Inc [Member]
Payments to Acquire Investments			$ 900,000
Ceribell, Inc. [Member]
Payments to Acquire Investments		$ 14,000,000
Repayments of Debt		$ 11,300,000

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Management Fee Payable	$ 1,052	$ 1,065
Management Fee Expense	12,799	10,566	$ 7,617
Incentive Fee Payable	0	1,392
Administrative Fees Expense	$ 1,658	1,667	1,285
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2.00%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable	$ 1,100	1,100
Management Fee Expense	$ 12,800	10,600	7,600
Incentive Fee to Pre-incentive Net Investment Income	20.00%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7.00%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100.00%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Incentive Fee Expense	$ 3,100	7,700	7,100
Incentive Fee Cap and Deferral Mechanism Reduction to Expense	9,800	1,000
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	10,800
Incentive Fee Payable	0	1,400
Investment Management Agreement [Member] \| December 31, 2025 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	1,000
Investment Management Agreement [Member] \| March 31, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	200
Investment Management Agreement [Member] \| June 30, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	3,100
Investment Management Agreement [Member] \| September 30, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	3,500
Investment Management Agreement [Member] \| December 31, 2026 Expiration [Member]
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability	3,000
Administration Agreement [Member]
Administrative Fees Expense	1,700	1,700	$ 1,300
Administrative Fees Payable	$ 400	$ 600

Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 716,319	$ 457,557
Purchase of investments	218,689	421,978
Warrants and equity received and classified as Level 3	2,852	5,672
Principal payments received on investments	(152,293)	95,871
Payment-in-kind interest on investments	8,433
Proceeds from sale of investments	(11,066)	49,835
Net realized (loss) gain on investments	(28,264)	(9,094)
Unrealized (depreciation) appreciation included in earnings	(44,148)	(6,880)
Transfer out of Level 3	(5,111)	(1,371)
Transfer out of debt and warrant investments	0	0
Other	1,447	(5,837)
Balance	706,858	716,319
Principal payments received on investments	152,293	(95,871)
Proceeds from sale of investments	11,066	(49,835)
Debt [Member]
Balance	686,458	437,317
Purchase of investments	217,285	421,372
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(151,777)	95,558
Payment-in-kind interest on investments	8,433
Proceeds from sale of investments	(9,565)	49,371
Net realized (loss) gain on investments	(29,146)	(8,221)
Unrealized (depreciation) appreciation included in earnings	(35,564)	(10,044)
Transfer out of Level 3	(5,000)	0
Transfer out of debt and warrant investments	(12,399)	(3,200)
Other	1,447	(5,837)
Balance	670,172	686,458
Principal payments received on investments	151,777	(95,558)
Proceeds from sale of investments	9,565	(49,371)
Warrant [Member]
Balance	26,145	19,837
Purchase of investments	0	0
Warrants and equity received and classified as Level 3	2,763	5,664
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	(1,495)	464
Net realized (loss) gain on investments	1,003	264
Unrealized (depreciation) appreciation included in earnings	(5,436)	2,215
Transfer out of Level 3	0	(1,371)
Transfer out of debt and warrant investments	(5)	0
Other	0	0
Balance	22,975	26,145
Principal payments received on investments	(0)	0
Proceeds from sale of investments	1,495	(464)
Equity Securities [Member]
Balance	2,416	203
Purchase of investments	1,260	606
Warrants and equity received and classified as Level 3	89	8
Principal payments received on investments	0	0
Payment-in-kind interest on investments	0
Proceeds from sale of investments	(6)	0
Net realized (loss) gain on investments	(121)	0
Unrealized (depreciation) appreciation included in earnings	(2,496)	(401)
Transfer out of Level 3	(111)	0
Transfer out of debt and warrant investments	6,250	2,000
Other	0	0
Balance	7,281	2,416
Principal payments received on investments	(0)	0
Proceeds from sale of investments	6	0
Other Investments [Member]
Balance	1,300	200
Purchase of investments	144	0
Warrants and equity received and classified as Level 3	0	0
Principal payments received on investments	(516)	313
Payment-in-kind interest on investments	0
Proceeds from sale of investments	0	0
Net realized (loss) gain on investments	0	(1,137)
Unrealized (depreciation) appreciation included in earnings	(652)	1,350
Transfer out of Level 3	0	0
Transfer out of debt and warrant investments	6,154	1,200
Other	0	0
Balance	6,430	1,300
Principal payments received on investments	516	(313)
Proceeds from sale of investments	$ (0)	$ 0

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Investments at cost	$ 759,182	$ 721,248
Investments at fair value	709,085	720,026
Biotechnology Sector [Member]
Investments at cost	145,544	193,372
Investments at fair value	117,781	195,006
Medical Device Sector [Member]
Investments at cost	147,064	132,803
Investments at fair value	145,019	135,960
Communications Sector [Member]
Investments at cost	19,192	22,892
Investments at fair value	22,188	26,176
Consumer-related Sector [Member]
Investments at cost	105,669	121,961
Investments at fair value	101,327	114,050
Data Storage Sector [Member]
Investments at cost	417	476
Investments at fair value	418	1,316
Internet and Media Sector [Member]
Investments at cost	329	329
Investments at fair value	1,582	1,159
Networking Sector [Member]
Investments at cost	5,451	11,831
Investments at fair value	5,297	11,710
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,700	2,610
Semiconductor Sector [Member]
Investments at cost	45	56
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	164,133	120,157
Investments at fair value	160,749	118,716
Energy Efficiency [Member]
Investments at cost	111	8
Investments at fair value	13	27
Other Sustainability Sector [Member]
Investments at cost	98,906	84,633
Investments at fair value	80,370	85,524
Diagnostics Sector [Member]
Investments at cost	19,735	9,851
Investments at fair value	19,701	9,858
Other Healthcare Sector [Member]
Investments at cost	102	7,559
Investments at fair value	1,366	3,870
Software, Healthcare Information and Service [Member]
Investments at cost	50,899	13,735
Investments at fair value	50,574	14,044
Debt [Member]
Investments at cost	721,231	701,074
Investments at fair value	670,172	686,458
Warrant [Member]
Investments at cost	16,526	14,790
Investments at fair value	24,594	29,712
Other Debt Obligations [Member]
Investments at cost	6,982	1,200
Investments at fair value	6,430	1,300
Equity Securities [Member]
Investments at cost	14,443	4,184
Investments at fair value	$ 7,889	$ 2,556

Note 5 - Transactions With Affiliated Companies

12 Months Ended

Dec. 31, 2023

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 5. Transactions with affiliated companies

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2023 were as follows:

					*Year ended December 31, 2023*
	*Fair value at*							*Transfers*					*Net*					*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*		*December 31,*		*Interest*
Company	*2022*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*		*2023*		*income*
	(In thousands)
Aulea Medical, Inc.	$	—	$	—	$	—		$	—		$	—	$	—		$	—	$	—	$	—
Cadrenal Therapeutics, Inc. (1)		—		—		—			(906	)		—		906			—		—		—
Evelo Biosciences, Inc.		—		—		(2,443	)		7,663			8		(5,006	)		—		222		277
		—		11		(3,667	)		11,509			11		(7,528	)		—		336		414
		—		—		(1,467	)		4,601			5		(3,006	)		—		133		166
		—		—		(1,467	)		4,598			3		(3,001	)		—		133		163
		—		—		(978	)		3,067			4		(2,005	)		—		88		114
		—		—		(978	)		3,067			4		(2,005	)		—		88		111
		—		—		—			5,000			—		(4,868	)		—		132		—
Total non-controlled affiliates	$	—	$	11	$	(11,000	)	$	38,599		$	35	$	(26,513	)	$	—	$	1,132	$	1,245

(1) As of December 31, 2023, the Company no longer owns 5% of more of the portfolio company.

Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2022 were as follows:

					Year ended December 31, 2022

	*Fair value at*							*Transfers*				*Net*				*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Discount*		*unrealized*		*Net realized*		*December 31,*		*Interest*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*Accretion*		*gain/(loss)*		*gain/(loss)*		*2022*		*income*
	(In thousands)
MVI (ABC) LLC fka StereoVision, Inc.		—		—		(30	)		—		—		—		30		—		—
Total non-controlled affiliates	$	—	$	—	$	(30	)	$	—	$	—	$	—	$	30	$	—	$	—

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). Transactions related to investments in controlled affiliated companies for the year ended December 31, 2023 were as follows:

					*Year ended December 31, 2023*

	*Fair value at*									*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*				*Principal*					*in/(out) at*		*Discount*		*unrealized*			*Net realized*		*December 31,*		*Interest*
Company	*2022*		*Purchases*		*Payments*			*PIK*		*fair value*		*accretion*		*gain/(loss)*			*gain/(loss)*		*2023*		*income*
	(In thousands)
Better Place Forests Co.	$	—	$	61	$	—		$	213	$	1,675	$	5	$	1,385		$	—	$	3,339	$	225
		—		—		—			107		844		1		678			—		1,630		112
		—		1,250		—			—		2,061		—		(287	)		—		3,024		—
HIMV LLC		—		146		(516	)		—		6,154		—		446			—		6,230		—
Total controlled affiliates	$	—	$	1,457	$	(516	)	$	320	$	10,734	$	6	$	2,222		$	—	$	14,223	$	337

Transactions related to investments in controlled affiliated companies for the year ended December 31, 2022 were as follows:

					*Year ended December 31, 2022*
	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Discount*		*unrealized*		*Net realized*			*December 31,*		*Interest*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*accretion*		*gain/(loss)*		*gain/(loss)*			*2022*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

Note 13 - Financial Highlights

12 Months Ended

Dec. 31, 2023

Investment Company, Financial Highlights [Text Block]

Note 13. Financial highlights

The following table shows financial highlights for the Company:

	*Year ended December 31,*
	*2023*				*2022*				*2021*				*2020*				*2019*
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.47			$	11.56			$	11.02			$	11.83			$	11.64
Net investment income		1.98				1.46				1.41				1.18				1.52
Realized loss		(0.97	)			(0.38	)			(0.18	)			(0.84	)			(0.31	)
Unrealized (depreciation) appreciation on investments		(1.57	)			(0.22	)			0.16				0.02				0.24
Net (decrease) increase in net assets resulting from operations		(0.56	)			0.86				1.39				0.36				1.45
Distributions declared ⁽¹⁾		(1.37	)			(1.28	)			(1.25	)			(1.25	)			(1.20	)
From net investment income		(1.37	)			(1.28	)			(1.25	)			(1.25	)			(1.20	)
From net realized gain on investments		—				—				—				—				—
Return of capital		—				—				—				—				—
Other ⁽²⁾		0.17				0.33				0.40				0.08				(0.06	)
Net asset value at end of period	$	9.71			$	11.47			$	11.56			$	11.02			$	11.83
Per share market value, beginning of period	$	11.60			$	15.92			$	13.24			$	12.93			$	11.25
Per share market value, end of period	$	13.17			$	11.60				15.92				13.24				12.93
Total return based on a market value⁽³⁾		25.3	%			(19.3	)%			29.7	%			12.1	%			25.6	%
Shares outstanding at end of period		33,367,389				27,753,373				21,217,460				19,286,356				15,563,290
Ratios to average net assets:
Expenses without incentive value ⁽⁴⁾		14.1	%			11.5	%			10.5	%			10.0	%			10.8	%
Incentive fees⁽⁴⁾		0.9	%			2.6	%			3.1	%			2.6	%			3.2	%
Net expenses ⁽⁴⁾		15.0	%			14.1	%			13.6	%			12.6	%			14.0	%
Net investment income with incentive fees⁽⁴⁾		18.2	%			12.1	%			12.2	%			10.4	%			12.8	%
Ratios, without waivers, to average net assets:
Expenses without incentive value⁽⁴⁾		14.1	%			11.5	%			10.5	%			10.0	%			10.8	%
Incentive fees ⁽⁴⁾		0.9	%			2.6	%			3.1	%			2.6	%			4.4	%
Net expenses ⁽⁴⁾		15.0	%			14.1	%			13.6	%			12.6	%			15.2	%
Net investment income with incentive fees⁽⁴⁾		18.2	%			12.1	%			12.2	%			10.4	%			11.6	%
Net assets at the end of the period	$	323,981			$	318,448			$	245,335			$	212,597			$	184,055
Average net asset value	$	336,915			$	299,182			$	231,215			$	199,302			$	160,008
Average debt per share	$	13.93			$	13.70			$	11.27			$	9.97			$	10.05
Portfolio turnover ratio		17.2	%	⁽⁵⁾		14.6	%	⁽⁵⁾		45.4	%	⁽⁵⁾		38.7	%	⁽⁵⁾		82.0	%	⁽⁶⁾

(1)

Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

(2)

Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

(3)	The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

(4)	During the years ended December 31, 2019, the Advisor waived $1.8 million of incentive fee.

(5)	Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance

(6)	Calculated by dividing net debt investment purchases by the monthly average debt investment balance.

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	*Principles of consolidation* As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements. Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities and 2022-1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).
Use of Estimates, Policy [Policy Text Block]	*Use of estimates* In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	*Fair value* The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date. The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 for additional information regarding fair value.
Segment Reporting, Policy [Policy Text Block]	*Segments* The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	*Investments* Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Company's board of directors (the “Board”) designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's Board oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff. Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of December 31, 2023, there were four investments on non-accrual status with a cost of $72.5 million and a fair value of $27.6 million. As of December 31, 2022, there were three investments on non-accrual status with a cost of $20.9 million and a fair value of $8.3 million. For the year ended December 31, 2023 and 2022, the Company did not recognize any interest income from debt investments while on non-accrual status. For the year ended December 31, 2021, the Company recognized, as interest income, payments of $1.3 million received from two portfolio companies whose debt investments were on non-accrual status. The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. For the year ended December 31, 2023, 7.4% of the Company’s total investment income was attributable to non-cash PIK interest. For the years ended December 31, 2022 and 2021, the Company recorded no PIK interest income. The Company will generally cease accruing PIK interest if management does not expect the portfolio company to be able to pay all principal and interest due. For the year ended December 31, 2023, two debt investments, which had accrued PIK interest into income of $3.9 million and $0.2 million during the years ended December 31, 2023 and 2022, respectively, were placed on nonaccrual status. The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status. Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the years ended December 31, 2023, 2022 and 2021 was 4.2%, 7.4% and 5.9%, respectively. In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
Debt, Policy [Policy Text Block]	*Debt issuance costs* Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of December 31, 2023 and 2022 was $5.8 million and $7.1 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of December 31, 2023 and 2022 were $6.9 million and $4.8 million, respectively. The amortization expense for the years ended December 31, 2023, 2022 and 2021 was $1.9 million, $1.6 million and $1.1 million, respectively.
Income Tax, Policy [Policy Text Block]	*Income taxes* As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the years ended December 31, 2023, 2022 and 2021, the Company reclassified $1.5 million, $0.7 million and $0.4 million, respectively, to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable. Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the years ended December 31, 2023, 2022 and 2021, $1.5 million, $0.7 million and $0.4 million, respectively, was recorded for U.S. federal excise tax. The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at December 31, 2023 and 2022. The Company’s income tax returns for the 2023, 2022, 2021 and 2020 tax years remain subject to examination by U.S. federal and state tax authorities.
Distributions [Policy Text Block]	*Distributions* Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment. The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.
Stockholders' Equity, Policy [Policy Text Block]	*Stockholders’ Equity* On July 30, 2020, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2020 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc., (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2020 Equity Distribution Agreement provided that the Company may offer and sell shares of common stock from time to time through the Sales Agents representing up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. On August 2, 2021, the Company entered into an ATM sales agreement (the “2021 Equity Distribution Agreement”), with the Sales Agents. The 2021 Equity Distribution Agreement provided that the Company may offer and sell its shares of common stock from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. On September 22, 2023, the Company terminated the 2021 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2023 Equity Distribution Agreement”), with the Sales Agents. The remaining shares available under the 2021 Equity Distribution Agreement are no longer available for issuance. The 2023 Equity Distribution Agreement provides that the Company may offer and sell its shares of its common stock from time to time through the Sales Agents up to $150.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the Nasdaq or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. During the year ended December 31, 2023, the Company sold 2,248,830 shares of common stock under the 2023 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $26.2 million, including $0.7 million of offering expenses, from these sales. During the year ended December 31, 2022, the Company sold 3,982,684 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $50.3 million, including $1.0 million of offering expenses, from these sales. During the year ended December 31, 2021, the Company sold 1,907,234 shares of common stock under the 2021 Equity Distribution Agreement and the 2020 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $30.1 million, including $0.8 million of offering expenses, from these sales. The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of December 31, 2023, shares representing approximately $146.7 million of its common stock remain available for issuance and sale under the 2023 Equity Distribution Agreement. On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses. On June 2, 2023, the Company completed a follow-on public offering of 3,250,000 shares of its common stock at a public offering price of $12.50 per share, for total net proceeds to the Company of $38.9 million, after deducting underwriting commission and discounts and other offering expenses.
Stock Repurchase Program [Policy Text Block]	*Stock Repurchase Program* On April 28, 2023, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2024 or the repurchase of $5.0 million of the Company’s common stock. During the years ended December 31, 2023, 2022 and 2021, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through December 31, 2023, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	*Transfers of financial assets* Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company). Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.
New Accounting Pronouncements, Policy [Policy Text Block]	*Recently adopted accounting pronouncement* In October 2023, the FASB issued Accounting Standards Update No. 2023-06, Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (“ASU 2023-06”). ASU 2023-06 amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification including requiring investment companies to disclose the components of capital on the balance sheet. The amendments in ASU 2023-06 were effective on the date which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K became effective. The adoption of ASU 2023-06 did not have an impact on the Company's consolidated financial statements. *Recently issued accounting pronouncement* In June 2022, the FASB issued Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company has concluded that the adoption of ASU 2022-03 will not have a material impact on its consolidated financial statements.

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Recurring [Member]
Investments, fair value	$ 709,085	$ 720,026
Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	670,172	686,458
Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	24,594	29,712
Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	6,430	1,300
Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	7,889	2,556
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	608	140
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	608	140
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	1,619	3,567
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	1,619	3,567
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	706,858	716,319
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	706,858	716,319
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	670,172	686,458
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	22,975	26,145
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	6,430	1,300
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	$ 7,281	$ 2,416

Note 3 - Related Party Transactions

12 Months Ended

Dec. 31, 2023

Note 3. Related party transactions

Investment Management Agreement

On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement dated as of March 7, 2019 (the “2019 Investment Management Agreement”). At a meeting of the stockholders convened on May 25, 2023 and reconvened on June 28, 2023, the stockholders approved a new Investment Management Agreement which became effective on June 30, 2023 (the “New Investment Management Agreement” and collectively with the 2019 Investment Management Agreement, the “Investment Management Agreement”) upon the closing of the acquisition of the Advisor by MCH Holdco LLC, an affiliate of Monroe Capital LLC. The New Investment Management Agreement replaced the previously effective 2019 Investment Management Agreement on June 30, 2023. The 2019 Investment Management and the New Investment Management Agreement contain the same economic terms. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee is calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at December 31, 2023 and 2022 was $1.1 million. The base management fee expense was $12.8 million, $10.6 million and $7.6 million for the years ended December 31, 2023, 2022 and 2021, respectively.

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was $3.1 million, $7.7 million and $7.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was subject to the Incentive Fee Cap and Deferral Mechanism for the year ended December 31, 2023 and 2022, which resulted in $9.8 million and $1.0 million, respectively, of reduced expense and additional net investment income. This deferral represents a contingent future liability and is not accrued until the amount can be reasonably estimated and payment is probable. The remaining deferred amount may be paid up to three years after the date of deferment. The total contingent future liability as of December 31, 2023 was $10.8 million, of which $1.0 million expires on December 31, 2025, $0.2 million expires on March 31, 2026, $3.1 million expires on June 30, 2026, $3.5 million expires on September 30, 2026, and $3.0 million expires on December 31, 2026, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the year ended December 31, 2021. There was no performance based incentive fee payable at December 31, 2023. The performance based incentive fee payable at December 31, 2022 was $1.4 million. The entire incentive fee payable at December 31, 2022 represented part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $1.7 million, $1.7 million and $1.3 million for years ended December 31, 2023, 2022 and 2021, respectively. The administrative fee payable at December 31, 2023 and 2022 was $0.4 million and $0.6 million, respectively. The administrative fee payable is included other accrued liabilities on the Company's Consolidated Statements of Assets and Liabilities.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Note 8 - Federal Income Tax - Undistributed Ordinary Income Earnings on a Tax Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Undistributed ordinary income	$ 38,616	$ 18,813	$ 10,825
Long term capital loss carry forward	(102,908)	(73,055)	(63,571)
Unrealized appreciation	14,935	18,542	12,973
Unrealized depreciation	(65,032)	(19,771)	(8,738)
Other temporary differences	12,547	11,875	7,465
Total	$ (101,842)	$ (43,596)	$ (41,046)

Consolidated Schedule of Investments - Investments (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

$ 759,182

$ 721,248

Investment, Unaffiliated Issuer [Member]

709,085

720,026

716,077

721,248

Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

693,730

720,026

692,345

701,074

Investment, Unaffiliated Issuer [Member] | Equity Securities [Member]

664,203

686,458

6,132

4,184

Investment, Unaffiliated Issuer [Member] | Warrant [Member]

4,733

2,556

16,400

14,790

Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member]

24,594

29,712

1,200

Investment, Affiliated Issuer, Noncontrolled [Member]

1,300

28,677

Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member]

1,132

$ 0

Investment, Affiliated Issuer, Noncontrolled [Member] | Warrant [Member]

1,000

126

Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member]

Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member]

Investment, Affiliated Issuer, Controlled [Member]

^[1]

14,428

Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member]

14,223

$ 0

Biotechnology Sector [Member]

6,230

145,544

193,372

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 117,781

$ 195,006

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 5,000

4,979

4,891

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,979

$ 4,891

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 5,000

4,979

4,963

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Preferred Stock Warrants [Member]

4,979

4,963

214

$ 318

$ 335

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Common Stock [Member]

7,404

$ 250

$ 250

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index Three [Member]

1,162

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 3,000

2,987

2,978

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 2,987

$ 2,978

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 5,000

4,979

4,963

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 4,979

$ 4,963

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 5,000

4,979

4,963

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Term Loan, Prime Index, Six [Member]

$ 4,979

$ 4,963

13.25%

12.50%

4.75%

6.05%

9.55%

13.50%

5.50%

May 01, 2026

$ 3,000

2,987

2,978

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, One [Member]

2,987

$ 2,978

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 10,000

9,872

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 9,872

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 15,000

14,808

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Common Stock Warrants [Member]

14,808

126

$ 125

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Three [Member]

463,915

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 6,000

5,923

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 5,923

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 6,000

5,923

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Five [Member]

$ 5,923

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 4,000

3,949

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Six [Member]

$ 3,949

11.75%

4.75%

11.00%

0.00%

4.25%

Jan. 01, 2028

$ 4,000

3,949

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 3,949

13.75%

6.25%

9.50%

0.00%

3.00%

Jan. 01, 2025

$ 2,885

2,853

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 2,777

13.75%

6.25%

9.50%

0.00%

3.00%

Jan. 01, 2025

$ 2,885

2,823

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Common Stock Warrants [Member]

2,750

311

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index Three [Member]

117

26,442

13.75%

6.25%

9.50%

0.00%

3.00%

Jan. 01, 2025

$ 1,442

1,411

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 1,374

13.75%

6.25%

9.50%

0.00%

3.00%

Feb. 01, 2025

$ 2,885

2,821

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Five [Member]

$ 2,748

13.75%

6.25%

9.50%

0.00%

3.00%

Feb. 01, 2025

$ 2,885

2,821

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Six [Member]

$ 2,748

13.75%

6.25%

9.50%

0.00%

3.00%

Apr. 01, 2025

$ 1,442

1,408

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Term Loan, Prime Index, Seven [Member]

$ 1,371

13.75%

6.25%

9.50%

0.00%

3.00%

Apr. 01, 2025

$ 1,442

1,408

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, Prime Index, One [Member]

1,371

13.22%

4.72%

9.75%

0.00%

5.00%

Jun. 01, 2024

$ 1,414

1,410

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 1,410

13.22%

4.72%

9.75%

0.00%

5.00%

Jun. 01, 2024

$ 1,414

1,410

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Preferred Stock Warrants [Member]

1,410

178

176

$ 246

$ 263

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Common Stock [Member]

110,402

$ 356

$ 356

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, Prime Index Three [Member]

32,831

13.22%

4.72%

9.75%

0.00%

5.00%

Nov. 01, 2025

$ 5,000

4,950

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, One [Member]

$ 4,950

12.07%

7.90%

9.75%

0.00%

5.00%

Jun. 01, 2024

$ 1,979

1,962

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 1,962

13.22%

4.72%

9.75%

0.00%

5.00%

May 01, 2026

$ 5,000

4,949

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]

4,949

12.07%

7.90%

9.75%

0.00%

5.00%

Jun. 01, 2024

$ 1,979

1,963

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]

$ 1,963

12.07%

7.90%

9.75%

0.00%

5.00%

Nov. 01, 2025

$ 5,000

4,923

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]

$ 4,923

12.07%

7.90%

9.75%

0.00%

5.00%

May 01, 2026

$ 5,000

4,912

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Corvium, Inc [Member] | Preferred Stock Warrants [Member]

4,912

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Imunon, Inc [Member] | Common Stock Warrants [Member]

661,956

$ 66

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Term Loan, Prime Index, One [Member]

19,671

16,502

13.25%

12.25%

4.75%

8.50%

0.00%

5.50%

May 01, 2027

$ 6,250

6,199

6,077

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 6,199

$ 6,077

13.25%

12.25%

4.75%

8.50%

0.00%

5.50%

May 01, 2027

$ 6,250

6,199

6,177

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Preferred Stock Warrants [Member]

6,199

6,177

$ 53

$ 60

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mustang Bio, Inc [Member] | Common Stock Warrants [Member]

48,076

48,077

$ 146

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Term Loan, Prime Index, One [Member]

16,611

252,161

13.25%

6.25%

9.50%

0.00%

4.00%

Apr. 01, 2025

$ 2,500

2,476

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 2,476

13.25%

6.25%

9.50%

0.00%

4.00%

Jul. 01, 2025

$ 2,500

2,473

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Common Stock Warrants [Member]

2,473

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Term Loan, Prime Index, One [Member]

21,120

13.75%

12.75%

5.25%

8.50%

0.00%

5.00%

Nov. 01, 2026

$ 3,750

3,716

3,630

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,716

$ 3,630

13.75%

12.75%

5.25%

8.50%

0.00%

5.00%

Nov. 01, 2026

$ 2,500

2,478

2,469

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Preferred Stock Warrants [Member]

2,478

2,469

$ 157

$ 162

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Term Loan, Prime Index, One [Member]

103,679

14.25%

13.25%

5.75%

9.00%

0.00%

3.00%

Jul. 01, 2025

$ 3,000

$ 5,000

2,914

4,857

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 2,870

$ 4,857

14.25%

13.25%

5.75%

9.00%

0.00%

3.00%

Jul. 01, 2025

$ 1,500

$ 2,500

1,458

2,430

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Common Stock Warrants [Member]

$ 1,436

2,430

366

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index, One [Member]

47,452

14.25%

13.25%

5.75%

9.75%

0.00%

3.75%

Sep. 01, 2026

$ 10,000

9,911

9,701

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index Two [Member]

$ 9,911

$ 9,701

14.25%

13.25%

5.75%

9.75%

0.00%

3.75%

Sep. 01, 2026

$ 3,750

3,717

3,697

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Common Stock Warrants [Member]

3,717

3,697

160

$ 606

$ 3,024

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Term Loan, Prime Index Three [Member]

299,848

14.25%

13.25%

5.75%

9.75%

0.00%

3.75%

Sep. 01, 2026

$ 3,750

3,717

3,697

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 3,717

3,697

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 4,666

4,579

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,414

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 4,666

4,579

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Common Stock Warrants [Member]

4,414

278

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Preferred Stock Warrants [Member]

175,098

$ 312

399

$ 225

$ 648

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index Three [Member]

691,895

203,017

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,281

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, One [Member]

$ 2,199

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 4,667

4,597

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 4,597

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,281

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Two [Member]

$ 2,199

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 4,667

4,597

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index, Five [Member]

$ 4,597

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,278

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Three [Member]

$ 2,196

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,280

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, Prime Index, Six [Member]

$ 2,280

13.86%

5.36%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,278

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Four [Member]

$ 2,196

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,280

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Five [Member]

$ 2,280

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,274

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Term Loan, LIBOR Index, Six [Member]

$ 2,274

12.67%

8.50%

9.50%

0.00%

5.50%

Dec. 01, 2024

$ 2,333

2,274

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Term Loan, Prime Index, One [Member]

$ 2,274

13.25%

5.75%

9.00%

0.00%

5.00%

Jul. 01, 2025

$ 5,000

4,946

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,946

13.25%

5.75%

9.00%

0.00%

5.00%

Jul. 01, 2025

$ 2,500

2,473

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Common Stock Warrants [Member]

2,473

$ 0

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Term Loan, Prime Index Three [Member]

39,774

13.25%

5.75%

9.00%

0.00%

5.00%

Jan. 01, 2026

$ 5,000

4,947

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,947

13.25%

5.75%

9.00%

0.00%

5.00%

Jan. 01, 2026

$ 5,000

4,947

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 4,947

14.00%

13.00%

5.50%

8.75%

0.00%

6.00%

Oct. 01, 2025

$ 4,250

$ 5,000

4,193

4,914

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,193

$ 4,914

14.00%

13.00%

5.50%

8.75%

0.00%

6.00%

Oct. 01, 2025

$ 2,125

$ 2,500

2,096

2,457

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Common Stock Warrants [Member]

2,096

2,457

264

$ 113

$ 37

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Term Loan, Prime Index, One [Member]

318,181

12.75%

4.25%

12.25%

0.00%

4.00%

Aug. 01, 2027

$ 2,500

2,230

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 2,230

12.75%

4.25%

12.25%

0.00%

4.00%

Aug. 01, 2027

$ 2,500

2,459

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Preferred Stock Warrants [Member]

2,459

194

$ 172

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Xeris Pharmaceuticals, Inc [Member] | Common Stock Warrants [Member]

1,600,002

$ 72

$ 33

$ 3

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Rocket Pharmaceuticals Corporation [Member] | Common Stock Warrants [Member]

126,000

$ 17

$ 14

Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | vTv Therapeutics Inc [Member] | Common Stock Warrants [Member]

7,051

$ 44

$ 0

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member]

95,293

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 5,532

5,228

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 222

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 8,298

7,867

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Common Stock [Member]

336

5,000

$ 132

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index Three [Member]

2,164,502

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 3,319

3,137

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 133

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 3,319

3,137

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Five [Member]

$ 133

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 2,213

2,091

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Warrant [Member]

126

$ 0

Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Term Loan, Prime Index, Six [Member]

23,196

12.75%

4.25%

11.00%

0.00%

2.27%

Jan. 01, 2028

$ 2,213

2,091

Medical Device Sector [Member]

147,064

$ 132,803

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 145,019

$ 135,960

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Nov. 01, 2026

$ 3,500

3,469

3,360

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 1,574

$ 3,360

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Nov. 01, 2026

$ 3,500

3,563

3,460

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Preferred Stock Warrants [Member]

$ 1,617

3,460

$ 16

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Term Loan, Prime Index, One [Member]

86,066

12.25%

5.25%

8.50%

0.00%

20.00%

Sep. 15, 2022

$ 2,500

2,500

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 2,500

12.25%

5.25%

8.50%

0.00%

20.00%

Sep. 15, 2022

$ 2,500

2,500

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 2,500

13.25%

11.75%

4.75%

8.50%

0.00%

5.00%

Jan. 01, 2027

$ 3,750

3,722

3,597

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,722

$ 3,597

13.25%

11.75%

4.75%

8.50%

0.00%

5.00%

Jan. 01, 2027

$ 3,750

3,722

3,706

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Preferred Stock Warrants [Member]

3,722

3,706

103

$ 215

$ 46

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index Three [Member]

34,410

19,662

13.75%

5.25%

9.00%

0.00%

5.00%

Jan. 01, 2027

$ 5,000

4,943

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 4,943

13.75%

5.25%

9.00%

0.00%

5.00%

Jan. 01, 2027

$ 5,000

4,900

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 4,900

13.59%

5.09%

10.00%

0.00%

5.00%

Jan. 01, 2024

$ 500

500

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 500

13.59%

5.09%

10.00%

0.00%

5.00%

Jan. 01, 2024

$ 33

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Preferred Stock Warrants [Member]

174

$ 153

$ 124

$ 150

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, Prime Index Three [Member]

3,341,376

1,375,727

13.59%

5.09%

10.00%

0.00%

5.00%

Mar. 01, 2024

$ 800

794

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, One [Member]

$ 794

12.37%

8.20%

10.00%

0.00%

5.00%

Jan. 01, 2024

$ 1,625

1,610

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, Two [Member]

$ 1,610

12.37%

8.20%

10.00%

0.00%

5.00%

Jan. 01, 2024

$ 108

107

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Term Loan, LIBOR Index, Three [Member]

$ 107

12.37%

8.20%

10.00%

0.00%

5.00%

Mar. 01, 2024

$ 2,000

1,983

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Embody, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 1,983

14.00%

6.50%

9.75%

0.00%

28.00%

Aug. 01, 2026

$ 2,500

2,482

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 2,482

12.00%

13.50%

3.50%

6.50%

11.75%

9.75%

0.00%

8.00%

Sep. 01, 2027

Jun. 01, 2025

$ 2,500

2,297

2,476

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 2,297

$ 2,476

12.00%

13.50%

3.50%

6.50%

11.75%

9.75%

0.00%

8.00%

Sep. 01, 2027

Jun. 01, 2025

$ 2,500

2,473

2,476

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Preferred Stock Warrants [Member]

2,473

2,476

275

$ 269

$ 123

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index Three [Member]

2,637,043

605,313

12.00%

13.50%

3.50%

6.50%

11.75%

9.75%

0.00%

8.00%

Sep. 01, 2027

Jun. 01, 2025

$ 5,000

$ 2,500

4,946

2,476

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 4,946

$ 2,476

12.00%

13.50%

3.50%

6.50%

11.75%

9.75%

0.00%

8.00%

Sep. 01, 2027

Apr. 01, 2026

$ 5,000

$ 2,500

4,946

2,453

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Term Loan, Prime Index, Five [Member]

4,946

$ 2,453

13.50%

6.50%

9.75%

0.00%

8.00%

May 01, 2026

$ 2,500

2,455

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 2,455

13.25%

6.25%

9.50%

0.00%

4.00%

Oct. 01, 2024

$ 3,208

3,143

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 3,143

13.25%

6.25%

9.50%

0.00%

4.00%

Jun. 01, 2025

$ 1,000

974

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Preferred Stock Warrants [Member]

974

124

$ 26

$ 113

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, One [Member]

2,010,424

317,647

12.00%

5.00%

9.75%

0.00%

4.00%

Mar. 01, 2025

$ 5,000

4,939

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,939

12.00%

5.00%

9.75%

0.00%

4.00%

Mar. 01, 2025

$ 5,000

4,939

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Preferred Stock Warrants [Member]

4,939

$ 194

194

$ 368

$ 385

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index Three [Member]

809,931

12.00%

5.00%

9.75%

0.00%

4.00%

Mar. 01, 2025

$ 5,000

4,933

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,933

12.00%

5.00%

9.75%

0.00%

4.00%

Mar. 01, 2025

$ 5,000

4,933

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 4,933

12.50%

5.00%

9.75%

0.00%

4.00%

Jan. 01, 2027

$ 5,000

4,913

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Term Loan, Prime Index, Six [Member]

$ 4,913

12.50%

5.00%

9.75%

0.00%

4.00%

Jan. 01, 2027

$ 5,000

4,913

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 4,913

15.50%

14.50%

7.00%

10.25%

0.00%

1.00%

Oct. 01, 2025

$ 5,000

4,978

4,966

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,978

$ 4,966

15.50%

14.50%

7.00%

10.25%

0.00%

1.00%

Apr. 01, 2026

$ 2,500

2,489

2,481

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Common Stock [Member]

$ 2,489

2,481

2,000

$ 1,700

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Royalty Agreement [Member]

392,651

$ 1,200

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 1,100

13.75%

12.25%

5.25%

9.00%

0.00%

5.00%

Jul. 01, 2027

$ 3,500

3,467

3,349

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,467

$ 3,349

13.75%

12.25%

5.25%

9.00%

0.00%

5.00%

Jul. 01, 2027

$ 3,500

3,467

3,454

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Preferred Stock Warrants [Member]

3,467

3,454

$ 1

$ 83

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index Three [Member]

135,484

13.75%

5.25%

9.00%

0.00%

5.00%

Jul. 01, 2027

$ 3,500

3,456

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 3,456

13.75%

5.25%

9.00%

0.00%

5.00%

Jul. 01, 2027

$ 3,500

3,456

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | ZetrOZ, Inc [Member] | Royalty Agreement [Member]

3,456

$ 0

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | AccuVein Inc [Member] | Common Stock Warrants [Member]

200

$ 0

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerin Medical, Inc [Member] | Preferred Stock Warrants [Member]

1,175

$ 66

$ 64

$ 1,199

$ 1,200

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Term Loan, Prime Index, One [Member]

1,818,183

12.25%

3.75%

12.25%

0.00%

4.00%

Jan. 01, 2029

$ 15,000

14,675

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Term Loan, Prime Index Two [Member]

$ 14,675

12.25%

3.75%

12.25%

0.00%

4.00%

Jan. 01, 2029

$ 10,000

9,784

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Preferred Stock Warrants [Member]

9,784

432

$ 53

$ 379

$ 1

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Term Loan, Prime Index Three [Member]

4,109

408

12.25%

3.75%

12.25%

0.00%

4.00%

Jan. 01, 2029

$ 5,000

4,892

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Term Loan, Prime Index, Four [Member]

$ 4,892

12.25%

3.75%

12.25%

0.00%

4.00%

Jan. 01, 2029

$ 2,500

2,446

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Term Loan, Prime Index, One [Member]

2,446

13.75%

6.25%

9.50%

0.00%

6.00%

Apr. 01, 2026

$ 2,500

2,463

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Term Loan, Prime Index Two [Member]

$ 2,364

13.75%

6.25%

9.50%

0.00%

6.00%

Apr. 01, 2026

$ 2,500

2,463

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Preferred Stock Warrants [Member]

2,364

$ 9

$ 31

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Term Loan, Fixed Index One [Member]

8,800

27,330

9.00%

0.00%

0.00%

0.00%

18.00%

Apr. 01, 2028

$ 2,500

2,468

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Term Loan, Fixed Index Two [Member]

$ 2,342

9.00%

0.00%

0.00%

0.00%

18.00%

Apr. 01, 2028

$ 2,500

2,468

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Term Loan, Fixed Index Three [Member]

$ 2,342

9.00%

0.00%

0.00%

0.00%

18.00%

Jun. 30, 2024

$ 200

200

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index, One [Member]

190

12.75%

5.75%

9.00%

0.00%

7.00%

Nov. 01, 2024

$ 2,500

2,475

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 2,475

12.75%

5.75%

9.00%

0.00%

7.00%

Nov. 01, 2024

$ 2,500

2,489

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Preferred Stock Warrants [Member]

2,489

$ 1,305

$ 1,864

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Term Loan, Prime Index Three [Member]

12,153

12.75%

5.75%

9.00%

0.00%

7.00%

Nov. 01, 2024

$ 2,500

2,473

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 2,473

12.00%

3.50%

11.50%

0.00%

5.00%

Sep. 01, 2027

$ 5,000

4,757

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,757

12.00%

3.50%

11.50%

0.00%

5.00%

Sep. 01, 2027

$ 2,500

2,454

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Preferred Stock Warrants [Member]

2,454

152

$ 135

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Term Loan, Prime Index Three [Member]

93,336

12.00%

3.50%

11.50%

0.00%

5.00%

Sep. 01, 2027

$ 2,500

2,454

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 2,454

12.00%

10.50%

3.50%

8.25%

0.00%

5.50%

Oct. 01, 2024

$ 3,750

$ 5,000

3,738

4,973

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,738

$ 4,973

12.00%

10.50%

3.50%

8.25%

0.00%

5.50%

Oct. 01, 2024

$ 3,750

$ 5,000

3,738

4,973

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Preferred Stock Warrants [Member]

3,738

4,973

$ 229

$ 209

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index Three [Member]

145,483

12.00%

10.50%

3.50%

8.25%

0.00%

5.50%

Oct. 01, 2024

$ 1,875

$ 2,500

1,866

2,478

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 1,866

$ 2,478

12.00%

10.50%

3.50%

8.25%

0.00%

5.50%

Oct. 01, 2024

$ 1,875

$ 2,500

1,866

2,478

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 1,866

$ 2,478

14.00%

13.00%

5.50%

8.75%

0.00%

6.00%

Aug. 01, 2026

$ 4,583

$ 2,500

4,546

2,466

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,546

$ 2,466

14.00%

13.00%

5.50%

8.75%

0.00%

6.00%

Aug. 01, 2026

$ 2,292

$ 5,000

2,273

4,932

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Preferred Stock Warrants [Member]

2,273

4,932

149

148

$ 167

$ 179

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, Prime Index, One [Member]

4,106,174

775,000

13.32%

4.82%

9.25%

0.00%

10.36%

Jul. 01, 2025

$ 3,960

3,923

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 3,923

13.32%

4.82%

9.25%

0.00%

10.36%

Jul. 01, 2025

$ 3,960

3,923

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Preferred Stock Warrants [Member]

3,923

221

$ 221

$ 206

$ 226

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, LIBOR Index, One [Member]

7,972,222

12.17%

8.00%

9.25%

0.00%

10.36%

Jul. 01, 2025

$ 3,960

3,898

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Term Loan, LIBOR Index, Two [Member]

$ 3,898

12.17%

8.00%

9.25%

0.00%

10.36%

Jul. 01, 2025

$ 3,960

3,898

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | CVRx, Inc [Member] | Common Stock Warrants [Member]

3,898

$ 76

$ 980

$ 394

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Meditrina, Inc [Member] | Preferred Stock Warrants [Member]

47,410

$ 83

$ 93

$ 101

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | MicroTransponder, Inc. [Member] | Term Loan, Prime Index, One [Member]

233,993

12.25%

3.75%

12.25%

0.00%

3.50%

Jan. 01, 2029

$ 3,750

3,689

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | MicroTransponder, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,689

12.25%

3.75%

12.25%

0.00%

3.50%

Jan. 01, 2029

$ 3,750

3,689

Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | MicroTransponder, Inc. [Member] | Preferred Stock Warrants [Member]

3,689

$ 47

Medical Device Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member] | Common Stock [Member]

103,172

$ 0

$ 0

Communications Sector [Member]

660,537

$ 19,192

$ 22,892

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 22,188

$ 26,176

14.50%

13.00%

6.00%

9.25%

0.00%

2.50%

Jun. 01, 2026

$ 6,250

$ 7,500

6,218

7,455

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 6,218

$ 7,455

14.50%

13.00%

6.00%

9.25%

0.00%

2.50%

Jun. 01, 2026

$ 6,250

$ 7,500

6,218

7,455

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Common Stock Warrants [Member]

6,218

7,455

$ 61

$ 67

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Term Loan, Prime Index Three [Member]

1,991

14.50%

13.00%

6.00%

9.25%

0.00%

2.50%

Jun. 01, 2026

$ 6,250

$ 7,500

6,218

7,455

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Preferred Stock [Member]

6,218

$ 7,455

261

$ 306

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Convertible Debt Securities [Member]

1,810

3.00%

Jul. 01, 2023

$ 250

250

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Intelepeer Holdings, Inc [Member] | Preferred Stock Warrants [Member]

306

$ 138

139

$ 3,036

$ 3,265

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | PebblePost, Inc [Member] | Preferred Stock Warrants [Member]

2,936,535

$ 92

$ 131

$ 173

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Preferred Stock [Member]

598,850

$ 89

$ 89

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Preferred Stock [Member]

2,688,971

$ 2,800

$ 1,281

Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Preferred Stock [Member]

280,000

$ 4

$ 193

66,127

Software Sector [Member]

$ 164,133

$ 120,157

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 160,749

$ 118,716

15.00%

14.00%

6.50%

9.75%

0.00%

3.50%

Apr. 01, 2026

$ 6,625

$ 6,500

6,519

6,347

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 6,176

$ 6,347

15.00%

14.00%

6.50%

9.75%

0.00%

3.50%

Apr. 01, 2026

$ 6,116

$ 6,000

6,018

5,859

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Common Stock Warrants [Member]

5,701

5,859

455

$ 46

$ 197

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Term Loan, Prime Index Three [Member]

516,732

15.00%

14.00%

6.50%

9.75%

0.00%

3.50%

Aug. 01, 2026

$ 2,548

$ 2,500

2,507

2,436

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Term Loan, Prime Index, One [Member]

$ 2,375

$ 2,436

14.75%

13.25%

6.25%

9.75%

0.00%

4.50%

Jul. 01, 2027

$ 3,750

3,728

3,678

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Term Loan, Prime Index Two [Member]

$ 3,728

$ 3,678

14.75%

13.25%

6.25%

9.75%

0.00%

4.50%

Jul. 01, 2027

$ 3,750

3,728

3,718

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 3,728

$ 3,718

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Apr. 01, 2026

$ 10,000

9,895

9,826

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 9,895

$ 9,826

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Apr. 01, 2026

$ 10,000

9,895

9,826

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Preferred Stock Warrants [Member]

9,895

9,826

273

$ 13

$ 296

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index Three [Member]

639,918

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Apr. 01, 2026

$ 5,000

4,947

4,913

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 4,947

$ 4,913

14.00%

13.00%

5.50%

10.25%

0.00%

4.00%

Apr. 01, 2026

$ 5,000

4,947

4,913

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 4,947

$ 4,913

15.00%

14.00%

6.50%

9.75%

0.00%

2.50%

Mar. 01, 2026

$ 5,000

4,971

4,947

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,971

$ 4,947

15.00%

14.00%

6.50%

9.75%

0.00%

2.50%

Mar. 01, 2026

$ 2,500

2,486

2,474

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Preferred Stock Warrants [Member]

2,486

2,474

$ 120

$ 41

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Term Loan, Prime Index, One [Member]

101,308

14.50%

13.00%

6.00%

14.25%

9.25%

0.00%

4.00%

3.00%

Nov. 01, 2026

Jul. 01, 2025

$ 2,500

2,471

2,396

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 2,373

$ 2,396

14.50%

13.00%

6.00%

14.25%

12.25%

0.00%

4.00%

3.00%

Dec. 01, 2026

$ 1,250

1,237

1,231

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Preferred Stock Warrants [Member]

1,188

1,231

$ 1

$ 44

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Term Loan, Prime Index Three [Member]

85,543

80,197

14.50%

6.00%

14.25%

0.00%

4.00%

Apr. 01, 2027

$ 1,000

994

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 954

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2028

$ 5,000

4,779

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,779

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2028

$ 5,000

4,915

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Common Stock Warrants [Member]

4,915

223

$ 247

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Term Loan, Prime Index Three [Member]

948,275

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2028

$ 5,000

4,915

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,915

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2028

$ 5,000

4,915

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 4,915

13.50%

5.00%

12.00%

0.00%

3.00%

Mar. 01, 2027

$ 10,000

9,885

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 9,885

13.50%

5.00%

12.00%

0.00%

3.00%

Mar. 01, 2027

$ 5,000

4,942

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Preferred Stock Warrants [Member]

4,942

115

$ 2

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Term Loan, Prime Index Three [Member]

84,037

13.50%

5.00%

12.00%

0.00%

3.00%

Mar. 01, 2027

$ 5,000

4,942

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 4,942

15.75%

14.25%

7.25%

10.50%

0.00%

3.00%

Aug. 01, 2025

$ 3,667

$ 5,000

3,625

4,932

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Preferred Stock Warrants [Member]

3,625

4,932

$ 80

$ 39

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index, One [Member]

3,731

14.25%

13.25%

5.75%

9.75%

0.00%

5.00%

Aug. 01, 2026

$ 5,000

4,959

4,870

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,959

$ 4,870

14.25%

13.25%

5.75%

9.75%

0.00%

5.00%

Aug. 01, 2026

$ 5,000

4,959

4,933

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Preferred Stock Warrants [Member]

4,959

4,933

123

$ 135

$ 133

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index Three [Member]

309,208

14.25%

13.25%

5.75%

9.75%

0.00%

5.00%

Aug. 01, 2026

$ 5,000

4,959

4,933

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 4,959

$ 4,933

14.25%

13.25%

5.75%

9.75%

0.00%

5.00%

Aug. 01, 2026

$ 5,000

4,959

4,933

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Term Loan, Prime Index, One [Member]

4,959

$ 4,933

16.93%

9.43%

12.68%

0.00%

50.43%

Dec. 31, 2022

$ 3,295

3,295

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Common Stock Warrants [Member]

3,295

$ 0

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Equity Securities [Member]

82,967

$ 230

$ 0

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Preferred Stock Warrants [Member]

72,638,663

$ 22

$ 42

$ 312

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Term Loan, Prime Index, One [Member]

71,305

288,115

12.75%

13.50%

4.25%

6.50%

12.00%

9.75%

0.00%

2.50%

4.00%

Jun. 01, 2028

Feb. 01, 2025

$ 2,500

$ 3,500

2,457

3,472

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Term Loan, Prime Index Two [Member]

$ 2,457

$ 3,472

12.75%

13.50%

4.25%

6.50%

12.00%

9.75%

0.00%

2.50%

4.00%

Jun. 01, 2028

Feb. 01, 2025

$ 3,500

3,489

3,472

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Preferred Stock Warrants [Member]

3,489

$ 3,472

$ 135

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Term Loan, Prime Index Three [Member]

682

12.75%

13.50%

4.25%

6.50%

12.00%

9.75%

0.00%

2.50%

4.00%

Jun. 01, 2028

Dec. 01, 2025

$ 2,500

2,492

2,472

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Term Loan, Prime Index, Four [Member]

$ 2,492

$ 2,472

12.75%

13.50%

4.25%

6.50%

12.00%

9.75%

0.00%

2.50%

4.00%

Jun. 01, 2028

Dec. 01, 2025

$ 1,500

$ 2,500

1,495

2,472

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 1,495

$ 2,472

14.00%

13.75%

5.50%

6.75%

14.00%

10.00%

0.00%

3.00%

5.00%

Oct. 01, 2028

Mar. 01, 2026

$ 5,000

$ 2,500

4,860

2,421

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,860

$ 2,421

14.00%

13.75%

5.50%

6.75%

14.00%

10.00%

0.00%

3.00%

5.00%

Oct. 01, 2028

Mar. 01, 2026

$ 2,500

2,466

2,487

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Preferred Stock Warrants [Member]

2,466

2,487

$ 174

$ 69

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index Three [Member]

161,215

77,828

14.00%

5.50%

14.00%

0.00%

3.00%

Oct. 01, 2028

$ 2,500

2,466

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 2,466

14.00%

5.50%

14.00%

0.00%

3.00%

Oct. 01, 2028

$ 2,500

2,466

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Term Loan, Prime Index, One [Member]

$ 2,466

12.50%

4.00%

11.75%

0.00%

3.50%

Jun. 01, 2027

$ 5,000

4,773

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Term Loan, Prime Index Two [Member]

$ 4,773

12.50%

4.00%

11.75%

0.00%

3.50%

Jun. 01, 2027

$ 2,500

2,467

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Preferred Stock Warrants [Member]

2,467

120

$ 105

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Term Loan, Prime Index Three [Member]

345,443

12.50%

4.00%

11.75%

0.00%

3.50%

Jun. 01, 2027

$ 2,500

2,467

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | E La Carte, Inc [Member] | Common Stock Warrants [Member]

2,467

$ 60

$ 0

$ 3

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Term Loan, Prime Index, One [Member]

147,361

13.00%

5.50%

11.00%

18.00%

3.00%

Dec. 01, 2026

$ 5,000

4,798

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,798

13.00%

5.50%

11.00%

18.00%

3.00%

Dec. 01, 2026

$ 5,000

4,948

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Preferred Stock Warrants [Member]

4,948

$ 6

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Everstream Holdings, LLC [Member] | Preferred Stock Warrants [Member]

86,300

$ 70

$ 63

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Revinate Holdings, Inc [Member] | Preferred Stock Warrants [Member]

350,000

$ 44

$ 46

$ 91

$ 99

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Riv Data Corp [Member] | Preferred Stock Warrants [Member]

682,034

$ 12

$ 296

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | SIGNiX, Inc [Member] | Preferred Stock Warrants [Member]

321,428

$ 225

$ 0

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Skyword, Inc [Member] | Warrant [Member]

186,235

$ 48

$ 1

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Supply Network Visiblity Holdings LLC [Member] | Preferred Stock Warrants [Member]

301,055

$ 64

$ 83

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Topia Mobility, Inc [Member] | Preferred Stock Warrants [Member]

682

$ 138

$ 0

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | xAd, Inc [Member] | Preferred Stock Warrants [Member]

3,049,607

$ 177

$ 5

$ 12

Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Branded Online, Inc [Member] | Common Stock [Member]

4,343,348

$ 1,079

$ 83

108,004

13.75%

6.25%

9.50%

0.00%

1.85%

Jul. 01, 2025

$ 5,000

4,951

$ 3,834

13.75%

6.25%

9.50%

0.00%

1.85%

Oct. 01, 2025

$ 2,500

2,474

1,916

$ 0

10,690

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 3,750

3,608

3,478

$ 3,608

$ 3,478

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 1,250

1,242

1,238

1,242

1,238

$ 250

$ 233

37,282

31,966

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 3,750

3,726

3,715

$ 3,726

$ 3,715

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 1,250

1,242

1,238

$ 1,242

$ 1,238

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 3,750

3,726

3,715

$ 3,726

$ 3,715

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2027

$ 1,250

1,242

1,238

$ 1,242

$ 1,238

11.25%

6.00%

9.50%

11.25%

3.00%

Jan. 01, 2028

$ 3,750

3,712

3,698

$ 3,712

$ 3,698

11.25%

6.00%

9.50%

11.25%

3.00%

Jan. 01, 2028

$ 3,750

3,712

3,698

$ 3,712

$ 3,698

11.25%

6.00%

9.50%

11.25%

3.00%

Apr. 01, 2028

$ 3,750

3,706

$ 3,706

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2028

$ 3,750

3,707

$ 3,707

11.25%

6.00%

9.50%

11.25%

3.00%

Jul. 01, 2028

$ 3,750

3,707

$ 3,707

15.75%

14.75%

7.25%

10.50%

0.00%

3.00%

May 01, 2026

$ 3,383

$ 3,500

3,356

3,461

3,356

3,461

$ 27

$ 61

75,997

17,605

14.25%

12.75%

5.75%

9.00%

0.00%

5.50%

Aug. 01, 2025

$ 1,667

$ 2,500

1,656

2,482

$ 1,656

$ 2,482

14.25%

12.75%

5.75%

9.00%

0.00%

5.50%

Aug. 01, 2025

$ 1,583

$ 2,500

1,573

2,482

1,573

2,482

$ 122

$ 125

46,745

13.75%

6.75%

10.00%

0.00%

3.00%

Jan. 01, 2025

$ 5,000

4,966

$ 4,966

13.75%

6.75%

10.00%

0.00%

3.00%

Jan. 01, 2025

$ 5,000

4,966

4,966

$ 93

$ 0

$ 64

20,000

13.75%

6.75%

10.00%

0.00%

3.00%

Jan. 01, 2025

$ 3,000

2,979

$ 2,979

13.75%

6.75%

10.00%

0.00%

3.00%

Dec. 01, 2025

$ 1,000

976

$ 976

13.75%

6.75%

10.00%

0.00%

3.00%

Feb. 01, 2026

$ 1,000

977

977

$ 195

195

$ 0

76,923

$ 65

$ 68

$ 1,055

$ 1,069

268,591

13.50%

12.50%

5.00%

5.00%

0.00%

4.00%

Mar. 01, 2027

$ 2,000

1,421

1,082

$ 1,421

$ 1,082

13.50%

12.50%

5.00%

5.00%

0.00%

4.00%

Mar. 01, 2027

$ 3,000

2,131

1,623

2,131

1,623

2,947

$ 2,259

$ 2,947

1,312,500

12.00%

11.00%

3.50%

10.50%

0.00%

7.78%

Feb. 01, 2028

$ 2,813

2,813

$ 2,813

12.00%

11.00%

3.50%

10.50%

0.00%

7.78%

Feb. 01, 2028

$ 2,813

2,813

$ 2,813

13.50%

6.50%

9.75%

0.00%

4.00%

Jan. 01, 2026

$ 3,210

3,151

$ 0

13.50%

6.50%

9.75%

0.00%

4.00%

Jan. 01, 2026

$ 2,963

2,886

103

$ 0

553,710

15.25%

14.25%

6.75%

10.00%

0.00%

3.00%

Oct. 01, 2025

$ 3,667

$ 5,000

3,647

4,954

$ 3,647

$ 4,954

15.25%

14.25%

6.75%

10.00%

0.00%

3.00%

Oct. 01, 2025

$ 1,833

$ 2,500

1,824

2,477

1,824

2,477

$ 56

$ 37

250

143

12.00%

10.00%

3.50%

6.75%

9.00%

10.00%

0.00%

1.00%

0.00%

Sep. 01, 2027

$ 2,500

2,591

2,588

$ 2,429

$ 2,279

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 5,752

$ 5,000

5,752

4,943

$ 5,018

$ 4,715

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 2,301

$ 2,000

2,301

1,981

2,007

1,890

188

$ 0

12,618

$ 9

197

$ 0

$ 17

1,224,752

1,261,253

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 2,876

$ 2,500

2,876

2,477

$ 2,509

$ 2,363

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 3,451

$ 3,000

3,451

2,971

$ 3,011

$ 2,835

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 2,876

$ 2,500

2,876

2,459

$ 2,510

$ 2,345

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 2,876

$ 2,500

2,876

2,459

$ 2,510

$ 2,345

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 5,752

$ 5,000

5,752

4,914

$ 5,018

$ 4,688

14.25%

12.75%

5.75%

9.00%

0.00%

5.25%

2.00%

Oct. 31, 2023

Dec. 30, 2022

$ 2,876

$ 2,500

2,876

2,456

2,510

$ 2,342

$ 71

65,569

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Aug. 01, 2027

$ 2,500

2,416

2,347

$ 2,416

2,347

14.75%

6.25%

9.50%

0.00%

4.00%

Jul. 01, 2028

$ 1,875

1,787

1,787

182

104

$ 145

$ 104

11,550

6,600

14.25%

7.25%

10.50%

0.00%

3.00%

Mar. 01, 2025

$ 2,700

2,673

$ 2,673

14.25%

7.25%

10.50%

0.00%

3.00%

Mar. 01, 2025

$ 2,700

2,673

2,673

$ 57

$ 591

$ 429

553,778

14.25%

7.25%

10.50%

0.00%

3.00%

Sep. 01, 2025

$ 3,000

2,967

2,967

$ 325

325

$ 533

$ 534

6,191

$ 253

$ 57

87,082

16.25%

15.25%

7.75%

11.00%

0.00%

0.00%

May 01, 2027

Jul. 01, 2025

$ 1,204

$ 2,500

1,086

2,473

$ 872

$ 2,473

16.25%

15.25%

7.75%

11.00%

0.00%

0.00%

May 01, 2027

Jul. 01, 2025

$ 602

$ 1,250

543

1,236

436

1,236

$ 0

$ 22

171,081

16.25%

15.25%

7.75%

11.00%

0.00%

0.00%

May 01, 2027

Jul. 01, 2025

$ 602

$ 1,250

543

1,236

436

1,236

$ 0

$ 42

114,659

108,333

$ 8

$ 83

82,974

$ 5,335

$ 4,969

12.25%

3.75%

12.00%

0.00%

1.85%

Aug. 01, 2029

$ 3,547

3,585

$ 3,339

12.25%

3.75%

12.00%

0.00%

1.85%

Aug. 01, 2029

$ 1,773

1,750

Other Sustainability Sector [Member]

1,630

98,906

$ 84,633

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

80,370

85,524

999

$ 542

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Common Stock [Member]

$ 250

$ 250

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Term Loan, Prime Index, One [Member]

1,162

15.25%

6.75%

10.00%

0.00%

4.33%

Dec. 01, 2026

$ 3,750

3,685

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 3,685

15.25%

6.75%

10.00%

0.00%

4.33%

Dec. 01, 2026

$ 3,750

3,685

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Preferred Stock Warrants [Member]

3,685

$ 72

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | LiquiGlide, Inc [Member] | Common Stock Warrants [Member]

400,000

$ 39

$ 50

$ 55

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Common Stock [Member]

61,359

61,539

$ 355

$ 355

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, One [Member]

32,831

15.50%

7.00%

10.25%

0.00%

2.50%

Mar. 31, 2024

$ 8,425

8,353

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,549

15.50%

7.00%

10.25%

0.00%

2.50%

Mar. 31, 2024

$ 8,425

8,229

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Common Stock Warrants [Member]

4,481

490

$ 0

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index Three [Member]

215,171

15.50%

7.00%

10.25%

0.00%

2.50%

Mar. 31, 2024

$ 8,425

8,229

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,481

15.50%

7.00%

10.25%

0.00%

2.50%

Mar. 31, 2024

$ 5,617

5,480

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 2,984

15.50%

7.00%

10.25%

0.00%

2.50%

Mar. 31, 2024

$ 5,617

5,480

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Six [Member]

$ 2,984

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 735

726

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Seven [Member]

$ 395

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 586

578

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Eight [Member]

$ 315

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 292

288

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Nine [Member]

$ 157

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 290

286

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Ten [Member]

$ 156

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 174

172

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Eleven [Member]

$ 93

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 802

791

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Term Loan, Prime Index, Twelve [Member]

$ 431

15.50%

7.00%

10.25%

0.00%

0.00%

Mar. 31, 2024

$ 1,091

1,083

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 590

15.25%

14.25%

6.75%

10.00%

0.00%

2.75%

Apr. 01, 2026

$ 5,000

$ 2,500

4,959

2,463

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,959

$ 2,463

15.25%

14.25%

6.75%

10.00%

0.00%

2.75%

Apr. 01, 2026

$ 2,500

$ 5,000

2,479

4,927

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Preferred Stock Warrants [Member]

2,479

4,927

214

$ 340

$ 361

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index Three [Member]

681

15.25%

14.25%

6.75%

10.00%

0.00%

2.75%

May 01, 2026

$ 5,000

4,956

4,924

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,956

$ 4,924

15.25%

14.25%

6.75%

10.00%

0.00%

2.75%

May 01, 2026

$ 2,500

2,478

2,462

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 2,478

$ 2,462

14.00%

13.00%

5.50%

11.75%

10.00%

0.00%

2.75%

Dec. 01, 2026

$ 5,000

4,934

4,900

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Term Loan, Prime Index, Six [Member]

$ 4,934

$ 4,900

14.00%

13.00%

5.50%

11.75%

10.00%

0.00%

2.75%

Dec. 01, 2026

$ 2,500

2,467

2,450

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 2,467

$ 2,450

15.25%

14.25%

6.75%

10.00%

0.00%

2.50%

Apr. 01, 2028

Jun. 01, 2025

$ 3,750

3,694

3,697

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 3,694

$ 3,697

15.25%

14.25%

6.75%

10.00%

0.00%

2.50%

Apr. 01, 2028

Jun. 01, 2025

$ 3,750

3,694

3,717

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Preferred Stock Warrants [Member]

3,694

3,717

175

126

$ 80

$ 268

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index Three [Member]

46,311

35,906

15.25%

14.25%

6.75%

10.00%

0.00%

2.50%

Apr. 01, 2028

Oct. 01, 2025

$ 7,500

7,379

7,424

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 7,379

$ 7,424

15.25%

14.25%

6.75%

10.00%

0.00%

2.50%

Apr. 01, 2028

Oct. 01, 2025

$ 3,750

3,690

3,712

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 3,690

$ 3,712

15.25%

14.25%

6.75%

10.00%

0.00%

2.50%

Apr. 01, 2028

Oct. 01, 2025

$ 3,750

3,690

3,712

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Six [Member]

$ 3,690

3,712

14.50%

6.00%

10.00%

0.00%

2.00%

Jan. 01, 2029

$ 4,500

4,446

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Term Loan, Prime Index, Seven [Member]

$ 4,446

14.50%

6.00%

10.00%

0.00%

2.00%

Jan. 01, 2029

$ 2,000

1,976

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Common Stock [Member]

1,976

2,000

$ 1,700

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Cadrenal Therapeutics, Inc. [Member] | Common Stock [Member]

392,651

$ 0

$ 443

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Getaround, Inc [Member] | Common Stock [Member]

600,000

$ 253

$ 20

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | SnagAJob.com, Inc [Member] | Common Stock [Member]

87,082

$ 9

$ 83

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Common Stock [Member]

82,974

$ 111

$ 13

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Preferred Stock [Member]

5,205

$ 27

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Term Loan, Prime Index, One [Member]

22,313

14.25%

6.75%

10.00%

0.00%

3.00%

Apr. 01, 2026

$ 3,750

3,699

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 3,699

14.25%

6.75%

10.00%

0.00%

3.00%

Apr. 01, 2026

$ 3,750

3,699

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Preferred Stock Warrants [Member]

3,699

$ 74

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Term Loan, Prime Index, One [Member]

201,537

14.50%

7.00%

10.25%

0.00%

2.50%

Sep. 01, 2025

$ 7,500

7,371

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Term Loan, Prime Index Two [Member]

$ 7,371

14.50%

7.00%

10.25%

0.00%

2.50%

Sep. 01, 2025

$ 7,500

7,371

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Common Stock Warrants [Member]

7,371

488

$ 1,061

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Term Loan, Prime Index Three [Member]

204,832

14.50%

7.00%

10.25%

0.00%

2.50%

Sep. 01, 2025

$ 7,500

7,371

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Term Loan, Prime Index, Four [Member]

$ 7,371

14.50%

7.00%

10.25%

0.00%

2.50%

Jul. 01, 2026

$ 5,000

4,903

Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Term Loan, Prime Index, Five [Member]

$ 4,903

14.50%

7.00%

10.25%

0.00%

2.50%

Jul. 01, 2026

$ 5,000

4,903

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

4,903

$ 69,770

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

69,770

966

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Preferred Stock Warrants [Member]

1,871

$ 12

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Parse Biosciences, Inc. [Member] | Common Stock Warrants [Member]

171,370

$ 70

$ 70

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Parse Biosciences, Inc. [Member] | Preferred Stock Warrants [Member]

32,244

$ 166

$ 166

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Kate Farms, Inc [Member] | Preferred Stock Warrants [Member]

184,253

$ 102

$ 1,366

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Preferred Stock Warrants [Member]

82,965

$ 167

$ 0

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Preferred Stock Warrants [Member]

85,066

$ 192

$ 99

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Preferred Stock Warrants [Member]

652,250

$ 60

$ 108

Healthcare Information and Services Segment [Member] | Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Preferred Stock Warrants [Member]

7,097,792

$ 163

$ 50

Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

150,353

$ 275,026

268,468

Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

269,790

259,366

9,733

9,249

Technology Sector [Member] | Investment, Affiliated Issuer, Controlled [Member] | Equity Securities [Member]

14,506

16,148

3,311

Technology Sector [Member] | Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Common Stock [Member]

3,024

2,061

$ 2,165

Technology Sector [Member] | Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Preferred Stock [Member]

2,278,272

$ 1,250

$ 859

Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

3,124,448

$ 249,642

318,172

Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

244,815

317,568

4,197

$ 9,792

Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Other Investments [Member]

1,200

Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Royalty Agreement [Member]

200

1,200

Life Science [Member] | Investment, Unaffiliated Issuer [Member] | ZetrOZ, Inc [Member] | Royalty Agreement [Member]

200

Life Science [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member]

Life Science [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member]

23,551

5,000

$ 132

Life Science [Member] | Investment, Affiliated Issuer, Controlled [Member] | Other Investments [Member]

$ 5,782

Life Science [Member] | Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member] | Other Investments [Member]

6,230

5,782

Data Storage Sector [Member]

6,230

417

$ 476

Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | CPG Beyond, Inc [Member] | Preferred Stock Warrants [Member]

418

1,316

242

$ 294

$ 909

Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Silk, Inc [Member] | Preferred Stock Warrants [Member]

500,000

$ 175

$ 234

$ 124

$ 407

Internet and Media Sector [Member]

394,110

442,110

$ 329

Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Global Worldwide LLC [Member] | Preferred Stock Warrants [Member]

1,582

1,159

$ 63

$ 0

Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Rocket Lawyer Incorporated [Member] | Preferred Stock Warrants [Member]

245,810

$ 92

$ 318

$ 357

Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Skillshare, Inc [Member] | Preferred Stock Warrants [Member]

261,721

$ 162

$ 1,201

$ 802

Networking Sector [Member]

139,074

$ 5,451

$ 11,831

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 5,297

$ 11,710

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Sep. 01, 2024

$ 1,500

$ 3,333

1,481

3,286

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 1,481

$ 3,286

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Sep. 01, 2024

$ 1,500

$ 3,333

1,481

3,286

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Preferred Stock Warrants [Member]

1,481

3,286

364

$ 210

$ 243

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Term Loan, Prime Index Three [Member]

344,102

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Sep. 01, 2024

$ 750

$ 1,667

740

1,641

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 740

$ 1,641

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Sep. 01, 2024

$ 667

$ 1,667

656

1,641

Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Term Loan, Prime Index, Five [Member]

$ 656

$ 1,641

14.75%

13.25%

6.25%

9.50%

0.00%

4.00%

Sep. 01, 2024

$ 750

$ 1,667

729

1,613

Power Management Sector [Member]

729

1,613

1,585

Power Management Sector [Member] | Investment, Unaffiliated Issuer [Member] | Halio, Inc [Member] | Preferred Stock Warrants [Member]

2,700

2,610

1,585

$ 2,700

$ 2,610

Semiconductor Sector [Member]

38,241,466

5,002,574

$ 45

$ 56

Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Warrant [Member]

$ 0

Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Preferred and Common Stock [Member]

6,081

$ 0

Life Science Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

5,938

$ 4,702

Diagnostics Sector [Member]

7,675

19,735

$ 9,851

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 19,701

$ 9,858

14.50%

13.50%

6.00%

9.25%

0.00%

3.50%

Jun. 01, 2026

$ 2,500

2,484

2,385

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 2,484

$ 2,385

14.50%

13.50%

6.00%

9.25%

0.00%

3.50%

Jun. 01, 2026

$ 2,500

2,484

2,473

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Preferred Stock Warrants [Member]

$ 2,484

2,473

$ 54

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Term Loan, Prime Index Three [Member]

159,893

14.50%

13.50%

6.00%

9.25%

0.00%

3.50%

Jun. 01, 2026

$ 5,000

4,968

4,946

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Parse Biosciences, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 4,968

4,946

11.75%

3.25%

11.50%

0.00%

5.00%

Jan. 01, 2028

$ 5,000

4,633

Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Parse Biosciences, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 4,633

11.75%

3.25%

11.50%

0.00%

5.00%

Jan. 01, 2028

$ 5,000

4,884

Software, Healthcare Information and Service [Member]

4,884

50,899

13,735

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index, One [Member]

$ 50,574

$ 14,044

14.00%

12.50%

5.50%

9.50%

0.00%

3.00%

Aug. 01, 2027

$ 7,000

6,684

6,619

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index Two [Member]

$ 6,684

$ 6,619

14.00%

12.50%

5.50%

9.50%

0.00%

3.00%

Aug. 01, 2027

$ 3,500

3,463

3,448

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Preferred Stock Warrants [Member]

$ 3,463

3,448

160

$ 170

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index Three [Member]

80,544

14.00%

12.50%

5.50%

9.50%

0.00%

3.00%

Aug. 01, 2027

$ 3,500

3,463

3,448

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Term Loan, Prime Index, Four [Member]

$ 3,463

3,448

14.00%

5.50%

9.50%

0.00%

3.00%

Apr. 01, 2028

$ 2,750

2,710

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Term Loan, Prime Index, One [Member]

$ 2,710

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2027

$ 10,000

9,656

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 9,656

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2027

$ 5,000

4,925

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Term Loan, Prime Index Three [Member]

$ 4,925

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2027

$ 5,000

4,925

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Term Loan, Prime Index, Four [Member]

$ 4,925

12.00%

3.50%

11.75%

0.00%

4.00%

Oct. 01, 2027

$ 5,000

4,925

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Preferred Stock Warrants [Member]

$ 4,925

$ 359

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Term Loan, Prime Index, One [Member]

7,097,792

11.75%

3.25%

11.00%

0.00%

5.00%

Jun. 01, 2027

$ 5,000

4,648

Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 4,648

11.75%

3.25%

11.00%

0.00%

5.00%

Jun. 01, 2027

$ 5,000

4,918

Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

4,918

97,907

$ 83,705

Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

79,828

83,705

928

$ 1,819

Other Healthcare Sector [Member]

102

$ 7,559

Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Kate Farms, Inc [Member] | Preferred Stock Warrants [Member]

$ 1,366

3,870

102

$ 1,370

Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Term Loan, Prime Index, One [Member]

82,965

13.25%

5.75%

9.00%

0.00%

4.00%

Oct. 01, 2025

$ 4,943

4,943

Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Term Loan, Prime Index Two [Member]

$ 1,668

13.25%

5.75%

9.00%

0.00%

4.00%

Dec. 31, 2025

$ 2,500

2,467

Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Preferred Stock Warrants [Member]

832

$ 0

Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member]

77,690

$ 30,729

Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member]

25,819

416

Net asset value at beginning of period (in dollars per share)

$ 1,953

[1]	As of December 31, 2023, the Company no longer owns 5% of more of the portfolio company.

Note 13 - Financial Highlights - Financial Highlights (Details) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

$ 11.47

$ 11.56

$ 11.02

$ 11.83

$ 11.64

Net investment income (in dollars per share)

1.98

1.46

1.41

1.18

1.52

Realized loss (in dollars per share)

(0.97)

(0.38)

(0.18)

(0.84)

(0.31)

Unrealized (depreciation) appreciation on investments (in dollars per share)

(1.57)

(0.22)

0.16

0.02

0.24

Net (decrease) increase in net assets resulting from operations (in dollars per share)

(0.56)

0.86

1.39

0.36

1.45

Distributions declared (in dollars per share)

^[1]

(1.37)

(1.28)

(1.25)

(1.2)

From net investment income (in dollars per share)

(1.37)

(1.28)

(1.25)

(1.2)

From net realized gain on investments (in dollars per share)

Return of capital (in dollars per share)

Other (in dollars per share)

^[2]

0.17

0.33

0.4

0.08

(0.06)

Net asset value at end of period (in dollars per share)

9.71

11.47

11.56

11.02

11.83

Per share market value, beginning of period (in dollars per share)

11.6

15.92

13.24

12.93

11.25

Per share market value, end of period (in dollars per share)

$ 13.17

$ 11.6

$ 15.92

$ 13.24

$ 12.93

Total return based on a market value

^[3]

25.30%

(19.30%)

29.70%

12.10%

25.60%

Shares outstanding at end of period (in shares)

33,367,389

27,753,373

21,217,460

19,286,356

15,563,290

Expenses without incentive value

14.10%

11.50%

10.50%

10.00%

10.80%

Incentive fees

0.90%

2.60%

3.10%

2.60%

3.20%

Net expenses

15.00%

14.10%

13.60%

12.60%

14.00%

Net investment income with incentive fees

18.20%

12.10%

12.20%

10.40%

12.80%

Expenses without incentive value (4)

^[4]

14.10%

11.50%

10.50%

10.00%

10.80%

Incentive fees (4)

^[4]

0.90%

2.60%

3.10%

2.60%

4.40%

Net expenses (4)

^[4]

15.00%

14.10%

13.60%

12.60%

15.20%

Net investment income with incentive fees (4)

^[4]

18.20%

12.10%

12.20%

10.40%

11.60%

Net assets at the end of the period

$ 323,981

$ 318,448

$ 245,335

$ 212,597

$ 184,055

Average net asset value

$ 336,915

$ 299,182

$ 231,215

$ 199,302

$ 160,008

Average debt per share (in dollars per share)

$ 13.93

$ 13.7

$ 11.27

$ 9.97

$ 10.05

Portfolio turnover ratio

17.20%

^[5]

14.60%

^[5]

45.40%

^[5]

38.70%

^[5]

82.00%

^[6]

[1]	Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.
[2]	Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.
[3]	The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.
[4]	During the years ended December 31, 2019, the Advisor waived $1.8 million of incentive fee.
[5]	Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance
[6]	Calculated by dividing net debt investment purchases by the monthly average debt investment balance.

Note 12 - Subsequent Events

12 Months Ended

Dec. 31, 2023